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Abstract  
Introduction: Obstructive sleep apnoea (OSA) has been proposed as a contributing 
factor in the development and progression of primary open-angle glaucoma (POAG) but 
there is insufficient evidence to confirm or refute this hypothesis. The prevalence of OSA 
among people with POAG is unknown. To complicate the picture further, concerns have 
been raised that continuous positive airway pressure (CPAP) increases nocturnal 
intraocular pressure (IOP), currently the only treatable risk factor for POAG.  
Objectives: The objective of this thesis was to assess whether the prevalence of OSA 
among patients with POAG is different from that in people without glaucoma and to 
examine for associations between apnoea-hypopnea index (AHI) and markers of 
functional and structural changes in POAG. In addition, the thesis examined whether 
POAG patients with untreated OSA have faster rates of retinal nerve fibre layer (RNFL) 
loss than those without OSA. The impact of CPAP on IOP and ocular microvasculature 
were investigated.  
Methods: In order to examine the thesis’ questions, studies with the following 
methodology were conducted: a cross-sectional observational study with a control group, 
a retrospective longitudinal data analysis, a prospective longitudinal study examining the 
effect of intervention and a physiological experiment.  
Results:  Based on data from 235 POAG patients and 160 controls the prevalence of 
OSA was 58% and 54%, respectively. After statistical matching, the proportion of 
participants diagnosed with OSA was not different between the groups (p=0.91). The 
AHI was not associated with the severity of visual field defect or RNFL thinning after 
adjustment for confounders in a cross-sectional study but, in a longitudinal study, people 
with OSA had almost twice faster rates of RNFL loss than those without OSA (-1.1±1.5 
μm/year vs -0.6 ±1 μm/year, respectively, p=0.013) and this was independent of other 
risk factors. CPAP significantly raised nocturnal IOP in people with (+2.2±2.2mmHg) and 
without POAG (+3.2±2.2mmHg) but a diurnal application of CPAP at different levels in 
awake subjects was not associated with IOP elevation. A short-term treatment with 
CPAP did not alter the optic disc and retinal microvasculature.  
Conclusions: The burden of OSA among POAG patients is not higher than in people 
without glaucoma but OSA may be an independent progression risk factor in those with 
established POAG. CPAP raises IOP and the long-term impact of this on POAG 
progression should be investigated in future studies.  
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Chapter 1: Introduction 
1.1 Overview and motivation.  
This thesis examines several aspects of an intriguing and complex relationship that has 
been proposed between obstructive sleep apnoea (OSA) and primary-open angle 
glaucoma (POAG). Both conditions are common and each has been studied extensively 
over the last few decades by sleep specialists and ophthalmologists respectively. Much 
has been learnt about them separately, much is still unknown. Interdisciplinary research 
into the link between OSA and POAG has resulted in interesting hypotheses but also 
conflicting and often confusing findings. In many areas the existing evidence is 
insufficient to draw any conclusions.  
The overarching goals of this thesis are to produce good quality evidence for questions 
that have been asked but not answered, challenge beliefs that may be lacking support 
in solid data, explore the usefulness of new technologies and form new hypotheses. 
Specifically, this thesis examines: the prevalence of OSA among people with POAG, the 
hypothesised associations between OSA and POAG severity markers, the role of OSA 
in POAG progression, the impact of continuous positive airway pressure (CPAP) on 
intraocular pressure and on the novel angiographic indicators of retinal microvasculature. 
The body of work consists of: a large cross-sectional observational study, a retrospective 
longitudinal analysis, a prospective longitudinal study examining the effect of intervention 
and a physiological experiment.  
It is my hope that the work presented in this thesis will further the current knowledge on 
this puzzling interdisciplinary problem.  
 
1.2 POAG 
1.2.1 What is Glaucoma?  
The word “glaucoma” originates from the ancient Greek word glaucosis, meaning light 
blue or blue-green hue. During the Hippocratic period it was probably used to describe 
the appearance of the pupil which was clouded as a result of media opacity (1). Today, 
the term “glaucoma” has a different meaning and encompasses a group of progressive 
diseases which cause degeneration of the optic nerve through the damage of the retinal 
ganglion cells (RGCs). These neurons are part of the central nervous system and play 
an essential role in signal transmission from the photoreceptors to the vision centres in 
the brain. Their cell bodies are located in the inner part of the retina and their axons form 
the optic nerve. The damage to the RGCs is irreversible and in a large proportion of 
patients leads to impaired vision, and in some, causes blindness. In fact, glaucoma is 
one of the leading causes of irreversible blindness worldwide. It has been projected that 
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79.6 million people will be affected by glaucoma by 2020 (2). Of those, 4.5 million will 
have moderate to severe vision loss and 3.2 million will be bilaterally blind (3). More than 
half of people with glaucoma are not aware that they have it as the disease often remains 
asymptomatic until the advanced stages (2).  
There are different types of glaucoma, each with their own specific features and 
aetiologies. The most common form of glaucoma is POAG which is defined by the 
glaucomatous appearance of the optic disc in the presence of open anterior chamber 
angles. In the United Kingdom it is diagnosed in around 2% of people over 40 years of 
age (4). In contrast, angle-closure glaucoma is characterised by occlusion of the angle 
between the peripheral cornea and the iris where the eye drainage system is located and 
it is approximately five times less common (5). Glaucoma can be also caused by 
underlying factors such as blockage of the angle by exfoliated material from ocular 
structures (exfoliation glaucoma) or pigment granules (pigmentary glaucoma), formation 
of abnormal blood vessels on the iris (neovascular glaucoma) or inadequate 
development of ocular drainage channels (congenital glaucoma). Certain medications 
such as systemic corticosteroids can also lead to the development of glaucoma (6). 
However, these secondary forms of glaucoma are far less prevalent.  
 
1.2.2 How is POAG diagnosed and monitored?  
In healthy eyes, the axons of RGCs converge at the optic disc creating the neuroretinal 
rim which surrounds the cup, a central shallow pit with no nerve fibres. A progressive 
loss of RGCs and their axons which occurs in POAG leads to characteristic changes in 
the appearance of the optic nerve head (ONH); the cup enlarges in diameter until it takes 
up the area of the optic disc. In addition, as a consequence of mechanical strain from 
intraocular pressure (IOP), the lamina cribrosa (a collagenous structure which provides 
mechanical support to the axon fibres) is displaced posteriorly and thinned which results 
in deepening of the cup (7). Also, the retinal nerve fibre layer (RNFL) surrounding the 
disc becomes thinner. These changes can be observed during ophthalmic examination 
of the optic disc with a slit lamp biomicroscope. This examination is crucial in POAG 
assessment however because of its subjective nature and a wide variation of the optic 
disc appearance in the healthy population there is a large inter-observer variability 
particularly in identification of early damage when the changes are subtle and more 
difficult to detect. The loss of RGC axons can also be objectively evaluated with several 
available imaging techniques. Of these, Ocular Coherence Tomography (OCT) has 
become the most popular as it provides precise, automated and reproducible 
measurement of RNFL thickness and thus is particularly useful in quantitative monitoring 
of progression. Detection of the structural changes is essential as it informs the early 
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diagnosis of POAG and allows for initiation of treatment before irreversible changes in 
vision develop. It is estimated that as much as 50% of RGCs are lost before functional 
defects  can be demonstrated on standard visual field test (8,9). Nevertheless, it is the 
vision loss that matters most for the patient and it is important to make the connection 
between pathophysiological changes and patient related outcomes. For this reason, 
white-on-white automated perimetry has been used for decades and remains ubiquitous 
in glaucoma clinics. It employs white light stimuli with varying brightness on a white 
background in order to identify a minimum detection threshold at different locations in 
the visual field (VF). Peripheral vision usually declines first in glaucoma and central vision 
is preserved until the late stages of the disease. The typical pattern consist of 
superonasal followed by inferonasal field defects  which correspond to inferotemporal 
followed by superotemporal RNFL loss (6). Perimetry relies on a patient responding to 
the stimulus and as such the output can be impacted by a learning effect as well as 
fatigue during the test. Consequently, in the follow up the output of the first recorded test 
is typically excluded and the development of a new VF defect requires confirmation with 
repeated testing. Also, the VF reliability indices,  including: fixation losses, false negative 
and false positive errors should be taken into account when interpreting the results.  
There is no widely agreed single reference standard for POAG diagnosis. Assessment 
of all these components is helpful in the diagnostic process but in some patients it can 
still be difficult to confidently establish the diagnosis of POAG, particularly in the early 
stages. Longitudinal monitoring with repeated structural and functional evaluation is 
often required to differentiate between glaucomatous and non-glaucomatous 
neuropathies, or indeed normal anatomical variants. In clinical practice a cohort of 
patients are  described as ‘glaucoma suspects’ until the evolution of suspicious changes 
or the lack of it provides further clarification.  
 
1.2.3 POAG pathophysiology and risk factors.  
The biological basis of glaucomatous neuropathy is complex and not fully elucidated. 
Several potentially relevant pathophysiological processes and risk factors have been 
identified. Among them, IOP plays a dominant role in the optic nerve injury. Currently, it 
is also the only treatable risk factor for POAG. 
 
1.2.3.1 IOP 
IOP is a dynamic parameter which shows circadian variability and changes with posture, 
fluid status and physical exercise (10). Independently of these factors IOP also varies 
considerably from person to person and has a wide range of ‘population normal’ values 
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of between 10 to 21 mmHg. POAG in the context of IOP elevated above this population 
norm is often described as high tension glaucoma (HTG).  
The balance between aqueous humour production by the ciliary body and aqueous 
humour outflow by the trabecular meshwork and the uveoscleral outflow pathway is what 
determines IOP (6). Unlike in angle-closure glaucoma, where the approach to the 
trabecular meshwork is occluded by iridocorneal contact, in POAG there is no 
iridocorneal contact, however, there is increased resistance to the fluid flow in the 
trabecular meshwork (11). According to the ‘mechanical’ theory elevated intraocular 
pressure leads to axonal injury and the consequent death of RGCs. It has been proposed 
that this occurs through a biomechanical stress exerted on the optic nerve head which 
impedes the retrograde axoplasmic transport of essential neurotrophic factors and can 
trigger a signalling cascade which ultimately leads to apoptosis or autophagy of the 
neurone cells (6). The level of IOP is undoubtedly related to RGCs death. Numerous 
population-based studies have shown consistently that the prevalence of POAG rises 
exponentially as the level of IOP increases (12). Studies have also unequivocally 
demonstrated that reduction of IOP prevents the development of POAG in people with 
ocular hypertension and reduces the risk of progression in patients with already 
established glaucoma, including in those who have baseline IOP within the normal range 
(normal tension glaucoma-NTG) (13–17). Thus, IOP lowering is the mainstay of POAG 
treatment. It can be achieved by several methods, including: pharmacological therapy, 
laser and surgical interventions.  
Pharmacotherapy is typically the first line treatment and is usually administered in the 
form of eye drops applied to the ocular surface. They work by improving the drainage or 
reducing the production of the aqueous fluid which results in lowering of the pressure in 
the eye. There are several different classes of hypotensive agents available with different 
mechanisms of action, administration regimens and varying side-effect profiles. 
Prostaglandin analogues primarily enhance uveoscleral outflow and, due to minimal 
systemic side effects, once daily application and effective reduction of IOP during the 
day and at night, are the most commonly used topical drugs. An alternative to 
prostaglandins are β blockers, which work by decreasing the production of aqueous 
humour by the ciliary body. These agents are also widely used but can cause systemic 
respiratory and cardiovascular effects and are less efficacious in IOP lowering at night 
and in people who take systemic β blockers. Among other categories of topical 
medications are: carbonic anhydrase inhibitors which reduce aqueous humour secretion, 
and α adrenergic agonists which work by both decreasing aqueous humour production 
and by increasing its drainage. A combination of these medications can be used but the 
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main limitation of pharmacotherapy is low long-term adherence to daily administration of 
eye drops for what is often asymptomatic disease.  
Laser procedure is another treatment option for patients who require more aggressive 
IOP lowering, are not adherent to the eye drops or cannot tolerate them. There is also 
evidence in support of using laser trabeculoplasty as a first line treatment (18). Currently, 
the most commonly performed laser procedure is selective laser trabeculoplasty (SLT) 
which employs laser energy applied to the trabecular meshwork in order to induce 
remodelling of the extracellular matrix and increase aqueous outflow. In the majority of 
patients SLT is initially successful in lowering IOP but with time it may lose its 
effectiveness so that some patients require repeated procedures or other forms of 
treatment.  
The most invasive method of IOP lowering is incisional glaucoma surgery which is 
typically performed under local anaesthetics although general anaesthesia may be 
required for some patients. Several different types of surgical procedures with varying 
degree of invasiveness and long-term efficacy have been developed. The general 
principle is to create an additional outflow pathway for the aqueous fluid which enhances 
the drainage. In trabeculectomy which has been the most frequently performed filtration 
surgery for over 40 years, this is achieved by the creation of fistula connecting the 
anterior chamber and the subconjunctival space (6). The aqueous fluid is then drained 
to a ‘bleb’ formed by a scleral flap and covered by the conjunctiva.  
Surgical interventions result in reduction of IOP which is often sustained for many years 
without the need for taking eye drops but are expensive and not free from complications.  
For some patients, multimodality treatment is required to bring their IOP under control 
but even if this is achieved the glaucomatous damage may continue progressing. For 
example, in one landmark randomised interventional study in glaucoma which has shown 
the benefit of IOP lowering (the Early Manifest Glaucoma Trial), 45% of patients in the 
treatment arm (vs 62% of patients in the no treatment arm) still progressed during the 
median follow up of 6 years despite receiving a combined treatment with laser 
trabeculoplasty and a topical β blocker (14). It is also well recognised that in 30-50% 
POAG patients the IOP is within normal population range at least at the point of diagnosis 
(NTG) and only 10% of people with ocular hypertension will eventually develop glaucoma 
(19). 
It is therefore important to identify other risk factors. So far, studies have shown that, 
apart from IOP, the main risk factors for glaucoma development and/or progression are: 
age, ethnic background, myopia and family history of glaucoma. Pooled data from 
population-based studies indicate that the risk of developing POAG increases by 1.73 
(95% CI: 1.63 to 1.82) for every decade increase in age beyond 40 years (20). People 
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of African ancestry are 2.8 times more likely (95% CI, 1.83-4.06) to have POAG than 
people of European ethnic background (20). In addition, African-Americans tend to 
present with more severe visual field defect at younger age in comparison to white 
Americans (21).  First-degree relatives of patients with POAG are several times more 
likely to develop the disease (22). A moderate to high degree of myopia is a risk factor 
for glaucomatous damage (23). Also, structural and biomechanical properties of the 
cornea (lower CCT=central corneal thickness and lower hysteresis) have been 
associated with faster POAG progression in some studies, although the evidence for 
these factors is weaker (23,24).  
Identification and assessment of all these components in clinical practice allows for more 
accurate risk stratification so that aggressive IOP lowering can be implemented for 
patients at higher risk of progression. However, at least currently, none of these factors 
is modifiable. In contrast, impaired blood flow and oxidative stress which may also 
contribute to RGCs death are potential targets for disease modifying interventions.  
 
1.2.3.2 Vascular factors and oxidative stress  
It has long been proposed that vascular dysfunction promotes the optic nerve damage 
by either increasing the individual susceptibility to IOP or as an independent mechanism. 
According to the ‘vascular’ theory unstable perfusion pressure and impaired 
autoregulation result in insufficient blood flow in the ocular microvasculature and the 
consequent ischaemic injury as the metabolic demands of the neurone cells cannot be 
met (25). Retinal cells have a high metabolic rate and are particularly sensitive to 
disturbances in the supply of their energy sources, that is: oxygen, glucose and other 
metabolic substrates. Due to the requirement for relative optical transparency, the 
density of the vascular network which serves to meet this demand is constrained. 
Therefore, the blood flow must be precisely regulated as even minor disruptions in the 
homeostatic mechanisms can have deleterious consequences for the supplied tissues 
(26).  
The anatomy and physiology of blood supply to the ONH are complex. The primary 
source of blood supply is the posterior ciliary artery circulation via the peripapillary 
choroid and short posterior ciliary arteries but the superficial layers of the ONH, including 
the RNFL, are supplied by small branches of the central retinal artery (27). Retinal 
vessels fully supply the central RGCs but  the peripheral RGCs rely on both the retinal 
and choroidal vascular supply (28). These two vascular beds have different physiological 
properties (25,29). The retinal circulation has no autonomic innervation but otherwise 
resembles the brain circulation; tight endothelial junctions create a blood-retinal barrier 
and the blood flow is autoregulated within a certain range of perfusion pressure. The 
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autoregulation is at least partly based on partial pressure of oxygen and carbon dioxide. 
Blood flow level in the retinal circulation is low but high oxygen extraction ensures 
adequate tissue oxygenation. In contrast, choroidal microcirculation is characterised  by 
high blood flow but low oxygen extraction. The endothelium of choroidocapillaries is 
fenestrated which means that relatively large vasoactive molecules such as endothelin-
1 and angiotensin II have direct access to the smooth-muscle cells and pericytes of larger 
vessels and can also diffuse to the ONH. Further, choroidal circulation has poor 
autoregulatory properties and therefore is more dependent on perfusion pressure. It is 
also regulated by the autonomic nervous system.  
It has been stipulated that this unique situation where some RGCs and their axons are 
dependent on both the retinal and choroidal capillaries for critical nutrition and oxygen,  
can render them more vulnerable to various insults affecting the vasculature particularly 
when, with increasing age, the autoregulatory and autonomic mechanisms become less 
robust (28).  
There is now compelling evidence that vascular dysregulation exists in POAG and may 
be pathogenic. Whilst precise measurements of ocular blood flow, particularly in the 
microcirculation relevant to the optic nerve is challenging because of the complex angio-
architecture, studies found deficiencies in retinal, choroidal and retrobulbar circulations 
in patients with glaucoma compared with individuals without the disease (30–32). 
Abnormal autoregulation of ONH and retinal blood flow in response to isometric exercise 
and posture change has been demonstrated in people with POAG and is more common 
than in healthy controls (33–35).  
Moreover, there is evidence that the blood flow alterations are not limited to ocular 
circulation but represent more diffuse systemic vascular dysregulation present in POAG. 
For instance, studies which assessed flow mediated vasodilatation in the brachial artery, 
a marker of systemic endothelial dysfunction, have found that both NTG and HTG 
patients have reduced responses compared to controls which indicates impaired nitric 
oxide  signalling (36–38). Endothelin-1, a potent vasoconstrictor, may also play an 
important role in vascular dysregulation in POAG. Intravitreal injection of endothelin-1 in 
animal studies induced chronic hypoperfusion in the ONH and led to thinning of the 
ganglion cell layer and loss of axons in the optic nerve (39–41). In a meta-analysis of 10 
human studies, patients with NTG (but not those with HTG) had significantly higher 
plasma endothelin-1 levels compared to non-glaucomatous controls (42). People with 
HTG had however higher endothelin-1 levels in the aqueous humour. The authors 
concluded that in NTG there may be both a local and a systemic component in 
endothelin-1 mediated vascular dysregulation, while in HTG the effect of this peptide 
could be localised to the ocular vasculature. Another study has found that patients with 
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progressive POAG had higher serum endothelin-1 levels then those with stable disease 
(43). Endothelin-1 is constitutively expressed in different ocular structures and its role 
probably extends beyond the regulation of vascular tone. In vitro studies demonstrated 
that human trabecular meshwork cells contract in response to endothelin-1 which would 
increase aqueous outflow resistance and thus raise the IOP (44). Importantly, the 
synthesis and release of endothelin-1 are upregulated under hypoxic conditions and this 
process seems to be mediated by tumour necrosis factor α (TNF α) (45). 
Also, there is evidence in support of generalised autonomic dysfunction in people with 
POAG. Several case-control studies of heart rate variability have shown that the 
autonomic balance is shifted towards higher sympathetic activity in POAG patients 
versus controls and that autonomic control of cardiovascular responses is blunted in 
NTG patients (46–50). Apart from vascular regulation the autonomic nervous system 
may also, at least partly, influence IOP fluctuation. In animal models, chemical 
stimulation of central autonomic regulatory neurons in hypothalamus increased IOP by 
nearly 70% from baseline (51).  
More recently oxidative stress has been recognised as one of the main molecular 
mechanisms in the signalling pathway leading to RGCs death (6). The segments of 
RGCs axons which pass through the lamina cribrosa are not insulated by myelin sheaths 
which means that they require more energy to generate action potentials. This is 
reflected by high concentration of mitochondria in RGCs soma and the intra-retinal 
portions of their axons (52). Mitochondria are therefore critical to survival and function of 
RGCs but can be easily damage by oxidative stress and excessive formation of free 
radicals under hypoxic conditions and this process leads to apoptosis (53). Trabecular 
meshwork cells are also prone to degeneration by free radicles accumulating in the 
anterior chamber which causes cytoskeletal rearrangements and the consequent 
impairment in aqueous drainage (54). There are several potential sources of hypoxic 
stress in POAG, including mechanical stress imposed on the axons by high IOP, periods 
of relative ischaemia and reperfusion caused by vascular dysregulation and potentially 
systemic hypoxaemia. In support of the latter are data from a meta-analysis of 22 case-
control studies which have shown significantly increased levels of oxidative stress 
markers not only in the aqueous humour but also in serum in POAG patients (55). In 
addition, depleted antioxidant potential has been demonstrated in serum of POAG 
patients and malonyldialdehyde was proposed as the best serum biomarker of oxidative 
stress in POAG. Importantly, this meta-analysis found that the differences in the serum 
level of oxidative markers are significantly higher between POAG and control patients 
than between angle-closure glaucoma and controls which would indicate that systemic 
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oxidative stress plays a more important role in the pathophysiology of POAG than in 
other types of glaucoma.  
Various strategies, including already established and novel pharmacological agents, 
have been trialled to improve vascular dysregulation and reduce oxidative stress as ways 
of complementing IOP lowering treatment but so far none of  them have made it to clinical 
practice (42,56,57). Attenuation of the underlying risk factors which promote the 
oligaemic/hypoxic injury in the ONH would be an ideal way of preserving the RGCs. A 
common and treatable disorder which, among other potentially relevant 
pathophysiological consequences, causes vascular dysfunction and induces systemic 
oxidative stress is obstructive sleep apnoea (OSA).  
 
 
1.3 OSA 
1.3.1 What is OSA?  
OSA is a common sleep-related breathing disorder (SBD) characterised by recurrent 
episodes of complete (apnoea) or partial (hypopnoea) occlusion of the upper airway. 
Occasional nocturnal obstructive respiratory events are normal but when their frequency 
increases to ≥5 per hour of sleep (the current diagnostic threshold for OSA) they can be 
associated with daytime symptoms and adverse health outcomes (58). Obstructive 
apnoeas and hypopnoeas cause transient interruption of ventilation and are usually 
terminated by brief arousals (microarousals) which disrupt sleep continuity. Interrupted 
ventilation is associated with oxygen desaturations, intrathoracic pressure swings and 
sympathetic drive activation. Collectively, these physiological changes and sleep 
fragmentation lead, in turn, in some individuals, to a range of symptoms including: 
excessive sleepiness, impairment of memory and cognition, mood alterations, and 
changes in driving competence (59–64). However, a substantial proportion of people, 
even those with severe OSA are not symptomatic or aware of having a sleep disorder 
(65,66). On the contrary, about 20% of people report excessive daytime sleepiness in 
the absence of SDB (58). For this reason OSA cannot be diagnosed based on symptoms 
or subjective reports alone. A sleep recording, either a full polysomnography (PSG), 
which consist of: electroencephalography, electrooculography and electromyography in 
addition to respiratory and cardiac signals, or a respiratory polygraphy (rPG) which does 
not include the neurophysiological monitoring is required to confirm or refute the 
diagnosis of OSA. In some patients nocturnal oximetry alone can be sufficient to 
diagnose OSA but it is less sensitive as it allows detection of only these respiratory 
events which are associated with 4% oxygen desaturations and cannot reliably 
differentiate between different types of SDB.  
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OSA is one of the most common chronic disorders and a major public health issue in 
most countries (67). In a recent systematic review, the overall population prevalence of 
OSA ranged across the studies from 9% to 38% but was higher in men and elderly (68). 
Moreover, its prevalence increases worldwide in line with rising rates of obesity. For 
instance, based on longitudinal data from the Wisconsin cohort, it has been estimated 
that over the last two decades the prevalence of moderate to severe OSA has increased 
by 14-55%, depending on sex and age subgroups (69).  
Apart from causing sleepiness and affecting quality of life in some individuals, OSA is 
associated with cardiovascular, cerebrovascular and metabolic co-morbidities as well as 
increased risk of certain cancers and all-cause mortality (70–75).  In fact, OSA is now 
considered as a systemic disorder which can affect most, if not all, organs (76).  
Obesity is the strongest risk factor for OSA. Even modest changes in weight can worsen 
OSA severity. For instance, in a longitudinal study by Peppard et al. 10% weight gain 
has been associated with a 32% increase in apnoea-hypopnoea index (AHI) (95% CI 20-
45%) and a six folds increase in the odds of developing moderate to severe OSA 
(AHI>15 events/hr) but 10 % weight loss has led to a 26% (95% CI 18-34%) reduction in 
AHI (77). Several mechanisms have been proposed to explain the contribution of 
excessive weight to the development of OSA including deposition of fat around 
pharyngeal airways and particularly in the tongue, reduction of functional residual 
capacity as well as low lung volumes leading to decreased oxygen reservoir and 
ventilatory control instability (78,79). Nonetheless, approximately a third of OSA patients 
are not obese and not all obese patients, even those with large neck circumferences 
suffer from OSA (80). From the pathophysiological perspective, OSA is a multifactorial 
disease although the combination of identified anatomical and non-anatomical factors 
and their relative contributions vary between individuals. In some, excessive weight, 
craniofacial or soft tissue changed play major roles, in others non-anatomical factors, 
such as impaired pharyngeal dilator muscle function, low respiratory arousal threshold, 
and high loop gain causing unstable control of breathing may be the predominant 
mechanisms leading to upper airway instability during sleep (81). 
In general, OSA is twice more common in men than in premenopausal aged-matched 
women (82). The reasons for male predominance are not fully elucidated but hormonal 
influences on breathing control and upper airway muscle activation, relatively longer 
pharyngeal airway and sex-specific fat distribution may explain some of this disparity. 
Hormonal changes and redistribution of fat tissue to the upper body, including the neck, 
could be responsible for a relative increase in OSA after the menopause in women 
(83,84).  
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Age is also important in OSA epidemiology and pathophysiology. The prevalence of OSA 
increases with age up until the age of 65 years when it seems to plateau (85,86). 
Preferential deposition of fat around the pharynx, independent of systemic fat and 
deteriorating genioglossus negative pressure reflex have been proposed as potential 
mechanisms of increased upper airway collapsibility with aging (87,88). Most patients 
are however diagnosed with OSA between the age of 40 and 50 years and the 
association of OSA with sleepiness and vascular co-morbidities such as hypertension 
seems weaker in elderly people (89–91). Thus, it has been suggested that OSA may 
represent a different entity in older age groups but, as most studies to date predominantly 
included young to middle-aged adults more data are needed to better understand the 
differential effect of age on OSA consequences (92).  
 
1.3.2 Pathophysiological mediators of OSA 
Recurrent obstructions of the upper airway activate a range of stressors which contribute 
to cardiac, vascular and metabolic diseases. Transient hypoxaemia and hypercapnia are 
inherently associated with obstructed breathing. The hypoxaemic stress is further 
augmented by the subsequent re-oxygenation which results in the generation of reactive 
oxygen species (ROS). Excessive production of ROS cannot be counterbalanced by the 
limited capacity of the anti-oxidant systems and results in hypoxic stress, which is 
thought to promote inflammation and sympathetic activation. These, in turn, potentiate 
the oxidative stress creating a vicious cycle which may ultimately lead to endothelial 
dysfunction, hypertension and atherosclerosis (93). Complex cellular and molecular 
mechanisms are involved in increased ROS production in response to hypoxia, including: 
mitochondrial dysfunction, activation of nicotinamide adenine dinucleotide phosphate 
(NADPH) oxidase and xanthine oxidase, and uncoupling of nitric oxide synthase, which 
generates ROS rather than nitric oxide (94).   
Biomarker studies in OSA patients have provided evidence for enhanced release of 
superoxide from leucocytes, diminished bioavailability of nitric oxide, reduced antioxidant 
capacity and increased peroxidation of lipids and oxidative DNA damage (95). Notably, 
marked mitochondrial dysfunction in animal models of intermittent hypoxia has been 
associated with apoptotic cell death in the cerebral cortex (96). An abnormal 
mitochondrial distribution and impaired oxidative activity have also been demonstrated 
in the soft palate muscles of OSA patients (97). 
Various blood cells of people with OSA exhibit a pro-inflammatory and a pro-thrombotic 
phenotype with a higher expression of adhesion molecules and inflammatory cytokines, 
such as interleukin-8 or TNFα, which promote endothelial injury and thrombosis (94). 
Endothelial dysfunction is well documented in OSA at least at the macrovascular level 
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(98). The bioavailability of nitric oxide, a key vasodilator, is reduced and accompanied 
by increased production of endothelin-1, a potent vasoconstrictor (99,100). 
Intermittent hypoxia and hypercapnia alter chemo- and baro-reflexes and this leads to 
augmented sympathetic activity in sleep which carries over to wakefulness contributing 
to  nocturnal and diurnal hypertension and blunted heart rate variability (101).  
The mechanical consequence of obstructed breathing events are acute intrathoracic 
pressure swings which stretch intrathoracic structures, in particular, the atria. They 
induce haemodynamic and electrophysiological alterations and may promote 
arrhythmias (102).  
All these mechanisms and cellular pathways are interconnected and thought to be 
collectively responsible for OSA related co-morbidities.  
 
1.3.3 OSA treatment 
OSA treatment is directed to alleviating symptoms, improving quality of life, reducing the 
risk of road traffic collisions and, at least in some patients, reducing the burden of 
cardiovascular co-morbidities.  
General therapeutic options include: lifestyle modifications, such as reduction in body 
weight, abstinence from alcohol and positional interventions to prevent sleeping in a 
supine position (103,104). Oral appliances can be used to control mild to moderate OSA, 
if feasible from a dental perspective (105).  For highly selected individuals maxillofacial 
surgery is a valid treatment option but it is rarely used due to its invasive nature (106).  
For the majority of people however, the usual first line treatment, particularly in the 
context of moderate to severe OSA, is continuous positive airway pressure (CPAP) 
which is applied via a nasal or a full face mask to splint open and maintain patency of 
the upper airway throughout the breathing cycle. When used throughout the entirety of 
sleep, CPAP can eliminate nearly all obstructive breathing events in the majority of 
patients (107,108). CPAP therapy has been shown to have positive impacts on several 
of the deleterious pathophysiological effects of OSA, including; ameliorating sympathetic 
overactivity, improving endothelial function, eliminating negative intrathoracic pressure 
swings and, in some studies, reducing circulating markers of systemic inflammation 
(109–112). The effect of CPAP on oxidative stress is less clear; the majority of 
observational studies have shown a significant decrease in the biomarkers of oxidative 
stress and an increase in antioxidant capacity but  randomised sham controlled trials 
have yielded contradictory results (113–115). There is little doubt that consistent use of 
CPAP improves the quality of sleep, normalises sleep architecture, reduces daytime 
sleepiness, enhances neurobehavioural performance and eliminates the increased risk 
of motor vehicle crashes (61,116,117). Patients who are compliant with CPAP achieve 
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better blood pressure control and this effect is larger in those with resistant hypertension 
(118,119). Whether CPAP reduces the risk of cardiovascular events and mortality is still 
uncertain. Multiple observational studies have indicated the cardiovascular benefits of 
CPAP but this has not been confirmed in randomised controlled trials (RCTs), possibly 
due to suboptimal CPAP usage (120).  
 
1.4 POAG and OSA Associations  
1.4.1 Hypothetical pathophysiological links 
Through intermittent hypoxia and hypoxic stress promoting RGCs apoptosis, endothelial 
dysfunction and sympathetic hyperactivity affecting blood flow regulation in the ocular 
vessels, intrathoracic pressure swings potentially causing IOP fluctuations and transient 
hypercapnia altering intracranial pressure, OSA may directly or indirectly compromise 
the optic nerve head perfusion and oxygenation contributing to RGCs degeneration 
(121,122).  
It is remarkable that many of the physiological deficits which characterise OSA have also 
been found in people with POAG. These observations are, of course, not sufficient to 
conclude that OSA is behind these changes in POAG patients or indeed that it 
contributes to glaucomatous neuropathy, but the overlapping nature of these findings 
and theoretically plausible physiological mechanisms prompt further exploration of the 
potential associations between OSA and the optic nerve damage.  
 
1.4.2 Associations of OSA with ocular parameters  
Previous studies have largely examined cross-sectional associations between OSA 
metrics and parameters of the optic nerve structure and function in people with otherwise 
healthy eyes. Most of these studies have shown a thinner RNFL, reduced retinal 
sensitivity (lower mean deviation-MD) and impaired electrophysiological properties 
(delayed latency and reduced amplitude of the P100 waveform on visual evoked 
potential testing) when compared with people without OSA, although, in some studies 
these observations have been limited to severe OSA only and data on RNFL thickness 
are not unanimous (123–125). As already alluded to, testing retinal sensitivity with 
perimetry is problematic in people with OSA as their performance may be affected by 
impaired attention and decreased reaction times, giving falsely underestimated visual 
field indices. Measurements of RNFL thickness with OCT devices allows for a more 
objective assessment with less variability and so would be preferred over functional 
testing to assess for the impact of OSA.  
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The above associations have not to date been examined in people with already 
established POAG. Such studies are more challenging as they require a relatively large 
sample of participants with well characterised glaucoma to enable adjustment for IOP 
and other glaucoma risk factors.  
Critically, there are no longitudinal data on RNFL thickness change over time in people 
with and without OSA, and therefore it is unclear whether OSA contributes to POAG 
progression.  
 
1.4.3 Prevalence of OSA in POAG 
Most of the studies to date have focused on examining the prevalence of glaucoma in 
people with OSA. Three meta-analyses of these studies have concluded that OSA is a 
risk factor for the development of glaucoma but, as many of the included studies did not 
adjusted for known risk factors or OSA severity, were retrospective and at high risk of 
selection bias, the authors rightly attributed low confidence to these data (126–128). The 
additional problem faced even by prospective studies is that, for the reasons outlined in 
paragraph 1.2.2, it is often difficult to confidently diagnose POAG based on a single 
examination and the previous cross-sectional studies have not offered a repeated 
ophthalmic evaluation. There are only two longitudinal controlled studies, both showing 
increased risk of subsequent POAG diagnosis in people with OSA, but they were based 
on retrospective review of data derived from health insurance databases (129,130).  
Several controlled studies have assessed the prevalence of OSA in people with 
glaucoma. OSA was reported in up to 42% of patients with POAG, which was thought to 
be higher than in the general population (131). These studies were also summarised in 
a recent meta-analysis (128). Based on a fixed-effects model, the pooled OR of OSA 
was 1.96 (95% CI 1.37- 2.80) among POAG patients vs controls. However, the individual 
studies included had important methodological limitations related to small sample sizes, 
pre-selecting patients based on symptoms, using only low grade sleep tests or 
questionnaires alone, or ICD (International Classification of Diseases) codes in 
retrospective health record linkage designs. One particular problem with database 
retrospective studies is that both POAG and OSA are largely underdiagnosed in the 
general population and hence identification of these patients based on ICD codes 
(diagnosed cases only) has limited value even in relatively large samples. These studies 
are summarised in Table 1-1 which also describes one further study published more 
recently which used the STOP-BANG questionnaire to assess for the risk of OSA (132). 
Because of all these limitations, it is still unclear whether OSA is truly more prevalent in 
people with POAG. In addition to prevalence, it is important to establish the burden of 
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OSA symptoms and the distribution of OSA severity across different stages of visual 
impairment in POAG. There may be a dose response effect in the possible impact of 
OSA on glaucoma; mild OSA may not be at all relevant. Furthermore, OSA may be 
contributing to the pathogenesis of glaucoma only in certain POAG subgroups, such as 
NTG where the glaucomatous damage seems less IOP dependent. On the contrary, 
exposure to intermittent hypoxia and impaired blood flow may have a synergistic effect 
in HTG where raised IOP is already posing mechanical stress on the optic nerve and its 
vasculature. 
OSA is a treatable condition and if proven to be an independent risk factor for glaucoma, 
those patients diagnosed with glaucoma may benefit from routine screening and 
potentially from treatment for OSA. However, screening of unselected patients in busy 
glaucoma clinics with complex sleep tests is unlikely to be feasible or cost-effective. 
Therefore, there is a need to evaluate tools such as questionnaires, for their usefulness 
in identifying patients at a higher risk of OSA.
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Table 1-1. Summary of studies that assessed the prevalence of OSA in people with POAG.  
Study  Participants  Diagnostic test  % with SDB diagnosis 
Onen 2000(133) 212 POAG 
218 Controls  
Semi-structured questionnaire  POAG-48% snoring, 27% snoring + EDS 
Controls- 38%snoring, 17.8% snoring + EDS 
Marcus 2001(134) 23 NTG 
14 NTG 
suspects 
30 Controls  
‘sleep history’,  
PSG only on selected subjects  
NTG-30%  
NTG suspects-14.3%  
Controls-3%  
Girkin 2006(135) 667 Newly 
diagnosed 
Glaucoma  
6667 Controls  
Unknown,  
diagnosis based on ICD code  
Glaucoma-1% 
Controls-0.5 
Khandgave 2013(136) 40 POAG  
40 Controls  
Sleep disturbance 
questionnaire + ESS,  
PSG only on selected subjects  
Glaucoma-10% 
Controls-2.5% 
Roberts 2009(137) 52 Glaucoma 
60 Controls  
Oximetry  Glaucoma-17% 
Controls-12% 
Bilgin 2014(131) 24 NTG 
24 Controls 
(matched) 
PSG NTG-41.7% 
Controls-12.5% 
Cabrera 2018(132) 437 POAG 
441 Controls 
STOP-BANG questionnaire  POAG-62.7% at high risk of OSA 
Controls-59.4% at high risk of OSA  
Abbreviations: POAG=primary open-angle glaucoma, NTG=normal tension glaucoma, PSG=polysomnography, OSA=obstructive sleep 
apnoea, SDB=sleep-disordered breathing, ESS=Epworth Sleepiness Scale Score, EDS=excessive daytime sleepiness.
25 
 
 
1.4.4 CPAP, IOP and ocular microvasculature 
Many people with glaucoma and concomitant OSA associated with the relevant 
symptoms, receive standard treatment with CPAP. However, the impact of CPAP on 
their glaucoma is unknown. On one hand CPAP, by eliminating the negative 
consequences of OSA, may have a protective effect on RGCs and their axons. On the 
other hand, there are concerns that it raises IOP. The evidence for this is limited and 
comes from two studies which only examined people without glaucoma (138,139). I will 
describe these studies in detail in the relevant chapters but, briefly, they have found that 
IOP increases significantly during the nocturnal CPAP therapy compared to the pre-
treatment baseline. People with glaucoma, particularly those with HTG, may be more 
susceptible to IOP change when on CPAP and in comparison to normal subjects may 
experience a greater increase in IOP. Furthermore, the relationship between CPAP level 
and IOP has not been studied. It is unknown if IOP increases in a correlated way to 
CPAP or whether there is no straightforward correlation. If the first is true, application of 
CPAP only up to a certain pressure level would be safe and perhaps the threshold to use 
other treatment modalities, such as bi-level positive airway pressure which is equally 
effective but allows for application of lower pressure in the expiratory phase of the 
breathing cycle, should be lower in patients with glaucoma. If, however, IOP changes 
are a matter of individual response to CPAP, perhaps dependent on body mass index 
(BMI), lung volumes or OSA severity, a routine measurement of IOP should be 
performed once CPAP is started. This is currently not a part of standard clinical practice. 
It is also possible that CPAP set within the pressure range used in clinical practice does 
not influence IOP or its effect is not mediated by simple mechanical pressure 
transmission from the airways to the ocular veins, as it has been proposed (138).  
Understanding the relationship between CPAP and IOP is important as it may inform the 
management of people with OSA and concomitant glaucoma. In fact, this research is in 
part inspired by a patient with glaucoma who was diagnosed with OSA and attended one 
of our sleep disorders clinics to start CPAP therapy. One of her questions was whether 
CPAP would affect her IOP and this was a question we could not answer.  
Apart from IOP, CPAP can potentially influence ocular blood flow and the 
microcirculation of the optic disc. Again, it may have a negative effect by increasing IOP 
and thus reducing ocular perfusion pressure or positively influence the blood supply by 
improving endothelial function and autoregulation of the ocular blood flow. New, non-
invasive imaging techniques, such as OCT angiography, allow for a direct and precise 
assessment of ocular microvasculature and could provide useful data on the vascular 
effects of CPAP in glaucoma and beyond.  
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1.5 Objectives of the Thesis  
 
Chapter 3 
The work described in Chapter 3 is dedicated to establishing what proportion of 
unselected patients with POAG attending glaucoma clinics in a secondary care hospital 
meet the diagnostic criteria for OSA. Their symptoms and OSA severity will be examined 
and compared with a concurrent group of individuals without POAG after matching for 
known OSA risk factors. Further, I will examine for associations between OSA severity 
markers and indicators of functional and structural optic nerve damage while controlling 
for other glaucoma risk factors. The burden of OSA in terms of its prevalence and severity 
will be compared between patients with NTG and HTG. I will also assess the usefulness 
of the STOP-BANG questionnaire as a screening tool for OSA in POAG patients.  
 
Chapter 4 
Based on longitudinal data extracted from electronic health records of patients who 
participated in the study reported in Chapter 3, this Chapter will examine whether the 
rates of structural POAG progression (RNFL thinning) are different between patients with 
glaucoma, with and without OSA, and whether OSA could be an independent risk factor 
for POAG progression.  
 
Chapter 5 
The work reported in Chapter 5 seeks to establish whether CPAP therapy increases 
nocturnal IOP in patients with POAG. The potential mediators of IOP response to CPAP 
will be examined and the effect of CPAP of IOP will be compared between POAG 
patients and control subjects.  
 
Chapter 6 
This Chapter will examine the effect of the acute application of CPAP on IOP in people 
with treated and untreated POAG as well as in control subjects. The specific aim of this 
Chapter is to establish whether there is a relationship between applied CPAP level and 
the level of IOP.  
 
Chapter 7  
The work described in Chapter 7 will explore whether a short course of CPAP therapy in 
people with OSA with and without POAG can alter ocular microvascular parameters 
measured with a novel angiographic device.  
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Chapter 8  
This Chapter will summarise the main results of all previous chapters and will discuss 
directions for future work.  
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Chapter 2: Materials and Methods  
This Chapter describes general methods used across the studies, including; research 
settings and population, data collection and management, outcome measurement tools, 
funding sources as well as my own and others’ contributions to each study. Specific 
procedures are detailed separately in the relevant chapters. 
 
2.1 Research settings and population  
For the purpose of this thesis an interdisciplinary collaboration between sleep specialists 
and ophthalmologists was established. The studies were conducted across two sites: the 
Respiratory Support and Sleep Centre (RSSC) at the Royal Papworth Hospital NHS 
Foundation Trust and the Huntingdon Glaucoma Diagnostic & Research Centre based 
in the Department of Ophthalmology at Hinchingbrooke Hospital-North West Anglia 
Foundation Trust.  
RSSC is an accredited, tertiary sleep disorders unit with a national referral base and 
specialist expertise in the diagnosis and management of OSA and other sleep disorders. 
The Huntingdon Glaucoma Diagnostic & Research Centre was established in 2007 with 
a research team consisting of consultant ophthalmologists supported by research 
optometrists, orthoptists and research nurses. The unit conducts the majority of 
glaucoma clinical studies (both commercial and non-commercial) in Eastern England.  
 
Participants who took part in the POSAG study (Chapter 3) were recruited among 
patients who attended glaucoma clinics at Hinchingbrooke Hospital and their relatives. 
All study procedures took place in a specially set up Glaucoma Research Clinic held on 
three days a week for 18 months. Sleep studies were analysed in the RSSC.  
Recruitment to research studies described in Chapters 5,6 and 7 took place 
predominantly in the RSSC, with a prior screening and ocular examination for some 
participants carried out at Hinchingbrooke Hospital as required.  
 
2.2 Data collection and management 
With the exception of the retrospective study described in Chapter 4, data for all other 
studies were collected prospectively and recorded in electronic Case Report Forms 
(eCRF) developed in OpenClinica which is an electronic data repository currently 
preferred by the Sponsor (Royal Papworth Hospital) for data capture and management. 
For each study, eCRFs were designed based on the study protocol and built with 
incorporated validity checks to minimise data entry errors. Data integrity was monitored 
throughout the study by the data management team from the Sponsor’s institution. In 
29 
 
addition, the accuracy and consistency of data entry were audited by the Sponsor’s 
representative. Adverse and Serious Adverse Events were reported electronically using 
the eCRFs and in accordance with the Trust Standard Operating Procedures and the 
principles of Good Clinical Practice.  
 
2.3 Outcome measurement tools  
Across the studies the following tools were used to examine the main outcomes: 
 Respiratory polygraphy (rPG) was the chosen sleep test for OSA screening. It 
was performed using the Embletta portable device (Embletta MPR and GOLD; Natus 
Medical Inc., Pleasanton, USA) with the following channels (Figure 2-1):   
i. Airflow measured by thermistor and nasal pressure-flow cannula  
ii. Thoracic and abdominal effort through XactTrace Respiratory Inductive 
Plethysmograph sensors 
iii. Continues pulse-oximetry  
iv. Body position determined by a sensor which collects X/Y/Z gravity information.  
v. Activity sensor which detects movements.  
The sleep study kit was collected from the participants on the day after the sleep test 
and data were downloaded using RemLogic-E software to assess whether the study was 
of adequate quality. All sleep studies were then scored manually in the RSSC by a single 
qualified sleep polysomnographer and in accordance with current American Academy of 
Sleep Medicine guidelines(140). Briefly, apnoeas were scored when there was a drop in 
the peak signal excursion by ≥ 90% of the pre-event baseline for ≥10 seconds using an 
oro-nasal thermal sensor and hypopneas were defined as ≥ 30%  reduction in the pre-
event nasal pressure signal which lasted for ≥10 seconds in association with ≥ 3% 
oxygen desaturation. Apnoeas were classified as obstructive, mixed, or central based on 
the respiratory effort (see Appendix 1 for an example of a multichannel recording 
demonstrating obstructive apnoeas).    
The diagnosis of OSA was given if the apnoea-hypopnoea index (AHI, the number of 
apnoea and hypopnoea events per hour of recording) was greater than or equal to 5 and 
the majority of respiratory events were obstructive in nature. The usual clinical thresholds 
were used to categorise OSA severity: mild (AHI≥5 to <15), moderate (AHI≥15 to <30), 
severe (AHI≥30). 
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Figure 2-1. Illustration of rPG (Embletta) montage.  
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 The Epworth sleepiness scale (ESS) was developed by Dr Murray Johns of 
Epworth Hospital in Melbourne, Australia and first introduced in 1991 (141). The ESS is 
now an internationally accepted scale used to measure the subject’s general level of 
daytime sleepiness. It estimates the chance of falling asleep in eight different situations 
where subjects rate their tendency to fall asleep on a scale of 0 to 3; 0= no chance of 
dozing, 1=mild chance, 2=moderate chance and 3 a high chance of dozing (Figure 2-2). 
A score of <11 is considered to be normal and a value of ≥ 11 suggests excessive 
daytime sleepiness. 
 
Figure 2-2. The Epworth Sleepiness Scale adopted by the RSSC. 
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 The STOP-Bang questionnaire was developed and validated as a pre-operative 
screening tool for assessing the risk of OSA in general surgical population in 2008 by 
Chung et al (142). Since then it has been validated in several different populations and 
settings, such as among bus drivers or in primary care (143). It is a concise and user-
friendly tool comprising eight equally weighted questions with binary responses; each 
positive response scores one point. A high risk of sleep apnoea is defined as a score of 
≥3 and a low risk as a score 0-2 (Figure 2-3).  
 
Figure 2-3. The STOP-Bang Questionnaire.  
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 Humphrey Field Analyser (HFA) (Carl Zeiss Meditec, Jena, Germany) is the 
most commonly used perimeter for visual field assessment in glaucoma clinics in the UK. 
HFA quantifies the sensitivity of a patient’s peripheral vision using standardised testing 
algorithms. All visual field examinations described in this Thesis were performed using 
the 24-2 tests pattern and the Swedish Interactive Thresholding Algorithm fast protocol 
(SITA Fast) which is the preferred method of VF assessment in the local glaucoma 
clinics. It is a fast threshold test which usually takes approximately 5 minutes per eye 
and offers high accuracy whilst reducing patient fatigue-related errors. The visual field is 
tested up to 24 degrees temporally and 30 degrees nasally from fixation. The threshold 
value for each of the tested location within the field represent the extent to which light 
can be dimmed and still detected by the patient and are referenced to age-matched 
normal population values (144). These multiple location-based data can then be 
aggregated and presented as global indices which provide a useful summary of the field. 
The Mean Deviation (MD) is derived from the Total Deviation and represents the overall 
mean departure of the test subject’s visual field sensitivity from the age-corrected norm 
(145). Negative values indicate field loss whereas positive values indicate that the field 
is above average. The Pattern Standard Deviation (PSD) summarises localised loss 
while correcting for an overall depression in light sensitivity. For this reason it is thought 
to be particularly useful in patient with cataract where lens opacity can cause excessive 
light scatter. The Visual field index (VFI) is also less affected by media opacity and has 
been developed to better correlate with RGCs loss by giving more weight to the points 
near the centre of the field. The VFI value of 100% represents a perfect age-adjusted 
visual field and 0% equates to perimetric blindness. These global field indices have been 
extracted for the purpose of this Thesis (see Appendix 2).  
 
 Ocular Coherence Tomography (OCT) is a non-invasive imaging technique 
which uses low-coherence interferometry to produce two- and three- dimensional cross-
sectional images of optical scattering from internal tissues (146). As an echo technique 
it is analogue to ultrasound imaging but since it uses light rather than sound waves the 
produced images have much higher longitudinal and lateral spatial resolution which is 
down to the level of a few micrometres. Spectral domain (SD)-OCT is the latest iteration 
of the OCT technology. In comparison to other OCT modalities, it offers an increased 
axial resolution and a faster scanning speed that result in higher density scans and 
decreased motion artefacts (147). Various ocular structures and retinal layers can be 
accurately assessed with the SD-OCT but the most widely used parameter in glaucoma 
research and clinical practice for the disease detection and progression monitoring is 
circumpapillary RNFL thickness measurement. It enables a cross-sectional assessment 
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of all the RGCs’ axons as they come together to form the ONH. For these reasons, the 
circumpapillary RNFL thickness has been selected in this Thesis as the primary 
parameter for assessment of structural glaucomatous damage and its progression.  
The images were acquired with the OCT Spectralis (Heidelberg Engineering Inc. MA, 
USA.), an SD-OCT device which uses 1024 A-scan points from a 3.45 mm circle centred 
on the ONH. RNFL thickness is automatically calculated by proprietary software (version: 
6.3.4) as the distance between the internal limiting membrane and the posterior border 
of the RNFL. The software output includes the average RNFL thickness for the whole 
globe and separately for each of the four quadrants (superior, inferior, nasal, and 
temporal) (148)  (see Figure 4-1 in Chapter 4).  
 
 OCT Angiography (OCT-A) is a novel functional extension of OCT which allows 
visualisation and quantitative assessment of retinal vasculature. This technique is based 
on high-speed OCT scanning and analysis of signal decorrelation between multiple  
sequential B-scans of the same cross-section of the retina (149). Blood vessels are 
defined by areas with high decorrelation and a static tissue has low decorrelation values 
(150). Unlike in conventional angiography there is no need for an extrinsic contrast as 
the signal is generated by the movement of erythrocytes within the vessels. Precise 
three-dimensional images of the vascular networks down to the level of capillaries are 
obtained and can be displayed as individual layers which allows for isolation of specific 
areas of interest (see Appendix 3). Importantly, these images are morphologically 
comparable to microscopic images of the histological specimens (151). 
The OCT-A device (AngioVueHD, Optovue Inc., Fremont, CA) used in this Thesis for the 
angiographic measurements has been validated in multiple recent studies. It has the 
capacity for automated and quantitative evaluation of the optic disc, peripapillary and 
choroidal vessels density. The Angiovue software (version: 2017.1.0.151)  calculates 
vessel density as the percentage of the measured area occupied by ‘flowing’ blood 
vessels which are defined by pixels with decorrelation values above a set threshold level. 
The measurements can be obtained with high within-visit, between-visit and 
interoperator reproducibilities (152–154).  
 
 Icare tonometers (IcarePro and IcareHome, Finland, Oy) were used for 
repeated IOP measurements in studies described in Chapters 6 and 7. These are new 
generation handheld devices constructed based on the principles of rebound tonometry. 
Briefly, a small probe held in place by an electromagnetic field is accelerated against the 
cornea. It makes a brief contact with the corneal surface and then bounces back. The 
deceleration is faster if the IOP is high and slower if the IOP is low. The device measures 
35 
 
the rebound acceleration and converts it into IOP (155). For each IOP measurement six 
consecutive readings are obtained either by pressing the measurement button 
individually six times or by activating six rapid automatic measurements in a ‘series’ 
mode. The value of the final IOP is calculated as the average of four measurements after 
discarding the highest and the lowest readings. IcarePro displays the measurements on 
the device panel with one decimal place and, in addition, indicates the reliability of the 
measurements by a colour code; if the variation is within normal limits the colour is green, 
if it is greater than normal the indicator is yellow and red when the variation is 
unacceptably high. The IcareHOME which is designed for self-measurement of IOP does 
not display the final IOP but informs the patient by a beep signal and a light illuminated 
on the back panel whether the obtained measurements are acceptable or whether they 
need repeating. The final IOP readings are stored in the device internal memory and can 
be subsequently downloaded by a healthcare professional using a dedicated software 
(see Appendix 4) 
Both devices have been validated against the Goldmann applanation tonometer which 
is still regarded as the gold standard for IOP measurements and have been shown to 
have good agreement (156–159). Rebound tonometry has important advantages over 
applanation tonometry. There is no need for application of topical anaesthetics and 
fluorescein which reduces the measurement acquisition time to a few seconds and 
minimises discomfort to the patient. The rebound technique does not require repeated 
calibration and is generally less operator dependent. Furthermore, an inclination sensor 
built in the IcarePro tonometer enables for the measurements to be performed also in a 
supine position. These characteristics made these rebound tonometers particularly 
suitable for the studies conducted within this Thesis.  
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2.4 Contributions to the Thesis  
 
My personal and others’ involvement in each study described in this Thesis was as 
follows:  
Chapter 3:  
- With help and supervision from Dr Ian Smith and Professor Rupert Bourne I have 
designed this study and developed the study protocol.  
- With support of my co-applicants (Dr Ian Smith and Professor Rupert Bourne) I 
have successfully applied for an external grant (Fight for Sight, 15K) which 
secured the necessary additional funding for this project. Dr Ian Smith was 
previously awarded an unrestricted research grant from Breas Medical which 
covered most of the expenses of the research projects reported in this Thesis, 
including my salary.  
- I have applied for ethical (NHS REC and ARU), HRA and Sponsor’s (Royal 
Papworth Hospital) approvals and have also secured NIHR CRN Portfolio status.  
- I have participated in the contract negotiations between the Trusts, prepared the 
study costings and drafted the contract with help from Dr Victoria Stoneman.  
- I have designed eCRFs and prepared all study documentation. Jo Steel has 
programmed the study electronic data repository in OpenClinica and provided 
support with data managements throughout the study.  
- I and Paula Turnbull, Dr Shabbir Harun, Aaron Woods and Professor Rupert 
Bourne have been involved in screening glaucoma patients and their relatives in 
glaucoma clinics.  
- I have contacted nearly all potential participants and scheduled the study visits 
for those willing to take part. Paula Turnbull provided administrative support with 
visits organisation and maintenance of study documentation.  
- I have participated in recruitment of all participants and performed the relevant 
sleep apnoea assessments with set up and evaluation of rPG studies, taken the 
relevant ophthalmic and medical history, performed anthropomorphic 
measurements and administered the questionnaires. The ophthalmic tests were 
performed by: Jane Kean, Dr Gil Peretz, Dr Catherine Willshire and Aaron 
Woods.  
- I have extracted all data and recorded in the electronic repository.  
- All sleep studies were scored by Sam Moir. In the process, I have also learnt 
scoring of rPG studies and have been formally signed off as competent in this 
task.  
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- I have reported the results of sleep studies to all participants and advised GPs 
accordingly.  
- I have performed data analysis including all statistical analyses with the exception 
of propensity matching which was done by Dr Sofia Villar and Dr Yi-Da Chiu who 
also verified some of the regression models constructed by me. Dr Jules 
Hernandez-Sanches previously provided guidance on the study sample 
calculation.  
- I have written this chapter and prepared the first draft of the manuscript. Dr Ian 
Smith and Professor Rupert Bourne provided critical review and edited the 
manuscript.  
- I have reported to the study funders, the HRA and the Ethics committee.  
 
Chapter 4:  
- Dr Malinga Ratwatte assisted with retrospective data extraction and evaluation 
of RNFL measurements reliability.  
- I have designed the study, performed all statistical analyses and written up the 
chapter.  
 
Chapters 5, 6 and 7 
- In collaboration with Dr Ian Smith and Professor Rupert Bourne I have designed 
these studies.  
- I have secured a second external research grant (Fight for Sight, 15K).  
- I have prepared ethical, HRA, Trust and NIHR Portfolio applications and studies’ 
documentation.  
- Jo Steel programmed the OpenClinica databases.  
- I have screened all patients and organised the study visits.  
- Hannah Munday provided administrative support.  
- Dr Ian Smith and Professor Rupert Bourne helped with screening in sleep and 
glaucoma clinics respectively.  
- Dr Catherine Willshire performed screening ophthalmic examination when 
required.  
- I have recruited all patients and performed the relevant measurements. Dr 
Matthew Schneiders assisted with IOP measurements.  
- I have extracted all data.  
- I have liaised with the AngioVue development team to secure the latest version 
of analytical software for angiographic data processing prior to its commercial 
release.  
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- I have performed data analysis, including all statistical analyses. Dr Jules 
Hernandez-Sanches advised on sample size calculations. 
- I have written the respective chapters.  
- I have reported to the funders, the HRA and the Ethics committee.  
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Chapter 3: Obstructive Sleep Apnoea in patients with 
Primary-Open Angle Glaucoma: prevalence and 
associations (the POSAG study). 
 
 
 
Null hypotheses:  
i. The prevalence of OSA among patients with POAG is the same as in control 
subjects without glaucoma.  
ii. There is no association between OSA severity markers and indicators of optic 
nerve structure and function in people with and without POAG. 
iii. The STOP-BANG questionnaire cannot accurately identify POAG patients at 
high risk of OSA. 
 
3.1 Introduction 
The progressive and irreversible nature of vision loss in people with POAG, often despite 
adequate IOP lowering, necessitates careful assessment of other potential risk factors 
which can be modified in order to preserve the optic nerve function. As discussed in 
Chapter 1, the pathophysiological consequences of OSA at systemic and cellular levels 
are potentially relevant and, hypothetically, could promote glaucomatous optic 
neuropathy. For this reason screening for OSA has been recommended as part of the 
systematic work up in glaucoma (127,160,161). However, before any screening 
programme is implemented several factors need to be considered, including: the 
causality, the strength of association between the two conditions, the risks and benefits 
of a new diagnosis and the cost of additional diagnostic tests. One starting point would 
be to understand the burden of OSA among patients with glaucoma. At present, it is 
unclear whether people with POAG are more likely to suffer from OSA, are more 
symptomatic or have a different profile of OSA risk factors than those without glaucoma. 
A few small studies have assessed the prevalence of OSA in patients with POAG but 
they had important methodological limitations and have provided contradictory 
results(131,137,162,163).  
Some authors have proposed the STOP-BANG questionnaire as a screening tool for 
OSA in those POAG patients who continue progressing despite adequately controlled 
IOP (160). Others  used this questionnaire in epidemiological studies to evaluate the risk 
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for OSA among POAG patients (132). Because of its simplicity the STOP-BANG 
questionnaire is an attractive screening tool which could be potentially administered in 
busy glaucoma clinics. However, it was originally developed for screening of general 
surgical preoperative patients and has not been validated in people with POAG who have 
different demographics than the original derivative cohorts of surgical patients.  
Several studies have shown excessive RNFL thinning and reduced retinal sensitivity in 
people with OSA and otherwise healthy eyes but these associations have not been 
examined in people with already established glaucoma and it is unclear how relevant 
these early changes are to the future risk of developing glaucoma (123–125).  
The aim of the current study was, therefore, to determine the prevalence of OSA in a 
larger sample of patients with POAG, assess whether this prevalence is higher than in 
people without glaucoma with the same risk factors for OSA and whether it differs 
between POAG subtypes (HTG vs NTG).  In addition, the study aimed to examine 
potential associations between OSA severity markers and indicators of optic nerve 
structure and function. The usefulness of the STOP-BANG questionnaire as a screening 
tool for OSA in patients with POAG is also assessed.  
 
3.2 Methods  
3.2.1  Study design and participants  
The study was observational and cross-sectional including unselected patients with 
POAG and control subjects. The project was approved by the East of England-
Cambridgeshire and Hertfordshire Research Ethics Committee (REC number 
15/EE/0292) and the Anglia Ruskin University Research Ethics Panel (ref. 15/16 014) 
(Appendix 5). Recruitment took place in the glaucoma clinic at a single secondary care 
hospital in the United Kingdom (Hinchingbrooke Hospital, North West Anglia Foundation 
Trust). Consecutive patients with a diagnosis of POAG who attended the clinic between 
March 2016 and September 2017 were invited provided they were historically able to 
perform reliable visual field tests. Control subjects with no history of glaucoma were 
recruited from spouses, partners, friends, and siblings of patients with POAG. There 
were two routes of approaching the potential control subjects: i. relatives of glaucoma 
patients who accompanied them in the glaucoma clinic were directly invited by the study 
personnel and provided written information outlining the study,  ii. unaccompanied 
glaucoma patients were asked to pass on the study information with an invitation letter 
to their partners, friends or siblings who were then advised to contact the research team 
should they wish to contribute to the study. Participants had to be at least 18 years old 
and able to give informed consent. We invited all potentially eligible subjects irrespective 
of sleep complaints, including known SDB to participate. 
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3.2.2  Study procedures 
Consented participants underwent the following assessments:  
 
Baseline assessment 
A brief medical history focused on cardiovascular, metabolic and ocular co-morbidities 
as well as medications was taken. Patients’ records were reviewed to obtain details 
about POAG diagnosis, risk factors and management. Demographic and 
anthropomorphic variables, including: age, weight, height, BMI and neck circumference 
were collected and blood pressure was measured. The ESS and the STOP-BANG 
questionnaires were administered.  
 
Ophthalmic examination  
All enrolled participants underwent a comprehensive ophthalmic examination which 
consisted of the following measurements: best-corrected visual acuity, refraction (Auto 
kerato-refractometer, Topcon, Tokyo, Japan), automated visual fields (HFA, SITA-Fast, 
Carl Zeiss Meditec, Jena, Germany), slit-lamp biomicroscopy and gonioscopy (Haag-
Streit International, Koeniz, Switzerland), Goldmann applanation tonometry (Haag-Streit 
International, Koeniz, Switzerland), CCT (Pachmate 2, DGH Technology Inc., Exton, 
USA) corneal hysteresis (Ocular Response Analyser, Reichert, N.Y., USA) and fundus 
photography. Circumpapillary RNFL thickness was automatically measured as a global 
average and also in four quadrants using Spectralis OCT (Heidelberg Engineering Inc. 
MA, USA).The global RNFL measurements were used in the analysis. The Mean 
Deviation (MD) and the Pattern Standard Deviation (PSD) from the visual field 
examination were used to categorize POAG patients into seven stages of glaucoma 
severity as per the enhanced Glaucoma Severity Staging system (eGSS) (164). Patients 
who had IOP≤21 mmHg prior to starting glaucoma treatment and during follow up 
constituted the NTG group. The diagnosis of POAG was confirmed by a consultant 
ophthalmologist specialising in glaucoma based on a typical optic disc appearance, 
reproducible visual field defect, and OCT results. Recruited POAG patients who did not 
meet the diagnostic criteria were excluded. Similarly, any control subjects found to have 
definite or suspected glaucoma were excluded.  
For the analysis of associations between ocular and OSA parameters, the eye with the 
lower MD (greater visual field loss) was selected for each participant, unless it was 
affected by a comorbid condition which could have impacted visual field results or RNFL 
thickness. These comorbidities included: retinal vascular disease, diabetic retinopathy, 
age-related macular degeneration, prior retinal detachment, advanced cataract or 
neurological scotomas. Subjects with ocular comorbidity in both eyes or in the 
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glaucomatous eye in case of unilateral POAG, and also those who were using treatment 
for OSA, were excluded from the association analysis (Figure 3-1). 
 
Sleep studies  
Participants who met the eligibility criteria following the ocular assessment underwent 
nocturnal multichannel cardiorespiratory monitoring at home (rPG, type 3 sleep study) 
using a portable device (Embletta MPR and GOLD; Natus Medical Inc., Pleasanton, 
USA). The sleep study kit was set up during the study visit and it was demonstrated to 
the participants how to put it on. They were asked to return it on the following day with 
the enclosed questionnaire (Patient’s Post Sleep Questionnaire) describing their sleep 
quality and estimated quantity on the sleep study night. Sleep studies of suboptimal 
quality or duration were repeated once; if the second attempt was unsuccessful or 
declined the participant was excluded. People using treatment for OSA were asked to 
withdraw it a week prior to the sleep test. 
All sleep studies were then scored manually in the RSSC by one polysomnographer as 
described in the Methods Chapter. The polysomnographer was blinded to the glaucoma 
status. Participants with predominantly central sleep apnoea were excluded.  
 
Individual follow up  
All participants (and their General Practitioners) were subsequently informed of the 
outcomes of their sleep studies in writing. In addition, I conducted a telephone interview 
with all participants diagnosed with moderate to severe OSA and those who reported 
excessive sleepiness (ESS>10) irrespective of the severity of OSA  to determine whether 
a formal assessment in the Sleep Disturbance Clinic for further investigation or treatment 
was needed.  
 
3.2.3  Study outcomes 
Primary: 
Difference between the groups in proportions of participants diagnosed with OSA 
(AHI≥5).  
Secondary:  
i. Difference between the groups in proportions of participants diagnosed with 
moderate to severe OSA (AHI≥15) and OSA syndrome (AHI≥5 +ESS>10).  
ii. Differences in OSA prevalence between HTG and NTG patients.  
iii. Associations between OSA severity (defined by AHI) and ocular parameters 
(functional visual impairment and RNFL thickness) in both groups.  
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iv. Predictive performance of the STOP-BANG questionnaire in discriminating 
between OSA vs No OSA (Area Under the Curve=AUC, sensitivity, 
specificity, predictive positive and predictive negative values for AHII≥5 and 
AHI≥15). 
v. Differences in the rate of RNFL thinning in POAG patients with and without 
OSA. This outcome will be reported separately in Chapter 4.  
 
3.2.4  Statistical Considerations  
3.2.4.1 Sample Size 
The sample size was estimated based on the primary study objective of comparing the 
proportions of participants diagnosed with OSA in both groups. Data reported by  
Arnardottir et al. were used to estimate the prevalence of OSA in the control group (65). 
In that study the prevalence of OSA (defined as ≥5 AHI, type 3 sleep study) in the general 
Icelandic population with a mean age of 55 years was reported at 43%. Assuming the 
same prevalence of OSA in the UK population, a sample size of 232 participants per 
group would be required to detect a minimum difference of 13% in prevalence between 
the groups with 80% power and 5% significance (two-sided z-test for the difference 
between two independent proportions). A precision of 5% would be achieved with this 
sample size so that, for instance, if the OSA prevalence in the POAG group was 56% 
the 95% confidence interval would be between 51% and 61%. Larger differences could 
be detected with smaller sample sizes (see Appendix 6). 
Based on these calculations and following feasibility assessment the study aimed to 
recruit 240 participants per group.  
 
3.2.4.2 Statistical analysis  
Continuous data are presented as mean (SD) or median (IQR) depending on the 
distribution. For all data, the assumption of normality was assessed using the Shapiro-
Wilk test and by visual inspection of histograms. Independent continuous variables were 
compared using Student's t-test or, in case of non-parametric data, the Mann-Whitney U 
test. The chi-square test was used to compare proportions. In order to reduce 
confounding from imbalances between the groups in known OSA predictors,  propensity 
score matching was performed using one-to-one nearest neighbour algorithm. The 
prevalence of OSA between POAG and control groups was then compared in the 
matched groups. I used an ordinal logistic regression model to assess for an association 
between POAG severity stages as the outcome measure and AHI as an independent 
variable. Univariate linear regression models were developed to examine the relationship 
between AHI and the global RNFL thickness. To assess whether OSA is a predictor of 
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RNFL thickness after adjusting for previously reported predictors of glaucoma 
progression and/or RNFL thinning I built a multivariable linear model with AHI and other 
predictors as co-variates (forced entry method).  
The area under the entire receiver operating characteristic curve (ROC AUC) was used 
to measure the overall discriminating ability of the STOP-BANG questionnaire in 
detecting OSA (separately for AHI ≥ 5 and AHI ≥15). The diagnostic performance 
(sensitivity, specificity, positive predictive values and negative predictive value) of the 
STOP-BANG questionnaire is reported at the conventional score of ≥3, and at the 
optimal cut-point defined by the Youden Index (J), which describes the maximum 
potential diagnostic effectiveness of the examined tool when equal weight is given to 
sensitivity and specificity (165).  
All statistical test assumptions were adhered to throughout the analysis and only models 
meeting these assumptions are reported.  
The propensity score matching was implemented in R (version 3.4.1) using the Matchit 
package.  The ROC curves were constructed in MedCalc statistical software version 
19.0.5 (Ostend, Belgium). All other analyses were conducted using SPSS software 
version 22.0 (IBM SPSS, IL, USA). 
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Figure 3-1. Flow diagram of the POSAG study. 
Abbreviations: POAG=primary open angle glaucoma, OHT=ocular hypertension, 
OSA=obstructive sleep apnoea, CSA=central sleep apnoea, CPAP=continuous positive 
airway pressure.  
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3.3 Results 
3.3.1  OSA prevalence  
A total of 395 participants was available for the OSA prevalence analysis comprising 235 
with POAG and 160 control subjects (see Figure 3-1 for the study flow chart and 
Appendix 7 for demographic data on invited POAG patients who consented vs those who 
declined participation in the study). Spouses, partners, and friends of recruited POAG 
patients constituted 99% of the control group. OSA was diagnosed in 58% (95% CI:52-
65) of POAG patients and in 54% (95% CI:47-62) of control participants (p=0.44, for 
between groups comparison). Moderate to severe OSA was found in 22% (95% CI:16-
27) of POAG patients and in 16% (95% CI:11-22) controls (p=0.15, for between groups 
comparison). In the POAG group, five patients had been previously diagnosed with OSA. 
Two of them were using CPAP. One participant in the control group had a prior diagnosis 
of OSA and was not on treatment. In the entire cohort age, male sex, BMI, neck size and 
diabetes were significant predictors of OSA in unadjusted analyses (see Appendix 8). 
There were statistically significant (or close to being statistically significant) imbalances 
between the groups for sex and age, however, each of the participants in the control 
group was successfully matched with one of 160 POAG patients (Table 3-1).  
There was no significant difference in OSA prevalence between the matched groups 
(53.8% [POAG] vs. 54.4% [Control], p=0.91). Similarly, the prevalence of moderate to 
severe OSA was not significantly different (18.1% [POAG] vs 16.3% [Control], p=0.66), 
Figure 3-2.  
The level of sleepiness and the prevalence of OSA syndrome defined by a diagnosis of 
OSA and the presence of self-reported sleepiness (ESS score ≥11) did not differ 
between the participants with and without POAG (see Table 3-1).  
Also, after excluding POAG patients with no measurable and mild visual field defects 
(stage 0, border and stage 1, according to the eGSS classification) there was no 
difference in the prevalence of OSA, and in OSA measures when the reminder of POAG 
patients were compared with the control group (see Appendix 9).  
Data on baseline IOP prior to starting IOP lowering treatment were available in 92% of 
POAG patients. Of those, 35.6% were diagnosed with NTG and the remainder with HTG 
(see Appendix 10 for the baseline characteristic of HTG vs NTG patients). The 
prevalence of OSA was not significantly different between these two subgroups (55.8% 
[NTG] versus 57.6% [HTG], p=0.89). Moderate to severe OSA was diagnosed in 16.9 % 
of NTG patients and 24.5% of HTG cases (p=0.23). To account for statistically significant 
baseline differences in gender and BMI, a multivariable logistic regression model with 
OSA status (OSA vs no OSA) as a categorical dependent variable and sex, BMI and 
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POAG subgroup (HTG vs NTG) as independent variables was build. In this model, the 
POAG subgroup was not a significant predictor of OSA (p=0.81).  
 
 
Table 3-1. Baseline Characteristics of Participants. 
 All POAG 
patients  
(n=235) 
Control 
Group 
(n=160) 
P value*  
 
Matched 
POAG 
patients 
 (n=160) 
P value† 
Baseline characteristic of participants in relation to OSA   
 
Male sex, n (%) 
Age, yr, (sd) 
White European, n (%) 
BMI, kg/m2, (IQR) 
Neck size, cm, (IQR) 
 
135 (57) 
70 (13) 
227 (97) 
27.3 (5.2) 
40 (6.0) 
 
69 (43) 
68.5 (11.8) 
156 (98) 
27.3 (6.4) 
39 (5.9) 
 
0.005 
0.056 
0.6 
0.39 
0.11 
 
73 (46) 
69 (11) 
154 (96) 
27.1 (5.6) 
39 (6.3) 
 
0.65 
0.92 
0.52 
0.52 
0.91 
 
 
Diabetes type 2, n (%) 
Hypertension, n (%) 
IHD, n (%) 
CVA, n (%) 
Atrial Fibrillation, n (%) 
 
28 (12) 
106 (45) 
25 (11) 
12 (5) 
14 (6) 
 
13 (8) 
74 (46) 
15 (9) 
7 (4) 
14 (9) 
 
0.23 
0.82 
0.68 
0.74 
0.29 
 
13 (8) 
74 (46) 
16 (10) 
5 (3) 
11 (7) 
 
1.0 
1.0 
0.85 
0.56 
0.53 
 
 
AHI, per h, (IQR) 
ODI, per h, (IQR) 
T90, %, (IQR) 
MeanSpO2, %, (IQR) 
MinSpO2, %, (IQR) 
#Sleep Time, h, (IQR) 
∞Time in Bed, h, (IQR) 
 
ESS score, (IQR) 
ESS score ≥11, n (%) 
OSAS, n (%) 
STOP-Bang score, (IQR) 
 
6 (10.8) 
4.1 (7.5) 
17 (82) 
93 (1.9) 
85 (6) 
7.3 (1.5) 
7.6 (1.2) 
 
6 (6) 
31 (13) 
19 (8) 
4 (3) 
 
5.7 (9.7) 
3.3 (7.1) 
15 (76) 
92.8 (2.0) 
86 (6.0) 
7.3 (1.3) 
7.6 (1.4) 
 
5 (6.0) 
26 (16) 
14 (9) 
3 (3) 
 
0.26 
0.29 
0.48 
0.98 
0.5 
0.55 
0.42 
 
0.92 
0.4 
0.84 
0.19 
 
5.2 (8.5) 
3.7 (6.4) 
15 (80) 
93 (2.0) 
86 (6.0) 
7.3 (1.5) 
7.6 (1.2) 
 
5 (5) 
16 (10) 
10 (6) 
3 (3) 
 
0.96 
0.79 
0.76 
0.72 
0.73 
0.92 
0.28 
 
0.35 
0.1 
0.4 
0.8  
 
Baseline characteristic of participants in relation to ocular parameters&  
 
MD, dB, (IQR) 
 
-3.6 (6.7) 
 
-0.7 (2.1) 
 
0.00 
 
-3.3 (6.9) 
 
0.00 
VFI, %, (IQR) 93 (18) 99 (1.0) 0.00 93 (18) 0.00 
cRNFL, μm, (sd) 68.6 (15.8) 93.9 (11.1)  0.00 68.6 (15.8)  0.00 
CDR, (IQR) 0.8 (0.3) 0.4 (0.2) 0.00 0.8 (0.3) 0.00 
      
*For the difference between All POAG patients and Control Group  
†For the difference between Matched POAG patients and Control Group 
 #Self-reported estimated sleep time 
∞Device recorded time in bed.  
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& Based on data from both eyesDefinition of abbreviations: BMI=body mass index, 
IHD=ischaemic heart disease, CVA=cerebrovascular accident, AHI=apnoea-hypopnoea 
index (the measurement of reduction and cessation of airflow per hour), ODI=oxygen 
desaturation index ( the number of 4% oxygen dip per hour), T90=time spent with oxygen 
saturation less than 90%, MeanSpO2=mean oxygen saturation, MinSpO2=minimum 
oxygen saturation, ESS=Epworth Sleepiness Scale, OSAS=obstructive sleep apnoea 
syndrome (AHI≥5 and ESS1≥11), STOP-Bang is a questionnaire used to evaluate the 
likelihood of OSA. It consists of questions about: snoring, tiredness/sleepiness/fatigue, 
witnessed apnoeas, hypertension, BMI, age, neck circumference and gender. The 
minimum score is 0 and the maximum 8, MD=mean deviation, VFI=visual field index, 
cRNFL=circumpapillary retinal nerve fibre layer thickness, CDR= cup to disc ratio 
(determined by the optometrist based on a slit lamp examination). 
 
 
Figure 3-2. Distribution of participants in the matched POAG and the control group 
according to OSA severity. 
 
Definition of abbreviations: POAG=primary open-angle glaucoma, OSA=obstructive 
sleep apnoea. 
49 
 
 
3.3.2  Associations between OSA and ocular parameters  
After exclusion of participants with treated OSA and ocular co-morbidities, data from 216 
POAG patients and 153 control subjects were available for the association analysis. 
The POAG group consisted of patients with all stages of functional visual field impairment 
(Figure 3-3). According to the chosen classification, Stage 0 represents no detectable 
visual field defect and the higher the stage the more severe the visual field loss.  
All visual field tests were reliable (false negative errors <20%, false positive errors <20%, 
fixation loses<33%) and there were no missing data. In an ordinal logistic regression 
analysis, AHI was not a significant predictor of the disease severity stages (p=0.40), 
Figure 3-4. To assess whether there was a relationship between AHI and the structural 
damage I used linear regression models. Subjects with missing data or inadequate 
quality images were not included in the models (for further details see Appendix 9). The 
AHI did not predict RNFL thinning in an unadjusted model and remained non-significant 
in a multivariable model. Highest ever recorded IOP, IOP measured at the study visit, 
and corneal hysteresis were independently associated with RNFL thickness. I 
constructed similar linear regression models in the control group and found no significant 
associations between AHI and RNFL thickness.  In a multivariable model, older age, 
male sex and higher degree of myopia were the only independent predictors of RNFL 
thinning (Table 3-2).  
Furthermore, there was no difference in the global RNFL thickness between people with 
and without OSA in both groups. The global RNFL thickness did not differ even when 
participants without OSA were compared with those with moderate to severe OSA (Table 
3-3). 
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Figure 3-3. Severity of functional damage among recruited POAG patients (unmatched 
POAG group) based on the Enhanced Glaucoma Staging System (eGSS). For each 
patient the eye with the lower MD was selected.  
 
 
Mean Deviation (MD) (median ±IQR) for each POAG severity stage: 
Stage 0: -1.1±0.77 dB, Border: -1.7±0.66 dB, Stage 1: -3.1±0.93 dB, Stage 2: -4.5±1.92 
dB, Stage 3: -7.3±2.1dB, Stage 4: -11.9±3.9 dB, Stage 5: -21.3±4.7 dB. 
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Figure 3-4. Distribution of AHI across POAG severity stages (Error bars represent 95% 
CI). Data analysed in an unmatched POAG group.  
 
Definition of abbreviations: AHI=apnoea-hypopnea index, 
POAG=primary-open angle glaucoma. 
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Table 3-2. Summary of the linear regression models for the associations between AHI 
and global RNFL thickness. All models were constructed in unmatched groups following 
exclusions described in Appendix 11.  
Model N Adjusted  
R2 
Beta t value  P value  95% CI 
  
 
POAG 
      
Unadjusted: AHI 202 0.004 0.095 1.4 0.18 -1.6 to 8.5 
 
Fully adjusted: 189 0.16   0.000  
        AHI   0.003 0.41 0.97 -0.18 to 0.19 
        IOPpeak   -0.23 -3.2 0.002 -0.77 to -0.18 
        IOPcurrent   0.29 3.9 0.000  0.48 to  1.5 
        Hysteresis    0.24 3.0 0.003  0.55 to  2.6 
        CVS   -0.13 -1.9 0.061 -8.10 to  0.19 
        Male sex   -0.12 -1.8 0.074 -3.50 to  7.6 
        Age    0.011 0.144 0.9  -0.23 to  0.26 
        CCT   0.048 0.65 0.52 -0.04 to  0.08 
        SER   0.058 0.77 0.44 -0.46 to  1.1 
 
Controls        
Unadjusted: AHI 146 .008 -0.12 -1.4 0.15 -7.4 to 1.1 
 
Fully adjusted:  131 0.2   0.000  
       AHI   0.01 0.13 0.9 -0.14 to 0.16 
       SER   0.34 4.4 0.000 0.9    to 2.4 
       Male sex   -0.27 -3.4 0.001 -9.2   to -2.4 
       Age   -0.16 -2.1 0.041  -3.8   to -0.01 
Definition of abbreviations: RNFL=retinal nerve fibre layer, AHI=apnoea-hypopnea 
index, N=number of subjects in the model (subjects without missing data), CI=confidence 
interval, AHI=apnoea-hypopnea index, IOPpeak=highest ever recorded intraocular 
pressure, IOPcurrent=intraocular pressure recorded at the study visit, SER= Spherical 
Equivalent Refraction, CCT=central corneal thickness, CVS=cardiovascular co-
morbidities (at least one of the following: diabetes, hypertension, ischemic heart disease, 
atrial fibrillation, cerebro-vascular accident, heart failure, over 20 pack year smoking 
history. 
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Table 3-3. Retinal Nerve Fibre Layer thickness according to OSA status. Data analysed 
in unmatched groups following exclusions described in Appendix 11. 
 *For the difference between No OSA (AHI<5) and OSA (AHI≥5). 
† For the difference between No OSA (AHI<5) and moderate to severe OSA (AHI≥15). 
Definition of abbreviations: OSA=obstructive sleep apnoea, RNFL= Retinal Nerve Fibre 
Layer. 
 
 
3.3.3  Assessment of the STOP-BANG questionnaire in detecting OSA in POAG patients 
and controls.  
The diagnostic performance of the STOP-BANG questionnaire was first analysed in the 
matched POAG group. Of the 160 POAG patients 109 (68%) had scores of ≥3 (Figure 
3-5). The AUC in the matched POAG group for predicting the diagnosis of OSA (AHI≥5) 
was only 0.64 (95% CI: 0.56–0.71, p=0.001). The Youden’s index indicated an optimal 
cut off point at the score of ≥3 but the associated sensitivity, specificity, positive predictive 
values and negative predictive value were low: 58%, 66%, 67% and 58%, respectively 
(also see Appendix 12). The questionnaire had no predictive value for moderate to 
severe OSA (AUC=0.56, p=0.30, 95% CI: 0.48-0.64). In the whole cohort of POAG 
patients (n=235) the AUC for the diagnosis of OSA also indicated poor discriminative 
value (AUC=0.61, p=0.004, 95% CI 0.54 to 0.67) and no discriminative value for 
predicting moderate to severe OSA (AUC=0.54, p=0.32, 95% CI: 0.48 to 0.61).  
The questionnaire performed better in the control group but still had only fair 
discriminative ability (AUC=0.75, p<0.001, 95% CI: 0.68 to 0.82 for AHI≥5 and 
AUC=0.78, p<0.001, 95% CI: 0.71 to 0.85 for AHI≥15). The differences between the 
matched groups in AUC were statistically significant (ΔAUC=0.112, p=0.049 for AHI≥5 
and ΔAUC=0.223, p=0.003 for AHI≥15) (Figure 3-6).  
 
 
 
 
 
 No OSA OSA P value* Moderate to 
Severe OSA 
P value† 
POAG group        
Global RNFL (μm) 62.6 (14.7) 63.9 (14.3) 0.54 65.2 (15.2) 0.37 
 
Control group      
Global RNFL (μm) 94.8 (11.1) 92.5 (10.5) 0.2 94.8 (9.9) 0.99 
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Figure 3-5. Distribution of STOP-BANG scores in matched POAG patients and 
proportions of patients diagnosed with obstructive sleep apnoea (OSA). 
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Figure 3-6. Receiver operating curves (ROC) for STOP-Bang to predict AHI≥5 and 
AHI≥15 in matched groups (top graphs) and in all POAG patients (bottom graphs). 
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A dissection of the STOP-BANG questionnaire items in relation to the distribution of 
these variables in the examined matched cohorts of participants and their individual 
predictive values sheds some light on the potential roots of the overall poor predictive 
performance of the questionnaire, particularly in the POAG group. For instance, the 
questionnaire uses age cut off >50 years. Only 2.5% of POAG patients 3.8% of controls 
were below this age, all others scored one point on this item. The threshold for BMI is 
set at >35kg/m2. Only 3.8% of POAG patients and 9.4% of the control subjects reached 
this threshold. Also, a logistic regression analysis run separately in each group indicates 
that, in contrast to expectations, male sex was not a significant predictor of OSA in either 
group (POAG: OR 1.6, 95% CI: 0.87 to 3.1, p=0.13, Controls: OR 1.77, 95% CI: 0.93 to 
3.3, p=0.08) and hypertension was associated with OSA only in the control group 
(POAG: OR 1.54, 95% CI: 0.82 to 2.88, p=0.18, Controls: OR 3.44, 95% CI: 1.78 to 6.65, 
p=0.000). Therefore, at least 4 items of this questionnaire in the POAG cohort and 3 in 
the control group were probably of limited contribution to its overall predictive ability.  
  
3.4 Discussion 
3.4.1 OSA prevalence  
Based on plausible pathophysiological mechanisms and some epidemiological data it 
has been hypothesised that OSA may play a role in the development and progression of 
glaucomatous optic nerve neuropathy (121,161,166,167). According to this hypothesis, 
a high OSA burden could be expected among glaucoma patients and there would be a 
rational to evaluate screening for OSA. In the current study of unselected POAG patients 
prospectively examined with a diagnostic test for SDB in a real-world clinic scenario, I 
found no evidence that patients with POAG are more likely to suffer from OSA or have 
more severe OSA than control subjects. After statistical matching of participants with and 
without glaucoma, the prevalence of OSA was remarkably close between the groups. In 
addition, I have found no difference between the groups in several markers of nocturnal 
hypoxia associated with OSA and the levels of subjective sleepiness (when considered 
on its own or in a combination with OSA diagnosis as OSA syndrome) were similar. This 
indicates that if routine OSA screening was to be implemented in glaucoma clinics the 
yield of patients who would then be considered for OSA treatment, according to the 
current clinical practice, would be the same as in the general population of middle to 
elderly aged people. The reported prevalence of OSA (defined as ≥5 AHI) in the general 
adult population varies widely from 9 % to 38% (68). There are multiple reasons for these 
differences across the studies. Of particular importance are population specific factors, 
such as: age, ethnicity and the prevalence of obesity. There are also factors related to 
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OSA measurement techniques including the type of sleep study used and the scoring 
criteria for respiratory events which have changed several times in the last two decades. 
This highlights the importance of having a well matched concurrent control group and 
using the same diagnostic tools whenever OSA prevalence is studied in disease-specific 
cohorts of patients. 
Although the OSA prevalence figures found in the current study in both groups seem 
high they are in keeping with relatively high rates of OSA reported in older people. For 
instance, in a study from Iceland OSA (AHI ≥5) was found in 43.1% of participants aged 
40-65 years who were also examined with type 3 sleep study (65). In a slightly older 
(mean age of 68 years) French cohort,  57% of participants were diagnosed with OSA 
(AHI ≥15) based on the same type of sleep study(168). The largest to date population 
based study conducted in Switzerland which used a more sensitive type 2 sleep study 
(unsupervised full polysomnography) found OSA (AHI ≥5) in 84% of people aged 60-85 
years (169).  
Previous prospective studies assessed the prevalence of OSA among POAG patients 
but had important methodological limitations related to small sample sizes, pre-selecting 
patients based on symptoms, including historic control groups, using only low-grade 
sleep tests or indeed just questionnaires to assess for possible OSA (131–133,137,162). 
Most of these studies suggested that OSA may be more common in patients with POAG 
but Roberts et al. who performed nocturnal oximetry on the largest previously published 
sample (52 POAG patients and 60 control subjects) found no significant differences in 
SDB prevalence. In their study, 17% of POAG subjects and 12% of controls were 
diagnosed with SDB based on a 4% oxygen desaturation index (ODI) above 20. The 
current study has the added value of a larger sample size, multichannel sleep tests which 
allowed me to assess SDB more accurately and a concurrent control group who had 
glaucoma excluded based on a detailed ocular examination.  
Although, it has been suspected that OSA may be particularly relevant in NTG where 
retinal ganglion cell apoptosis seems less IOP dependent, in this study the prevalence 
rates of OSA were not different when patients with NTG and HTG were compared. I have 
found no previous studies which directly compared OSA burden between patients with 
NTG and HTG.  
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3.4.2 AHI and RNFL thickness  
To further explore the relationship between OSA and POAG I examined potential 
associations between AHI and RNFL thickness. Despite adjusting for factors which were 
likely to have a dominant effect on RNFL thickness, including IOP, I have not found AHI 
to be a predictor of RNFL thinning in POAG patients or in the control group. Furthermore, 
the RNFL thickness was similar when people with moderate to severe OSA were 
compared with participants without OSA separately in both groups. Previous studies 
have assessed RNFL thickness in relation to OSA in people with otherwise healthy eyes. 
Most reported thinner RNFL in people with OSA as summarized in three recent meta-
analyses (170–172). The relationship between AHI, or other markers of OSA, and RNFL 
was rarely examined in the source papers for these meta-analyses, and when it was the 
models were not adjusted for other important RNFL predictors (173,174). Nevertheless, 
the findings of the current study cannot be simply compared with the previous studies 
due to a different cohort of subjects in our control group. In contrast with the previous 
studies which exclusively recruited people who presented to sleep centres with OSA 
symptoms (and therefore may have represented enriched samples of patients also at 
higher risk of systemic effects of OSA), the control group in this study consisted of a 
population-based sample of largely asymptomatic participants screened for OSA. Thus, 
it is possible that patients with only certain OSA phenotypes are at risk of aggravated 
RNFL loss. It is also noteworthy that the control subjects were older than in most previous 
studies. As RNFL thickness declines with age and older people are more likely to suffer 
from hypertension and atherosclerosis which can also potentially affect RNFL, it may 
have been more difficult to appreciate the impact of OSA in the current control group.   
 
3.4.3 STOP-BANG questionnaire as a screening tool for OSA in POAG patients 
When validated against a type 3 sleep study STOP-BANG scores did not discriminate 
well between the presence or absence of OSA in patients with POAG. This is evidenced 
by the low AUC and the lack of a cut off score with acceptable sensitivity and specificity. 
Any screening tool used to risk stratify patients to those who require further investigations 
and those in whom a condition can be confidently ruled out must have a high sensitivity. 
A STOP-BANG score of 3 and above is considered to represent a higher risk of OSA 
prompting further evaluation with a sleep study.  In the original validation study of surgical 
patients this cut-point had a sensitivity of 84% for AHI≥5 and 93% for AHI≥15 (142). 
Surprisingly, in the current study the questionnaire performed better for the lower rather 
than the higher AHI cut off in POAG patients.  However, it still had unacceptably low 
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sensitivity of 58% for the score of 3 which would give false reassurance to a substantial 
proportion of patients that they do not require further investigations. With higher scores 
the sensitivity fell dramatically. Moving the cut-point to 2 increased the sensitivity only to 
77% and, irrespective of this, would not be helpful in the examined population as the vast 
majority of patients had a score of at least 2. For instance, with a lower threshold nearly 
all male patients with POAG would be deemed at high risk of OSA based on sex and 
age alone.  
An older age, lower BMI and high prevalence of hypertension in the examined cohorts 
of patients in the current study compared to the surgical population could explain the 
worse predictive performance of the STOP-BANG questionnaire. Thus, recalibration of 
the questionnaire by either changing the cut offs for some items or reweighting the scores 
based on odds ratios estimated by logistic regression analysis could be attempted to 
align it with the characteristics of the examined population. However, this may not be 
sufficient to improve the diagnostic accuracy of the scores in the POAG group. The 
reasons behind significantly worse discriminative ability of STOP-BANG in POAG 
patients compared to matched controls are not entirely clear and may be related to other 
inherent risk factors not captured by the questionnaire. On the contrary, items which 
have been shown to predict the risk of OSA in other cohorts may have no predictive 
value in POAG patients. For instance, I cannot explain why hypertension was 
significantly associated with OSA in the control group but not in matched and unmatched 
POAG groups. A hypothesis that systemic hypertension in POAG patients is not driven 
or contributed by OSA could be formulated and set another direction for future research.  
 
3.4.4 Limitations  
The main limitation of this study is its cross-sectional design. Although we have recruited 
a representative sample of patients with all stages of glaucoma severity I cannot rule out 
the possibility that OSA contributes to POAG progression. OSA is not consistently 
present throughout the person’s lifetime but develops largely as a function of weight gain 
and aging. Therefore, whilst it is unlikely that OSA is a potent enough risk factor to alone 
cause glaucomatous optic neuropathy, particularly in people who had it for a relatively 
short period of time, it is still possible that it may promote the neural damage in those 
who have already developed glaucoma as a result of other risk factors. This can be 
determined only in a longitudinal study. 
We invited all consecutive glaucoma patients without prior knowledge of their sleep 
history but, since 58% of those invited declined study participation, I cannot exclude 
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selection bias. Further, because of the nature of our recruitment pathways in the control 
group I could not ascertain the proportion of potentially eligible subjects who were invited 
via the glaucoma patients but declined to take part in the study. Therefore, it was not 
possible to compare the actual recruitment rates between the groups. It could be argued 
that glaucoma patients were more likely to take part in the study even though they had 
no sleep related symptoms because of the long-term relationship with the health care 
provider and perceived benefits of contributing to a research into the disease which 
affected them. On the contrary, the control subjects may have been incentivised to enrol 
only if they had relevant sleep complaints. This could lead to underestimation of OSA 
prevalence in the POAG group and its overestimation in the control group. However, 
against this hypothesis there are no differences detected between the groups in the ESS 
which assesses subjective sleepiness, a cardinal symptom of OSA, and the STOP-
BANG questionnaire which incorporates questions about snoring, tiredness and 
witnessed apnoeas. It is also worth noting that spouses of glaucoma patients who took 
part in this study constituted 85% (spouses and friends-99%) of the control group and 
there were no recruits among relatives of those glaucoma patients who declined study 
participation. This indicates that glaucoma patients and their spouses were willing to 
contribute to this research as couples and this may have helped to reduce the risk of 
selection bias at least for the between group comparisons. If the selection bias did occur, 
most likely it would have affected the OSA prevalence rates in both groups in the same 
direction, although I cannot exclude other possible scenarios.  
The study recruited the originally planned number of POAG patients but under-recruited 
control subjects. The decision to terminate the study after reaching the desired number 
of POAG patients was based on minimal differences in OSA prevalence observed 
between the groups with largely overlapping confidence intervals and no indication from 
a simulation analysis that increasing the precision of the estimated parameter by 
recruiting a larger sample of controls would alter the significance of the comparisons. 
Even with a smaller sample of control subjects this is still the largest reported study of its 
kind. 
Finally, as over 90% of recruited patients were of white European origin the findings of 
this study are not generalisable to other ethnic backgrounds.  
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3.5 Conclusions  
In conclusion, based on the prevalence analysis and assessment of associations 
between OSA and POAG markers this study found no evidence to support the 
hypothesis that OSA causes glaucoma. In light of these findings the systematic 
screening of POAG patients for OSA cannot be recommended. The STOP-BANG 
questionnaire has poor diagnostic accuracy to detect OSA in these patients and in its 
current form should not be used as a screening tool. Future longitudinal studies should 
address the question of whether untreated OSA is associated with faster rates of 
glaucoma progression. The next Chapter is dedicated to examining this problem.   
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Chapter 4: Is OSA a risk factor for reduction of Retinal Nerve 
Fibre Layer Thickness in Primary Open-Angle Glaucoma? 
Longitudinal data.  
 
Null hypothesis:  
iv. A longitudinal change in RNFL thickness in POAG patients with OSA is the 
same as in those without OSA.  
 
4.1 Introduction 
The retinal nerve fibre layer (RNFL) is the innermost layer of the retina. It is formed by 
the retinal ganglion cell axons which connect the outer neuroretina to the dorsal lateral 
geniculate nucleus of the thalamus(175). Repeated RNFL evaluation is currently an 
integral part of glaucoma monitoring. It allows for an early detection of the disease and 
its progression, often several years before the corresponding visual field loss ensues. 
Peripapillary RNFL thinning observed over time represents progressive loss of retinal 
ganglion cell axons and can be quantitatively measured with several different techniques 
currently available. Of these, the spectral-domain optical coherence tomography (SD-
OCT) is probably the most precise (176). The structural OCT measurements are highly 
reproducible, relatively easy to obtain and, unlike visual field tests, do not rely on 
subjective responses of the patient (177,178). These characteristics make OCT a useful 
tool in examining the impact of OSA on glaucoma and potentially other 
neurodegenerative disorders such as Alzheimer’s disease which also affect the optic 
nerve (179). Cerebrovascular insufficiency, hypoxia and oxidative stress associated with 
OSA may contribute to premature and accelerated degeneration of retinal ganglion cells 
which due to their high metabolic activity are particularly sensitive to oxygen and energy 
depletion(53). Loss of retinal ganglion cells and their axons would lead to the structural 
changes detected by the OCT. 
As discussed in Chapter 3, several previous cross-sectional studies which examined 
RNFL thickness in OSA patients without glaucoma reported contradictory findings. Some 
of them found thinner RNFL in OSA subjects while others, including the study described 
in the previous Chapter, showed no relationship between RNFL thickness and OSA 
status or AHI (174,180–188). Differences between the studies in terms of demographics 
of recruited participants, the RNFL measurement techniques and whether or not other 
factors known to affect RNFL thickness were accounted for could partly explain the 
discordant outcomes. Nonetheless, the major limitation of cross-sectional studies is that 
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they only offer a snapshot of a single moment in the disease process without considering 
the temporal changes in the examined variables. In the case of OSA, one of the main 
challenges is that it is difficult to determine how long the individual patient has been 
affected by it. In addition to OSA severity, its duration, that is the exposure time to chronic 
intermittent hypoxia and other pathophysiological consequences of interrupted nocturnal 
ventilation, is likely to be an important determinant of its potential to cause end-organ 
damage. In terms of POAG, one-off measurements of RNFL may simply represent the 
end product of previously elevated IOP making it difficult to detect less potent risk factors. 
Longitudinal studies which measure changes in RNFL thickness over a period of time 
which is relatively close to a diagnostic sleep test and in patients previously established 
on hypotensive treatment to reduce the confounding effect of IOP would stand a better 
chance of more accurately assessing for the hypothesised contribution of OSA to the 
structural optic nerve damage.  
The purpose of this Chapter is to examine whether POAG patients with untreated OSA 
have greater loss of RNFL during the monitoring period than those without OSA.  
 
4.2 Methods  
4.2.1 Study design and procedures 
This was a retrospective analysis of longitudinal OCT data acquired as part of a routine 
follow up in the Glaucoma Clinic of POAG patients who took part in the POSAG study 
and underwent a prospective diagnostic sleep test for OSA as well as a comprehensive 
ocular examination described in Chapter 3. All 240 POAG patients who had successfully 
completed the POSAG study were screened for eligibility to this analysis.  
 
The following enrolment criteria were applied:  
Inclusion criteria  
1. A minimum of 3 years of OCT follow up data at the point of data extraction which 
took place approximately 6 months after recruitment to the POSAG study had 
finished.  
2. OCT scans of adequate quality. The image quality was assessed at the point of 
data extraction. Images with RNFL segmentation errors, inaccurate optic disc 
margins delineation, low signal strength and artifacts were excluded.  
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Exclusion criteria 
1. Patients diagnosed with central sleep apnoea. 
2. Patients who received treatment for OSA.  
3. Eyes with co-morbidities which could affect RNFL thickness, including: retinal 
vascular disease, diabetic retinopathy, age-related macular degeneration, prior 
retinal detachment, advanced cataract or neurological scotomas.  
 
For each patient, both eyes were included in the analysis provided they individually 
satisfied the eligibility criteria.  
All scans were acquired using Spectralis OCT (Heidelberg Engineering Inc. MA, USA), 
an SD-OCT scanner described in Chapter 2. This device was first introduced in the 
Glaucoma Clinic approximately 6 years before recruitment to the POSAG study started 
and gradually replaced the HRT (Heidelberg Retina Tomograph) device previously used 
for structural assessment of the optic nerve. Therefore, for the majority of patients less 
than 3 years of OCT follow up data were available. However, a minimum of 3 years of 
observation was thought to be required to detect measurable RNFL changes which could 
be attributed to glaucoma progression. This is in keeping with a monitoring period 
selected in other studies which investigated structural glaucoma progression (189–191). 
Data on global and quadrant specific (superior, temporal, inferior and nasal) 
circumpapillary RNFL thickness were extracted from the first and the last available 
adequate quality scans. Progression was determined by RNFL thickness change over 
the monitoring period and was calculated as the difference in RNFL thickness between 
the most recent and the first available scans divided by the number of follow up years 
(RNFLlast [μm]-RNFLbaseline [μm]/years) (see Figure 4-1 for an example of Spectralis OCT 
output for a patient with progressive RNFL loss).   
This analysis was performed under the ethical approvals granted for the POSAG study 
(East of England-Cambridgeshire and Hertfordshire Research Ethics Committee; REC 
number 15/EE/0292 and the Anglia Ruskin University Research Ethics Panel; ref. 15/16 
014, Appendix 5).  
 
 
 
 
 
Figure 4-1. Example of peripapillary OCT scans demonstrating progressive RNFL loss 
in a POAG patient with moderate OSA (AHI=27).  
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First scan: 27.03.2012 
 
 
Last scan: 08.01.2018 
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4.2.2 Statistical analysis  
All analyses were conducted using SPSS software version 22.0 (IBM SPSS, IL, USA). 
The level of significance was set at p < 0.05. Baseline continuous data are presented as 
mean (SD) or median (IQR) depending on the distribution. Categorical data are reported 
as percentages. Comparisons of clinical characteristics between the groups, with the 
exception of ophthalmic variables, were performed using independent-samples T-test or, 
if the data were not normally or approximately normally distributed, and in case of 
categorical variables, using the Mann-Whitney U test.  
For ophthalmic data analysis the generalized estimating equation (GEE) method was 
used to account for correlation between the two eyes of the same patient. To establish 
whether OSA status (OSA vs no OSA) is a significant predictor of RNFL thickness 
change a univariate linear regression model was developed within the framework of 
GEE. This model was subsequently adjusted for variables previously associated with 
RNFL loss, including: age, IOP, cardiovascular co-morbidities, baseline RNFL thickness, 
previous filtration surgery and corneal hysteresis (190,192–197).  
The GEE method is a population-level approach based on a quasilikelihood function and 
provides the population-averaged estimates of the parameters when accounting for 
correlated measurements (198). In order to confirm the significance of RNFL loss 
associated with OSA and obtain study subjects-specific estimates an additional 
multivariable model was constructed using the linear mixed-effects method which 
explicitly accounts for the correlations between paired eyes of subjects by adding a 
random effect (random intercepts and coefficients of subject and eye) in addition to the 
fixed effects (the examined predictors of interest). The model provides the conditional 
mean of the outcome given covariates and random effects.  
In addition, the analysis of variance (mixed model ANOVA) was used to compare RNFL 
thinning between OSA severity categories.  
 
4.3 Results  
A total of 167 eyes of 88 POAG patients were included in the analysis (Figure 4-2). 
Obstructive sleep apnoea was diagnosed in 54.5% of them and was moderate to severe 
in 21.6% of all patients. The median time separating the first and the last RNFL 
measurements was 4 (IQR-2.0) years and 66% of patients included in the analyses were 
diagnosed with POAG and established on hypotensive treatment before the first OCT 
scan used in this analysis was obtained. For between-group comparisons of baseline 
characteristics and the distribution of follow up periods in relation to the diagnostic sleep 
test please see Table 4-1 and Figure 4-3, respectively. 
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In keeping with the results reported in Chapter 3 for the cross-sectional associations 
between OSA and RNFL thickness, the AHI or the OSA status were not significant 
predictors of RNFL measured during the study visit (p=0.59 and p=0.081, respectively).  
However, average global RNFL thickness loss was significantly greater in patients with 
OSA than those without OSA (-1.1 ±1.5 μm/year versus -0.6 ±1 μm/year, respectively, 
p=0.013). The largest differences in RNFL thinning between the groups were observed  
in the superior and inferior quadrants (Table 4-2). On average, the greatest longitudinal 
changes in RNFL thickness were noted in people with severe OSA but the OSA severity 
categories and AHI were not significantly correlated with  global RNFL thinning (Table 4-
3 and Table 4-4). In a multivariable model adjusted for age, IOP, baseline RNFL 
thickness, corneal hysteresis, previous trabeculectomy, and a composite variable of 
cardiovascular co-morbidities, OSA status was independently associated with global 
RNFL progression (see Table 4-3 for the GEE model and Appendix 13 for the linear 
mixed effects model). The other significant predictors of RNFL loss in both models were: 
higher baseline RNFL thickness and cardiovascular co-morbidities. Higher IOP 
measured at the study visit was significantly associated with greater RNFL decline only 
in the linear mixed effects model. The peak IOP was a redundant co-variant in both 
models not associated with RNFL thinning (Beta= -0.01, p=0.48, GEE univariate model) 
and due to its correlation with the IOP measured at the study visit was removed from the 
adjusted models. The proportions of NTG patients among people with and without OSA 
were not different (Table 4-1) and there was no statistically significant interaction 
between OSA status (OSA vs No OSA) and the two POAG subgroups (NTG vs HTG) in 
relation to the change in RNFL thickness (GEE model; OSA vs No OSA*NTG vs HTG, 
p=0.63) which indicates that OSA does not preferentially affect structural progression in 
NTG patients (also see Table 4-5).  
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Figure 4-2. Study Flow Chart  
 
Abbreviations: POAG= primary open-angle glaucoma, OCT=ocular coherence 
tomography, CPAP=continuous positive airway pressure.  
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Table 4-1. Baseline characteristics of participants included in the RNFL loss analysis.  
 No OSA OSA P value  
Patients, n (%) 40 (45.5)  48 (54.5)  
Eyes, n (%) 75 (44.9) 92 (55.1)  
Demographics     
Male Sex, n (%) 16 (40) 29 (60) 0.06 
Age (yrs), sd 66.7±9.6  70.1±8.5 0.08 
BMI (kg/m2), sd 25.9±3.5 28±4.4 0.02 
OSA indices    
AHI (per h), IQR 2.25±2.2 11.8±12.8 0.000 
Mean SpO2 (%), sd 93.2±1.5 92.3±1.3 0.008 
T90% (%), IQR 4±50 45±105.8 0.002 
Ocular indices    
MDstudy visit (dB), IQR -3.5±5.7 -4.0±6.8 0.099 
#RNFL thickness baseline (μm), sd 73±16.5 69.8±19 0.25 
RNFL thickness study visit (μm), sd 70.9±18.4 66.1±17.1 0.08 
IOPcurrent (mmHg), sd 14.3±4.4 14.7±4.8 0.68 
IOPsupine (mmHg), sd  16.5±3.16 16.9±3.4 0.57 
IOPpeak (mmHg), sd 22.4±5.1 24±5.3 0.13 
CCT, (μm), sd 547±40.6 547.6±29.9 0.56 
SER (D), sd -0.98±3.2 -0.97±4.3 0.99 
High myopia, n (%) 8 (14.8) 12 (15.4) 0.93 
Hysteresis (mmHg), sd 9.1±2.3 8.9±2 0.6 
Filtration surgery, n(%) 20 (25) 23 (24) 0.96 
Other data    
Duration of OCT follow up, years, (sd) 4.7 ±1.4 4.3±1.2 0.18 
NTG, n (%) 15 (37.5) 12 (25.5) 0.25 
*Cardiovascular co-morbidities, n(%) 21 (43.8) 27 (56.3) 0.56 
    Abbreviations: RNFL=retinal nerve fibre laye, AHI=apnoea-hypopnoea index, T90=time 
spent with oxygen saturation less than 90%, MeanSpO2=mean oxygen saturation, 
IOPcurrent=intraocular pressure recorded at the study visit using Goldmann tonometer, 
IOPsupine=intraocular pressure measured with IcarePro tonometer in a supine position 
(after 15 min lying down) at the study visit, IOPpeak=highest ever recorded intraocular 
pressure,  CCT=central corneal thickness, NTG=normal tension glaucoma (POAG 
patients who never had IOP recorded above 21mmHg in either eye), *Cardiovascular co-
morbidities =at least one of the following: diabetes, hypertension, ischemic heart 
disease, atrial fibrillation, cerebro-vascular accident, heart failure, over 20 pack year 
smoking history, #Global RNFL thickness measured on the first scan included in the 
progression analysis, SER= Spherical Equivalent Refraction, High myopia; SER≤ -4.0 D.  
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Figure 4-3. OCT follow up time in relation to the diagnostic sleep test in individual 
patients. 
 
 
 
 
Table 4-2. RNFL thickness loss (μm/year) in OSA vs non-OSA group (GEE model).  
               No OSA                 OSA P value 
Mean±SD    95% CI Mean±SD 95% CI 
Average Global RNFL -0.6±1 -0.85 to -0.36 -1.12±1.5 -1.4 to -0.8 0.013 
      
Superior quadrant -0.59±2.1 -1.06 to -0.11 -1.28±2.1 -1.71 to -0.85 0.034 
Nasal quadrant -0.4±1.6 -0.75 to -0.05 -0.6±2.3 -1.06 to -0.13 0.5 
Inferior quadrant -0.86±2.4 -1.41 to -0.32 -1.77±2.9 -2.37 to -1.17 0.028 
Temporal quadrant -0.58±2.5 -1.16 to -0.01 -0.87±1.8 -1.25 to -0.5 0.4 
      Abbreviations: RNFL=retinal nerve fibre layer, OSA=obstructive sleep apnoea  
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Table 4-3. Summary of GEE regression models examining the association between 
OSA status and the global RNFL thinning [RNFLlast-RNFLbaseline, μm/year ], (n=167 
eyes). 
Model Beta Standard 
Error 
95% CI Wald Chi-
Suare 
P 
value  
 
Unadjusted: 
     
OSA  
(reference to no OSA) 
-0.51 0.21 -0.91 to -0.11 6.2 0.013 
AHI -0.5 0.28 -1.0 to 0.04 3.2 0.072 
Adjusted      
OSA  
(reference to no OSA) 
-0.62 0.21 -1.0 to -0.21 8.7 0.003 
CVS co-morbidities 
(reference to no CVS co-
morbidities) 
-0.47 0.23 -0.92 to -0.03 4.3 0.039 
Baseline RNFL thickness  -0.016 0.0063 -0.03 to -0.003 6.3 0.012 
IOPcurrent -0.062 0.036 -0.13 to 0.01 2.9 0.09 
Previous filtration surgery 
(reference to no surgery)  
-0.39 0.34 -1.1 to 0.27 1.4 0.245 
Corneal Hysteresis 0.038 0.039 -0.038 to 1.1   0.97 0.326 
Age 0.01 0.012 -0.013 to 0.03 0.74 0.39 
      
       Abbreviations: OSA= obstructive sleep apnoea, Baseline RNFL thickness measured on 
the first scan included in the analysis, AHI=apnoea-hypopnoea index, 
IOPcurrent=intraocular pressure recorded at the study visit, CVS=cardiovascular co-
morbidities (at least one of the following: diabetes, hypertension, ischemic heart disease, 
atrial fibrillation, cerebro-vascular accident, heart failure, over 20 pack year smoking 
history).  
 
 
Table 4-4. Average global RNFL loss (μm/year) according to OSA severity (mixed model 
ANOVA). 
 No OSA 
(n=70 eyes) 
Mild OSA 
(n=52 eyes) 
Moderate OSA 
(n=26 eyes) 
Severe OSA 
(n=10 eyes)  
P 
value 
Global RNFL loss 
 
(μm/year), sd 
-0.58±1 -0.98±1.0 -1.18±1.0   -1.32±1.01 0.15 
aAa 
 
     
Abbreviations: RNFL=retinal nerve fiber layer, OSA=obstructive sleep apnoea.  
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Table 4-5. Average global RNFL loss (μm/year ) according to POAG subgroups 
and OSA status. 
 NTG 
 
HTG 
No OSA 
 
(μm/year), sd 
-0.54±0.73 -0.64±0.8 
OSA -0.95±1.04 -1.26±1.05 
 
aAa 
 
  Abbreviations: NTG=normal tension glaucoma, HTG=high tension glaucoma 
OSA=obstructive sleep apnoea.  
 
4.4 Discussion  
This study, which is one of the first to examine the relationship between OSA and 
structural glaucoma progression, found that POAG patients with untreated OSA had 
almost twice greater RNFL thickness loss than those without OSA. Moreover, OSA 
status as a binary predictor was independent of other ocular and systemic factors 
previously associated with RNFL thinning. The lack of statistically significant correlation 
between AHI and the longitudinal RNFL change could be potentially explained by a small 
number of patients with severe OSA. Only 5 out of 88 participants were diagnosed with 
severe OSA and the median AHI among all OSA patients was relatively low at 11.8. Yet, 
there was a clear difference in RNFL progression between the groups which was not 
explained by other factors. It is possible that with a larger representation of patients with 
severe OSA a dose response effect would have been demonstrated.  
It has been proposed that OSA may be more relevant to glaucomatous neuropathy in 
patients with NTG rather than HTG (199). In fact, some studies exclusively examined the 
role of OSA in patients with NTG and excluded those with HTG (131,200,201). The 
current study found no differential effect of OSA on RNFL loss in the two POAG 
subgroups. This, in addition to the similar prevalence of OSA in NTG and HTG patients 
found in a larger sample of patients who participated in the study reported in Chapter 3, 
indicates that distinguishing these two subgroups is not necessary when the impact of 
OSA on glaucoma is examined.  
It should be noted that most patients in this study had been already diagnosed with 
POAG and started on treatment before the first RNFL measurements used in the 
analysis were acquired. It is therefore not surprising that the peak IOP, which for most 
patients was the IOP recorded at the point of diagnosis, was no longer a predictor of 
RNFL progression. It was, however, a significant predictor of RNFL thickness in the 
previous study (Chapter 3, Table 2) which indicates that the neural damage in the  cross-
sectional analysis was largely a function of historically raised IOP. Notably, the average 
IOP readings obtained just prior to the sleep test in the current study showed an effective 
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control of IOP. At that point RNFL loss may have been less IOP dependent which could 
have helped to detect the impact of untreated OSA.  
To my knowledge only one previous recently published study examined structural 
glaucoma progression in relation to OSA (202). In a retrospective design, the authors 
reviewed their PSG database and identified 25 POAG patients and 7 glaucoma suspects 
who had at least 3 years of follow up with OCT imaging. They performed an event-based 
analysis and found that the proportion of patients who progressed was significantly 
higher among those with moderate to severe OSA than in a combined no OSA/mild OSA 
group. Patients with severe OSA had 8.4-fold higher risk of RNFL progression although 
because of the small number of patients the confidence interval was wide (CI: 1.5-48.8). 
Furthermore, the analysis was not adjusted for any ocular co-variates, the rate of 
progression was not stated and a third of all patients were established on CPAP therapy 
or had undergone a surgery for OSA.  
The current study has the advantage of a larger sample size, better defined RNFL 
monitoring period in relation to the OSA diagnosis, accounting for other ocular factors 
and including only patients with untreated OSA which eliminated the potential 
confounding effect of CPAP. The results are however in agreement with the previous 
study.  
What is less certain is whether the differences in the magnitude of RNFL loss observed 
in the current study will translate into a future more severe functional visual impairment 
in OSA patients. This is not easy to predict as the correlation between longitudinal 
changes on OCT images and perimetry is generally poor with many studies reporting a 
discordance between progression defined by functional and structural outcomes 
(177,203). However, in general, faster rates of RNFL loss are associated with a higher 
risk of developing subsequent visual field defects. For instance, in a study by Yu et al. 
eyes with established POAG which progressed based on RNFL trend analysis had 8.4-
fold increased risk of developing visual filed progression (204). In terms of the reported 
average rates of RNFL thinning in relation to developing functional visual loss a 
prospective longitudinal multicentre study by Diniz-Filho et al. is one of the largest of its 
kind (205). The authors examined 547 eyes of 339 patients with treated POAG and 
glaucoma suspects who were followed up for average of 3.9 years and had repeated 
RNFL measurements with the same OCT device as the one used in the current study. 
They reported that eyes which showed progression on standard automated perimetry 
had an average rate of RNFL loss of -1.02 μm/year which compared to -0.61 μm/year 
(p=0.002) in non-progressing eyes. These progression rates are close to those reported 
in the current study which would suggest that the RNFL thinning observed in the OSA 
group may be clinically significant. Further perspective on this provides a comparison of 
the average RNFL decline among OSA subjects with age-related RNFL thickness loss 
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in people with healthy eyes which in longitudinal studies was consistently reported at -
0.5 μm/year (206,207). Thus, even before accounting for the differences in baseline 
average RNFL thickness which is much higher in people with non-glaucomatous eyes 
(100 μm in the study by Leung et al. vs 71 μm in the current study) and which is also an 
important negative predictor of RNFL loss, the estimated rate of structural progression 
in OSA patients was more than twice as fast as expected from aging alone.  
This study exclusively examined subjects with POAG and it could be concluded that OSA 
is a risk factor for progression of glaucomatous damage. Indeed, the greatest change in  
RNFL thickness and the largest differences between patients with and without OSA were 
noted in the superior and inferior quadrants which are preferentially affected in POAG 
(208–210). However, this topographic pattern is not a unique feature of POAG. It has 
also been clearly described in Alzheimer’s disease and multiple system atrophy where 
axonal loss predominantly affects the superior and inferior quadrants with relative 
sparing of the temporal and nasal regions (179). Therefore, it is also possible that the 
observed RNFL thinning is not specific to glaucomatous neuropathy but represents more 
general neurodegenerative process accelerated by chronic intermittent hypoxia. This 
hypothesis requires further examination in longitudinal studies of OSA patients without 
ocular diseases.  
The main limitation of this study is its retrospective design. The RNFL data were 
extracted from scans acquired as part of routine practice which lacks the scrutiny of 
systematic approach to progression monitoring which can be implemented in a 
prospective design. I accounted for IOP readings obtained during the POSAG study visit 
and for the highest IOP readings documented in patients’ records but not for average or 
repeated IOP measurements during the RNFL monitoring period which potentially could 
have also influenced the structural progression.  
The RNFL loss was simply calculated based on the first and the last available OCT 
scans. A similar approach was adopted in some other retrospective studies which for 
example measured the rate of visual field loss in the context of cardio-vascular diseases 
(211). The limitation of this approach is a potentially higher measurement variability of 
the calculated progression rate compared to a trend-based analysis which uses a 
regression slope to estimate the rate of change in the examined parameter. The latter 
method is less sensitive to a sudden change and the variability among consecutive tests 
which are neutralised by the overall rate of change (212). This method however 
increases the risk of ignoring true progression events when changes occur in early 
stages of monitoring and particularly when the observation period is relatively short. 
Moreover, one of the main assumptions of the trend-based analysis is that the 
progression is a linear process which may not be true for all individuals, particularly those 
with more advanced glaucomatous damage when the floor effect is likely to limit the 
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ability of structural measurements to detect the true progression rate. However, the main 
disadvantage of trend-based analysis is the requirement for a large number of tests 
before the analysis can be considered reliable. In the current study a substantial 
proportion of patients had only one or less adequate quality OCT scans per year. 
Therefore, adopting a trend-based analysis would lead to further exclusions and a lower 
number of participants. This method is however more appropriate for prospective studies 
where more frequent measurements taken at regular intervals can be organised.  
As already discussed, the relatively small number of patients with severe OSA may have 
affected the ability to detect statistically significant relationship between OSA severity 
metrics and  RNFL loss as well as the precision around the estimated size of the 
longitudinal RNFL change in the severe OSA group. In addition, due to the fact that just 
over a third of the original pool of POAG patients met the eligibility criteria for this 
analysis, I cannot exclude a selection bias.  
 
4.5 Conclusions 
This study indicates that OSA may be an independent risk factor for progressive 
structural damage of the optic nerve in patients with POAG. However, the findings should 
be confirmed in a larger prospective study, ideally with concomitant rigorous monitoring 
for visual field progression. At present it is unclear whether the magnitude of structural 
damage which can be attributed to OSA is large enough to cause noticeable visual loss 
in peoples’ lifetime.  
It is possible that RNFL thickness could also be a useful surrogate marker in examining 
the role of OSA in the development and progression of other neurodegenerative 
disorders. For this, however, the impact of OSA on longitudinal RNFL changes should 
be first assessed also in people with healthy eyes.  
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Chapter 5: CPAP related intraocular pressure increase at 
night in people with and without glaucoma (PAIR II study).  
 
Null hypothesis:  
CPAP therapy in people with OSA does not change IOP at night.   
 
5.1 Introduction  
Obstructive sleep apnoea is commonly treated with CPAP applied by a nasal or a full 
face mask which maintains patency of the upper airway during sleep. CPAP is the first 
line treatment for moderate to severe OSA and, among currently used non-invasive 
treatment modalities, it is also the most effective one in controlling intermittent airway 
obstructions in sleep. At present, people with OSA and co-existing glaucoma receive 
standard treatment with CPAP; glaucoma status is not taken into account during the 
CPAP set up and titration process. However,  whilst the long-term impact of CPAP on 
glaucoma is unknown, two previous studies showed that CPAP increases IOP at night 
(138,139). This is concerning as it means that CPAP could compromise the effect of IOP 
lowering therapies at night when IOP is already at its highest due to the recumbent sleep 
position and circadian variations. The influence of CPAP therapy on nocturnal IOP 
requires confirmation in further studies using newer tools which allow for accurate IOP 
monitoring whilst at the same time minimising sleep disruption. Crucially, we are yet to 
understand how IOP responds to CPAP in people with glaucoma in whom IOP control is 
of particular interest. With the exception of one patient with NTG, the two previous 
studies did not include glaucoma patients and IOP may plausibly behave differently in 
response to CPAP in people with glaucoma. A few scenarios are possible: i. CPAP has 
the same effect on IOP in glaucoma patients as in normal subjects, ii. IOP increases 
substantially more in people with glaucoma who are generally more prone to IOP 
fluctuations in response to a range of challenges to its regulation,  iii. IOP lowering 
treatment is protective and mitigates CPAP related IOP increase.  
Ultimately, only a prospective interventional randomised trial can confidently assess the 
impact of CPAP on important glaucoma outcomes, both in terms of its safety as well as 
potentially beneficial effects in slowing glaucoma progression. In the development of 
such studies which, given the slowly progressive nature of the optic nerve damage, will 
inevitably require long treatment and monitoring periods, it is important to consider the 
immediate effects of CPAP, their magnitude and potential mechanisms. This knowledge 
could help us to understand whether and how positive airway pressure therapy could be 
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optimised to prevent or minimise undesirable IOP increases. Any rise in IOP might 
negate the potential beneficial effect of controlling OSA on the eye. Such knowledge 
could inform the design of future clinical studies but also, importantly, guide the current 
practice of treating OSA patients with co-morbid glaucoma. 
This Chapter will focus on examining the impact of CPAP on nocturnal IOP in people 
with OSA with and without POAG. 
 
5.2 Methods  
5.2.1 Study Design  
This is a prospective observational controlled study designed to assess nocturnal IOP in 
people with POAG and control subjects at baseline and during nocturnal CPAP therapy 
4-6 weeks from its initiation.  
The study was approved by the East of England – Cambridge South Research Ethics 
Committee (REC number 16/EE/0074, Appendix 14) on 30th March 2016. The tenets of 
the Declaration of Helsinki were followed and written informed consent was obtained 
from all participants. The first subject was recruited on 24th March 2017 and the last 
patient completed the study on 10th February 2018. 
 
5.2.2  Participants and settings  
All invited participants were newly diagnosed with OSA and had clinical indications for 
CPAP therapy. POAG patients were established on IOP lowering therapies and had 
adequately controlled IOP. This was confirmed during POSAG visits or, for patients who 
did not take part in the POSAG study, during the screening visit. Any modalities of IOP 
lowering therapies, including ocular hypotensive drugs, previous laser treatment or 
trabeculectomy were allowed. As POAG is very rare among people younger than 40 
years old, and to avoid age discrepancy between the groups, only potential subjects 
aged 40 and above were invited to join the study. Further matching of participants in the 
two groups for BMI and OSA severity was contemplated. However, after conducting a 
feasibility assessment it was concluded that due to the complex nature of the study which 
required multiple visits, the anticipated low number of potentially eligible participants with 
POAG and with expected recruitment rate of 50%, the study would fail to reach the 
desired sample size within one year of recruitment if precise prospective matching for 
these variables was attempted. Nevertheless, in an attempt to mitigate any imbalances 
between the groups the majority of POAG patients had been enrolled first and the control 
subjects who had a BMI within +/- 5kg/m2 range of already recruited individuals with 
POAG and the same OSA severity category (mild, moderate, severe), were invited 
subsequently.  Furthermore, as the main IOP measurements were to be taken during 
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sleep at fixed intervals for all patients, people with insomnia, short sleep duration, 
irregular sleep habits, delayed or advanced sleep phase were excluded.  
 
Summary of eligibility criteria 
Inclusion criteria:  
All participants 
i. Newly diagnosed, untreated OSA with indications for CPAP 
ii. Age ≥ 40 years 
iii. Able to give informed consent and attend for the study visits 
 
Glaucoma patients  
i. Treated primary open-angle glaucoma 
 
Exclusion criteria: 
All participants 
i. Known or suspected pregnancy 
ii. Any contraindications to rebound tonometry, including: corneal scarring, 
microphtalmos, buphthalmos, nystagmus, keratoconus, abnormal central corneal 
thickness, corneal ectasia,  active corneal infection, and  corneal dystrophies. 
iii. Concomitant eye diseases known to affect IOP, including: treated wet age related 
macular degeneration (ARMD), central retinal vein occlusion (CRVO), branch 
retinal vein occlusion (BRVO), uveitis and diabetic retinopathy. 
iv. Indications to start CPAP treatment urgently unless the study visits could be 
organised at short notice to avoid a delay in treatment initiation.  
v. Acute infectious diseases precluding hospital admission.  
vi. Irregular sleep pattern and insomnia.  
 
Control group  
i. Any form of glaucoma 
ii. Inability to undergo screening ophthalmic examination 
 
 
There were two recruitment sources:  
i. People with and without POAG who had completed the POSAG study (described 
in Chapter 2) who had been found to have OSA associated with relevant symptoms were 
subsequently referred for assessment in the Sleep Disturbance Clinic (SDC) at the Royal 
Papworth Hospital where decisions on further management were made. Following 
review in SDC, those who met the above eligibility criteria were invited to take part in the 
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study and provided with a Participant Information Sheet (PIS). After a minimum of 3 days 
they were approached by telephone to discuss the study and enquire about their interest 
to participate. Those who chose to contribute were invited to attend for the study visit 
(Visit 1).  
 
ii. Patients with and without glaucoma who attend the SDC during the study 
recruitment period and were recommended CPAP treatment for newly diagnosed OSA 
were screened for eligibility and, if appropriate, were approached according to the 
procedure described above. Those who agreed to take part in the study were invited to 
attend for the screening visit (Visit 0).  
 
 
5.2.3 Study Plan  
Depending on the recruitment pathway, participants attended for 2 or 3 study visits. The 
study protocol illustrating these pathways and study procedures at each visit are depicted 
in Figure 5-1. 
 
Screening Visit 
Only participants recruited from the SDC who required a full eye examination and/or 
respiratory rPG attended for this visit which took place in the Glaucoma Clinic at 
Hinchingbrooke hospital. All patients diagnosed with OSA based on nocturnal oximetry 
had to undergo rPG to confirm the nature of SDB and assess its severity more precisely. 
Those, who already had rPG or a PSG as part of their diagnostic work up, were not 
required to repeat it. Participants recruited from the POSAG study had undergone rPG 
already.  
 
Consented participants underwent a full eye examination which allowed confirmation of 
POAG in participants treated in other centres, exclusion of eye diseases which could 
potentially affect IOP readings in control subjects and enabled me to obtain up to date 
ocular measurements. The following tests were carried out:   
 
1. Automated visual fields (HFA, SITA-Fast, Carl Zeiss Meditec, Jena, Germany) 
2. Slit-lamp biomicroscopy and gonioscopy (Haag-Streit International, Koeniz, 
Switzerland) 
3. Goldmann applanation tonometry (Haag-Streit International, Koeniz, 
Switzerland) 
4. Central corneal thickness (Pachmate 2, DGH Technology Inc., Exton, USA) 
5. Corneal hysteresis (Ocular Response Analyser, Reichert, N.Y., USA ) 
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6. Fundus photography 
7. OCT of the retina (Heidelberg Engineering Inc. MA, USA).  
 
rPG sleep studies were conducted according to the same procedure as described in 
Chapter 3.  
Participants who met the eligibility criteria following the screening visit were invited for 
Visit1.  
 
All participants were asked to regularise their sleep habits, particularly 7 days prior to 
Visit 1 and 2, to optimise alignment in their sleep-wake pattern between the visits and 
facilitate nocturnal IOP measurements at planned intervals. POAG patients continued 
taking their eye drops as recommended by their ophthalmologists and were specifically 
advised that they must not alter the time, frequency or doses of their glaucoma 
medications between Visit 1 and Visit 2. If any changes in IOP lowering therapies were 
needed during the study period, patients were advised to contact the study team to 
discuss their ongoing participation. 
 
Visit 1 
Participants attended the RSSC in the evening (7-8pm) and were placed in a dedicated 
quiet ward separate from other patients. This area is used predominantly as a day ward 
and so has overnight availability. Up to four patients were admitted at a time. Once 
participants had given informed consent, the following assessments and measurements 
were carried out:  
Baseline assessment: A brief medical history focused on cardio-respiratory co-
morbidities, glaucoma management and medications was taken. Demographic and 
anthropomorphic variables, including: age, weight, height, BMI and neck circumference 
were collected. Bedside spirometry was performed.  
Repeated measurements: IOP was measured in each eye using a rebound tonometer 
(IcarePro, Finland Oy) which was described in Chapter 2. Six single IOP measurements 
were obtained each time and a mean IOP was recorded as displayed by the device. If 
the variation between the six measurements was outside of acceptable limits set by the 
manufacturer, which is indicated by a yellow or red light, the measurements were 
repeated. Blood pressure (BP) was checked at the same time as IOP using a non-
invasive automated sphygmomanometer. Ocular perfusion pressure (OPP) was 
calculated based on IOP, systolic (SBP) and diastolic (DBP) blood pressure according 
to the following formula: OPP=2/3 [DBP+1/3(SBP-DBP)]-IOP(138). Oxygen saturation 
(SpO2) and heart rate (HR) were monitored overnight continuously using a finger probe 
pulse-oximeter.  
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The first measurements were performed between 9 and 10pm in the upright position and 
repeated 30 minutes later in the supine position. After this, participants were advised to 
switch the lights off when they felt ready with the expectation that the majority would fall 
asleep between 10 and 12pm. They were allowed to sleep in their habitual position but 
the number of pillows used and the angle of the head end of the bed was noted for 
consistency between visit 1 and visit 2.  
All the above measurements were repeated every 2 hours starting from 10pm and 
finishing at 8am. Participants were gently woken up and instructed to remain lying down 
in bed. The measurements were taken with the participants supine under dim light to 
minimise  sleep disruption. Two experienced operators were taking measurements at a 
time for each patient. Blood pressure was taken first and was immediately followed by 
IOP measurements. Unless IOP readings required repeating, both tests were completed 
in less than one minute. Sleep position prior to awakening the subject was recorded. 
After the final IOP measurements in the morning, participants underwent OCT-A imaging 
which will be described separately in Chapter 7. 
The final part of Visit 1 was training the participants to self-measure IOP using another 
rebound tonometer (iCareHome, Finland, Oy) previously described in Chapter 2. 
Participants took the device home and were instructed to record IOP in the daytime every 
2 hours between 10am and 8pm on two separate days: before they started CPAP and 
4-6 weeks into the treatment. They were also provided with an eye lubricant to apply at 
home in order to reduce any risk of corneal abrasion from repeated IOP measurements.  
 
Once all research procedures of Visit 1 were concluded, patients met with a CPAP 
Practitioner who initiated treatment with an auto-titrating CPAP (S9 Escape, ResMed).  
This is currently a standard practice in our centre. For participants’ convenience, this 
clinic appointment was co-ordinated with Visit 1. Patients were instructed how to use 
CPAP, fitted with an appropriate mask and had an opportunity to practice with the 
treatment. They then followed the usual treatment pathway which involves another 
review by a CPAP Practitioner 7 to 10 days later when the auto-CPAP is changed to a 
fixed pressure device based on the 90th percentile pressure level recorded by the auto-
CPAP machine. 
 
Visit 2 
Participants returned for the second overnight assessment 4-6 weeks after starting 
CPAP. The hours of machine usage and the pressure level set on the device were 
recorded. The IcareHome tonometers were collected and the IOP data recorded by the 
participants were downloaded.  
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All the measurements, following the same procedure as for Visit 1, were repeated this 
time with participants using CPAP. They were housed on the same ward and awakened 
at exactly the same time intervals starting from 10pm and finishing at 8am.  
OCT-A imaging were repeated on the following morning straight after participants took 
the CPAP off. This concluded Visit 2.  
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Figure  5-1. Study flow diagram  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Participants who took 
part in the POSAG study 
Participants referred to 
SDC from other sources  
Screening  
 Identification of potential participants 
 PIS and invitation letter given out in 
SDC or subsequently posted to the 
patient  
 Patients contacted by telephone after 
minimum of 3 days to discuss the 
study, assess the interest and check 
eligibility.  
 If eligible and willing to take part, Visit 1 
scheduled, appointment letters posted 
and hospital admission arranged.  
 
Screening Visit 
(Hinchingbrooke Hospital) 
 
 Eligibility check 
 Informed consent  
 Eye examination  
 rPG (if not done previously) 
 Collection of rPG equipment and 
sleep study scoring 
 Prospective data entry in eCRF 
 Confirmation of eligibility and, if 
appropriate, Visit 1 scheduled. 
 
                   Screening  
 Identification of potential participants 
 PIS and invitation letter given out in 
SDC or subsequently posted to the 
patient. 
 Patients contacted by telephone after 
minimum of 3 days to discuss the 
study, assess the interest and check 
eligibility.  
 If eligible and willing to take part, 
Screening Visit scheduled and 
appointment letter send out.  
 
Visit 1 
(Royal Papworth Hospital) 
 
 Eligibility check and informed consent  
 Baseline demographic and 
anthropomorphic variables, medical 
history, spirometry, upright/supine IOP 
 Repeated overnight IOP and BP 
measurements, continuous nocturnal 
pulse-oximetry.  
 OCT-A 
 Teaching of self-monitoring of IOP 
 Prospective data entry in eCRF 
 
Visit 2 
(Royal Papworth Hospital) 
 
 Data download from CPAP and IcareHome devices 
 Repeated overnight IOP and BP measurements, 
continuous nocturnal pulse-oximetry on CPAP.   
 OCT-A 
 Prospective data entry in eCRF 
 
 
Clinic appointments 
(Royal Papworth Hospital)  
 
 Auto-CPAP starter (paired with Visit 1) 
 Follow up with CPAP Practitioner and switch over to fixed CPAP (7-10 days later)  
 
84 
 
 
5.2.4 Study outcomes 
Primary: 
Change in IOP measured repeatedly at night in both eyes between Visit 1 (off CPAP) 
and Visit 2 (on CPAP).  
Secondary:  
i. Differences in IOP change (ΔIOP; IOPCPAP -IOPbaseline) between the groups. 
ii. Change in nocturnal OPP, BP, SpO2 between the visits and differences in 
responses to CPAP between the groups.  
iii. Change in diurnal IOP self-measured at home before and after CPAP treatment. 
iv. Correlation of IOP change (ΔIOP) in response to CPAP with: OSA severity (AHI), 
CPAP level, BMI, %predicted FVC. 
v. Change in OCT-A indices before and after CPAP treatment (this outcome is 
reported separately in Chapter 7).  
 
5.2.5 Statistical considerations  
5.2.5.1 Sample size  
The only published data which allowed sample size estimation for the purpose of this 
study came from paper by Pepin et al (139). The authors of this study measured IOP at 
baseline and one month into CPAP treatment in 12 subjects without glaucoma. They 
found that nocturnal IOP increased significantly from 14.8 (0.8) to 18.3 (1.2) mmHg 
(mean+/-SEM). Based on these data, and assuming 0.5 within subjects correlation 
between the two sessions, 11 participants per group were required to detect this 
difference separately in each group with 80% power and 5% significance (two-tailed t-
test for the difference between two dependent means, G*Power; version 3.0.10, 
Appendix 15). Allowing for 25% dropouts between the visits, the current study aimed to 
recruit 15 participants per group. 
It should however also be noted that the study design allows for comparisons of multiple 
correlated measurements taken at 5 time points over the two visits. For this reason, in 
analysis of the primary outcome F rather than T statistic was used. It is therefore likely 
that the above calculated power would have been achieved even with smaller sample 
size. However, no sufficient data to feed the F test power calculation model was available 
at the point of designing this study, thus it was thought that the above calculation was 
the closest estimation possible.  
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5.2.5.2. Statistical Analysis 
Continuous data are presented as mean (SD) or median (IQR) depending on the 
distribution. Categorical data are reported as percentages. Normality was checked using 
Shapiro-Wilk test and by assessment of skewness and its standard error. Comparisons 
of baseline characteristics between the groups was performed using independent-
samples T-test or, if the data were not normally or approximately normally distributed, 
and in case of categorical variables, using the Mann-Whitney U test. Summary indices, 
such as ODI and mean SpO2, were compared between Visit 1 and Visit 2 using paired-
sample T-test or non-parametric Wilcoxon test, as appropriate.  
A two way mixed-model ANOVA with Visit 1 and Visit 2, IOP measurement time points ( 
00am, 2.00am, 4.00am, 6.00am, 8.00am ) and eye (right and left) as within-subject 
factors, and the study groups (POAG vs Control) as between-subject factors was built to 
assess nocturnal IOP responses to CPAP. In addition, for between group comparisons 
of IOP change between the two visits, ΔIOP defined as: IOPVisit2-IOPVisit1, was 
calculated for each monitoring time point and each eye and plotted as a within-subject 
factor in a mixed-model ANOVA. This approach allowed for any possible differences in 
baseline IOP between the groups to be taken into account. Post hoc pairwise 
comparisons with Bonferroni correction were performed for any variables with a 
significant within-subject effect and interactions. Sphericity was evaluated and in cases 
where sphericity was violated, the sphericity-corrected P value is reported.  
Due to a substantial proportion of missing data, the ANOVA model could not be used for 
comparisons of pre- and post-treatment diurnal IOP values obtained at home by the 
participants. Here, mean IOP values were compared separately for each measurement 
time point with a paired-sample T-test and also compared as a pre- and post-treatment 
mean of these means.  
To examine predictors of CPAP related IOP change, linear univariate regression models 
with ΔIOP (IOPVisit2-IOPVisit1) as a dependent variable and CPAP level, AHI and BMI as 
independent variables were constructed. Pearson’s correlation coefficients were also 
calculated. The level of significance for each comparison was set at p < 0.05. All analyses 
were conducted using SPSS software version 22.0 (IBM SPSS, IL, USA). 
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5.3 Results 
5.3.1 Included Participants  
A total of 28 participants, including 15 POAG patients and 13 control subjects were 
recruited. Of these, one POAG patient and one control participant were unable to tolerate 
CPAP and were excluded from the analysis. The POAG patient who could not use CPAP 
because of claustrophobia returned for Visit 2 and had repeated overnight 
measurements taken without wearing CPAP which allowed for a limited assessment of 
between visits IOP reproducibility (Appendix 16). The control subject reported difficulties 
sleeping with the CPAP mask despite trying several different interfaces. She withdrew 
from the study after Visit 1. Of the 26 participants who successfully completed all study 
visits, 14 (11 POAG patients and 3 control subjects) were diagnosed with OSA via the 
POSAG study route and 12 (3 POAG patients and 9 controls) were routine referrals to 
SDC from other sources. Baseline characteristics of participants are outlined in Tables 
5-1 and 5-2. All but one of the participants were diagnosed with moderate to severe OSA. 
One control subject had mild OSA but had previously failed other treatment modalities 
and had clinical indications for a trial of CPAP. Control subjects had significantly higher 
ESS scores. They were also slightly younger and required higher CPAP levels to control 
their OSA, although the differences between the groups in these variables did not reach 
statistical significance, possibly as a result of a small sample size. POAG patients had 
adequately controlled IOP as indicated by average IOP readings which were taken with 
a Goldmann tonometer during POSAG/Screening visit and with IcarePro at Visit 1. They 
had elevated IOP at the point of diagnosis and mild visual field impairment. 
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Table 5-1. Baseline characteristics of participants who successfully completed PAIR II 
study and CPAP related data (T-test or Mann-Whitney U test). 
 POAG 
N=14 
Controls 
N=12 
P value  
Age (yr), sd 68.5±8.2 61.6±10.6 0.072 
Sex (% Male) 57.1 75.0 0.35 
BMI (kg/m2), sd 32.8±5.2 35.2±6.2 0.71 
Neck (cm), sd 41.5±6.2 43.8±5.4 0.34 
FEV1 predicted (%), IQR 97.5±22 100.5±38 0.70 
FVC predicted (%), sd 96.3±15.7 103±21 0.35 
FEV1/FVC, sd 0.81±0.05 0.8±0.08 0.90 
SBPupright (mmHg), sd 140.1±16.4 141.8±22.4 0.82 
DBPupright(mmHg), sd 82.3±11.2 84.7±6.2 0.52 
    
AHI (per h), IQR  32.5±25.5 31.8±34.8 0.64 
ESS score (baseline),sd  9.1±4.7 13.3±5 0.041 
CPAP level (cmH2O), sd 10.8±2.9 13.0±2.9 0.074 
CPAP usage (h/night),sd 5.1±1.7 5.3±1.6 0.99 
 
Hypertension,% 35.7 66.7 0.123 
    Antihypertensive 
    medications (%) 
28.6 58.3 0.133 
Type 2 DM 14.3 16.7 1 
Hyperlipidaemia  35.7 41.7 0.76 
IHD 7.1 8.3 0.91 
CVA 7.1 0 0.78 
AF 0 8.3 0.74 
Abbreviations: BMI=body mass index, FEV1=forced expiratory volume in one second, 
FVC=forced vital capacity, SBP=systolic blood pressure, DBP=diastolic blood pressure, 
AHI=apnoea-hypopnoea index, ESS=Epworth Sleepiness Scale, CPAP=continuous 
positive airway pressure, DM=diabetes mellitus, IHD=ischaemic heart disease, 
CVA=cerebro-vascular accident, AF=atrial fibrillation, POAG=primary open-angle 
glaucoma.  
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Table 5-2. Ocular characteristics of participants with POAG (N=14). 
 Right Eye  Left Eye  
MD (dB), sd -2.2±2.3 -2.5±1.9 
Cup/Disc ratio, IQR 0.75±0.2 0.7±0.3 
Average RNFL thickness (μm),IQR 77±14.5 75.8±22 
CCT (μm), IQR 551.5±48 547±46 
Corneal Hysteresis (mmHg), sd 9.8±3.5 8.4±1.5 
IOP at the point of POAG diagnosis, (mmHg), sd 24.3±6.4 22.3±4.2 
IOP (mmHg) Goldmann at POSAG/screening visit, sd 15.9±3.5 16.5±3.5 
IOP (mmHg) upright, IcarePro, Visit 1, sd 15.1±2.6 15.6±2.7 
IOP lowering treatment:    
                Prostaglandin analogue (%) 86 79 
                Beta blocker (%) 21 29 
                Carbonic anhydrase inhibitor (%) 29 29 
                Alpha agonist (%) 7 7 
       Combination of ≥ 2 topical hypotensives (%) 36 36 
       Previous SLT (%) 14 14 
Abbreviations: MD=mean deviation, RNFL=retinal nerve fibre layer, CCT=central 
corneal thickness, IOP=intraocular pressure, POAG=primary open-angle glaucoma, 
SLT=selective laser trabeculoplasty.  
 
5.3.2 Response to CPAP  
Adherence to CPAP was adequate with average machine usage between the visits of 
over 5 hrs/night in each group (Table 5-1). CPAP treatment resulted in a significant 
reduction of nocturnal oxygen desaturations and improvement in subjective daytime 
sleepiness in both groups (Table 5-3).  
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Table 5-3. Changes in nocturnal oximetry and ESS score with CPAP treatment (paired-
sample T-test). 
 Visit 1 Visit 2 P value  
POAG group (N=14)    
ODI (per h), sd 15.3±8.4 7.7±6.6 0.012 
Mean SpO2 (%), sd 94.1±0.89 96±1.2 0.000 
ESS score, sd 9.14±.4.7 5.8±3.2 0.001 
Control group (N=12)    
ODI (per h), sd 21.7±21 7.4±9.7 0.006 
Mean SpO2 (%), sd 94±1.9 95.9±1.3 0.003 
ESS score, sd 13.3±5 8±5.6 0.002 
    Abbreviations: ODI=oxygen desaturation index, SpO2=oxygen saturation, ESS=Epworth 
Sleepiness Scale, POAG=primary open-angle glaucoma.  
 
 
5.3.3 Primary Outcome: CPAP related changes in nocturnal IOP 
IOP measured with subjects using CPAP (visit 2; 5 repeated measurements in both eyes 
at: 00am, 2am, 4am, 6am, 8am) was significantly higher than at baseline (visit1; the 
same time intervals as per visit 2) with a mean increase of 2.6±2.2 mmHg across both 
groups and all measurement time points (F=36, p=0.000) (Figure 5-2). This was also true 
when data were analysed separately in each group (POAG group; mean IOP increase: 
2.2±2.6 mmHg, F=10.1, p=0.007, Control Group; mean IOP increase: 3.1±1.7 mmHg, 
F=40, p=0.000). The difference between the groups in IOP change was not statistically 
significant (mean difference in ΔIOP: 0.99±4.4mmHg, p=0.27) (Figure 5-3). It is worth 
noting that IOP measurements taken at 10pm in supine position off CPAP at both study 
visits were not different indicating reproducibility of IOP measurements between the visits 
(Visit 1 IOP10pm:17.6±2.8, Visit 2 IOP10pm:17.1±3.0, F=1, p=0.33). At visit 2, with 
participants being asleep and wearing CPAP for just 1-2 hrs between 10pm and 00am, 
IOP has already increased by 2.6±2.7 mmHg (F=24.7, p=0.000) when the first 
measurements on CPAP were taken. There was no significant difference in the 
magnitude of IOP change across the 5 measurement time points (F=1.6, p=0.2). In 50% 
of participants IOP increased by ≥5mmHg at one or more time points. The highest IOP 
readings were recorded in two POAG patients at 8 am reaching 28mmHg and 31mmHg 
in the right eye, which represented 12.1mmHg and 13.2mmHg increase compared with 
the same time at Visit 1, respectively. Overall, changes in IOP between the visits were 
more variable in people with POAG than in control subjects. For instance, the only patient 
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who had a mean nocturnal IOP lower during CPAP therapy (-1.5 mmHg) and a patient 
with the highest mean IOP increase (+8.5 mmHg) were both in the POAG group (Figure 
5-4). 
Of the examined potential predictors of IOP change, only CPAP level was positively 
correlated with a mean increase in nocturnal IOP. In a regression model it could explain 
19% of variability (R2) in IOP change between the visits (Table 5-4 and Figure 5-5).  
In a post-hoc analysis, the ANOVA model which examined the differences between the 
POAG group and the control group in nocturnal IOP change was adjusted for the CPAP 
level. This resulted in a decrease in the mean difference in IOP change between the 
groups and an increase in the p value (mean difference in ΔIOP; unadjusted model: 
0.99±4.4mmHg, p=0.27 vs adjusted model: 0.35±4.4mmHg, p=0.7).  
 
Missing data  
There were no missing data for the primary outcome analyses. However, three POAG 
participants and two control subjects woke up and discontinued CPAP between 6 am 
and 8 am. Therefore, the 8 am IOP measurements were taken off CPAP in those 
patients. In four of them, the 8 am IOP readings were lower than those obtained at 6 am. 
Whilst they remained lying in bed for all IOP checks, it is possible that overall differences 
in nocturnal IOP between the visits would have been slightly larger if all 8 am 
measurements were taken on CPAP.  
 
 
Figure 5-2. Nocturnal IOP before and during CPAP therapy. For between-visit 
comparisons only measurements taken between 00 am and 8 am were included. 
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Figure 5-3. Comparison of CPAP related IOP change between the groups (mixed-model 
ANOVA with post-hoc Bonferroni transformation).  
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Figure 5-4. Changes in mean nocturnal IOP between Visit 1 and Visit 2 in each group. 
Each line represents a patient (mean of both eyes). 
 
A. POAG Group 
 
B. Control Group 
 
93 
 
 
 
Table 5-4. Summary of the univariate linear regression models examining potential 
associations between selected variables and mean nocturnal IOP change between Visit 
1 and Visit 2.  
 
Model N R2 Beta t value  P value  95% CI 
  
CPAP level  26 0.19 0.32 2.4 0.025 0.04 to 0.6 
AHI 26 0.01 -0.013 -0.5 0.625 -0.7 to 0.04 
BMI  26 0.005 0.027 0.34 0.74 -0.14 to 0.19 
FVC %predicted  26 0.008 0.011 0.45 0.66 -0.04 to 0.06 
Abbreviations: CPAP=continuous positive airway pressure, AHI= apnoea-hypopnoea 
index, BMI=body mass index, FVC=forced vital capacity.  
 
 
 
 
Figure 5-5. Scattered plot representing a correlation between CPAP level and mean 
nocturnal IOP change between Visit 1 and Visit 2. 
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5.3.4 Secondary outcomes 
 
Changes in nocturnal BP and OPP 
There was a small but significant reduction in OPP at Visit 2 when all subjects were 
entered into the mixed-model ANOVA (mean ΔOPP: -2.7±4.4 mmHg, F=9.5, p=0.005). 
However, there was also a significant interaction between the groups and the visits 
(F=8.2, p=0.009). Post-hoc analysis showed that OPP was significantly reduced only in 
the control group (POAG group; ΔOPP: -0.19±3.6mmHg, F=0.041, p=0.84, Control 
Group; ΔOPP: -5.1±5.2mmHg, F=11.8, p=0.006) (Figure 5-6).  
Subsequent analyses indicated that the OPP changes were largely driven by IOP 
increase but there was also a contribution from BP changes. In the control group, there 
was a trend to reduction in SBP but in the POAG group SBP had increased (Control 
group; ΔSBP: -6.1±11.1 mmHg, F=3.5, p=0.087, POAG group; ΔSBP: 5±6.4 mmHg, 
F=5, p=0.038,) counterbalancing the effect of IOP elevation on calculated OPP.  
DBP was not significantly different during CPAP therapy in control subjects but increased 
in POAG patients with a difference close to being statistically significant (Control group; 
ΔDBP: -1.4±5.5 mmHg, F=0.7, p=0.41, POAG group: ΔDBP: 2.6±4.9 mmHg, F=4.4, 
p=0.057) (Fig. 5-7 and 5-8). 
 
Figure 5-6. CPAP related changes in calculated nocturnal OPP. For between-visit 
comparisons only measurements taken between 00 am and 8 am were included.  
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Figure 5-7. Changes in SBP between visits in each group. For between-visit comparisons 
only measurements taken between 00 am and 8 am were included.  
 
 
 
 
 
Figure 5-8. Changes in DBP between visits in each group. For between-visit 
comparisons only measurements taken between 00 am and 8 am were included.  
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Changes in diurnal IOP self-measured at home before and during CPAP treatment. 
After a short training, 20 out of 26 participants were able to self-measure IOP. 
Unfortunately, there was a substantial proportion of missing data due to the following 
reasons: missed recordings at one or more time points, measurements taken outside of 
the scheduled time, IOP measured only in one eye or no valid IOP measurements 
obtained despite multiple attempts. Only 4 participants collected all of the 24 required 
measurements (two eyes, 6 time points throughout the day, pre- and post- CPAP 
treatment). Data produced by them were analysed using repeated measures ANOVA 
which showed no significant change in diurnal IOP after CPAP therapy (ΔIOP: 
0.77±1.7mmHg, F=0.9, p=0.42). Due to a large proportion of missing data, imputation 
methods were deemed inappropriate. Instead, T-statistics was used to compare IOP 
readings at each time point and for each eye separately. This approach may have not 
increased the power but allowed data to be included from participants who provided 
reliable but incomplete measurements. In addition, pooled mean IOP recording pre- and 
post- CPAP were compared with a paired sample T-test. There was a good correlation 
in mean IOP measurements before and after 4-6 weeks of CPAP treatment but no 
significant change in daytime IOP was detected with any of these tests (Table 5-5 and 
5-6). 
 
Table 5-5. Comparison of pre- and post- CPAP diurnal IOP at all time points for both 
eyes (paired sample T-test). 
* ΔIOP= IOPpost-CPAP - IOPpre-CPAP 
Abbreviations: CPAP=continuous positive airway pressure, IOP-intraocular pressure 
 
 
 
 
 Right Eye  Left Eye  
Time  N ΔIOP* t value P value  N ΔIOP t value P value 
10.00 am  13 -2.8±4.8 -2.1 0.06 11 -0.9±4.5 -0.68 0.51 
12.00 am  15 -1±4 -9.8 0.35 10 -1.9±2.8 -2.1 0.06 
2.00 pm 14 0.21±2.4 0.34 0.74 12 -1.7±4.4 -0.13 0.9 
4.00 pm 11 0.00±4.1 0.00 1 10 -1.2±3.3 -1.16 0.27 
6.00 pm 13 -1.1±5.1 -0.76 0.46 12 -1.3±2.8 -1.56 0.15 
8.00 pm 15 0.27±4.4 0.24 0.82 11 -3.6±5.6 -2.1 0.06 
Mean IOP 20 -3.2±2.3 -0.61 0.55 19 -1.2±3.0 -1.8 0.1 
97 
 
 
Table 5-6. Correlation of mean diurnal IOP pre- and post- CPAP for each eye (Pearson 
correlation test). Please note that the p value relates to the correlation test rather than 
comparison of means.  
Abbreviations: CPAP=continuous positive airway pressure, IOP-intraocular pressure  
 
5.4 Discussion  
5.4.1 CPAP related IOP increase   
The main rationale for this study was to examine overnight IOP changes in response to 
CPAP therapy in people with POAG as no data existed for such patients. It was also 
important to verify findings of the two previous small studies which examined the impact 
of CPAP on nocturnal IOP in people without glaucoma but used different IOP 
measurement tools. Kiekens et al. monitored IOP every 2 hours over a 24-hour period 
at baseline and one month after starting CPAP (138). They used a Perkins tonometer 
which is a handheld version of the gold standard Goldmann tonometer and also requires 
the prior application of topical anaesthetic and fluorescein each time before 
measurements are taken. Therefore, this technique can cause potentially relevant sleep 
disruption and the measurements cannot be taken immediately after awakening the 
patient. As it relies on a skilful application of force required to maintain a uniform 
applanation of the surface of the cornea, it is operator dependent and thus there is a 
potential risk of bias in an unblinded design. In a sample of 21 patients, the authors of 
that study reported statistically significant change in IOP at 2, 4, 6 and 8 am. The average 
IOP increase was not reported in the paper but based on the published graph it was 
approximately 2.3 mmHg (Appendix 17). Daytime IOP was not different between the two 
sessions at any time point. In the second study by Pepin et al. IOP was measured every 
hour during the 24-hour period with an applanation tonometer (Tonopen XL) which also 
requires instillation of a local anaesthetic (139). This device is considered less accurate 
in measuring IOP when compared with Goldmann and other tonometers, and tends to 
give underestimated readings in the higher range of IOP (213–215). Using this 
tonometer, the authors found that in 12 patients who returned for repeated 
measurements on CPAP, nocturnal IOP increased by a mean of 3.5 mmHg.  
Right Eye N=20  Left Eye N=19 
IOPpre-CPAP IOPpost-CPAP r P value  IOPpre-CPAP IOPpost-CPAP r P value 
15.5±3.3 15.9±3.6 0.77 0.000 15.3±4 16.5±3.8 0.7 0.001 
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In line with these two studies, in the current study IOP increased at night during CPAP 
therapy in the control subjects but I have now shown that this effect is also seen in people 
with POAG. The IOP change was slightly larger in the control group than in the POAG 
group (3.2 vs 2.2 mmHg) but this difference was not statistically significant and could be 
potentially explained by baseline imbalances between the groups. Specifically, the 
groups were not perfectly matched for CPAP level, with POAG patients receiving slightly 
lower CPAP. This may be relevant as in the regression analysis CPAP level was the only 
factor positively correlated with a mean IOP increase. It is also worth noting that 
individual IOP responses to CPAP were quite uniform in the control group but more 
variable in the POAG group. IOP variability defined as the change during periods  longer 
than 24-hour and IOP fluctuation defined as the change within 24 hours are well 
documented in POAG and greater than in people with healthy eyes (216). In this context, 
variable individual responses to CPAP among POAG patients may reflect intrinsic 
features of IOP regulation in glaucoma. 
Another possibility is that ocular hypotensive medications play a role in shaping individual 
changes in IOP during CPAP exposure. It could be speculated that eye drops have some 
protective effect but differ in their ability to mitigate CPAP induced IOP increase much 
as they differ in their efficacy in lowering nocturnal IOP. For instance, several studies 
demonstrated that prostaglandin analogues provide more consistent coverage for the 
nocturnal period than beta-blockers or anhydrase inhibitors (217–219). Brimonidine, a 
selective alpha2-adrenergic receptor agonist, effectively lowers diurnal IOP but has little 
effect during the nocturnal period (220). There is also evidence that adding a carbonic 
anhydrase inhibitor  to a prostaglandin analogue monotherapy results in greater 
reduction of nighttime IOP than when a prostaglandin analogue is combined with a beta-
blocker (221). Whether any of these medications are also more effective in controlling 
nocturnal IOP in the context of CPAP therapy is unknown. Complicating matters further 
is the fact that patients with OSA have heightened sympathetic activity at night so, 
potentially, beta-blockers may be more effective in this population but this has not been 
studied. In the current study, most patients were applying eye drops at night and were 
established on prostaglandin analogues but there was a range of hypotensive agents 
used in different combinations and due to relatively small sample size the effect of 
individual therapies could not be elucidated.  
There were no significant changes in daytime IOP self-measured before and after CPAP 
treatment. Due to missing measurements and a different IOP monitoring strategy these 
data are less robust than for the nighttime period. Nevertheless, the results are 
consistent with the findings of the two previous studies, neither of which found significant 
changes in diurnal IOP. Importantly, Kiekens et al. demonstrated that IOP normalised 
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just 30 min after CPAP discontinuation. This indicates that the impact of CPAP on IOP 
is largely limited to the time that it is worn, which is predominantly during the sleep period.  
 
5.4.2 Potential mechanisms of nocturnal IOP elevation  
Several hypotheses have been proposed to explain why CPAP causes IOP elevation. 
Pepin et al. argued that normal nyctohemeral IOP rhythm is lost in OSA and that CPAP 
acts primarily by restoring this rhythm. Using the cosinor model for biological rhythms 
they categorised 18 patients into 3 subgroups: those who had a nocturnal rhythm (28%), 
a diurnal rhythm (22%) and those with no apparent rhythm (50%) at baseline (Appendix 
18). Twelve of these patients returned for the second session when they had IOP 
measurements performed while using CPAP and they all exhibited a nocturnal rhythm 
then. Based on this, the authors concluded that any concerns about CPAP induced IOP 
changes should be disregarded. However, in light of available data, the question arises 
as to whether this unequivocal interpretation is justified and the hypothesis credible. 
There is a large volume of evidence that IOP has a 24-hour rhythm with higher values at 
night and lower during the day. This is consistent across different age groups, people 
with healthy and glaucomatous eyes and has been demonstrated using several different 
IOP measurement techniques, including recently developed continuous non-invasive 
IOP estimation with a contact lens sensor (CLS) (222–225). The most important factor 
in nocturnal IOP elevation is the change in posture with IOP being higher in a supine 
than in a sitting position (226). There is also a circadian component to IOP regulation. 
Aqueous formation exhibits circadian rhythmicity; possibly as a result diurnal activity of 
the sympathetic nervous system its production is higher during the day and lower at 
night. However, as the nighttime aqueous outflow facility is reduced proportionally more, 
in most people, nocturnal IOP increases even when controlled for habitual body position 
(227,228). In their study, Pepin et al. measured IOP in a sitting position during daytime 
hours (from 8:00 am to 8:59 pm) and in a supine position at night (from 9:00 pm to 7:59 
am). If, as is claimed, OSA reversed diurnal IOP rhythm in some patients, it would have 
to have a profound effect on circadian IOP regulation to overcome the postural change. 
To my knowledge this has not been previously reported for any other condition or in any 
population of patients.  
In contrast with this study, the current study and also the study by Kiekens et al. indicate 
that the normal IOP rhythm is preserved in people with OSA. Although in the three 
studies IOP data were collected and analysed in slightly different ways certain 
comparisons are possible. In the study by Pepin et al. mean diurnal (sitting) IOP at 
baseline was 15.4 mmHg and nocturnal (supine) IOP was 14.8 mmHg which is 
consistent with the reported loss of nycthemeral rhythm in the majority of participants in 
that study. In the current study, mean diurnal (sitting) IOP was 15.4 mmHg but nocturnal 
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(supine) IOP increased to 17.9mmHg in all participants. In the study by Kiekens et al. 
mean daytime (supine) IOP was 16.4 mmHg but during the sleep period (supine) it 
increased to 17.5 mmHg. Furthermore, the authors reported that the mean of all trough-
peak differences in IOP was 6.7 mm Hg at baseline and 9.0 mmHg during CPAP therapy. 
In the current study, nocturnal IOP increased between the visits by ≥5mmHg at one or 
more time points in 50% of participants. In some, this difference was more than 10mmHg 
in the early morning hours. In the study by Pepin et al. nighttime IOP appeared higher 
when measured on CPAP across all three subgroups, including in patients who were 
deemed to have nyctohemeral IOP rhythm preserved at baseline (Appendix 18). 
Therefore, in all three studies these net increases in IOP seem to be in addition and 
beyond what could be expected from 24-hour IOP rhythm restoration.  
Contemplating further the data published by Pepin et al. a few other observations are 
noteworthy. The authors determined individual IOP rhythms based on measurements 
performed during one 24-hour session. One danger of this approach is that even short-
term intra-subject IOP measurement reproducibility, particularly in terms of acrophase 
and bathyphase is limited. Mean diurnal and nocturnal IOP and the IOP amplitude 
measures are more consistent. (226,229–231). Pepin et al. classified IOP rhythms as a 
diurnal (ie, between 8:00 AM and 8:59 PM) or nocturnal based on the time of the 
acrophase. Whether one off acrophase measurements truly represented one’s IOP 
rhythm would have to be determined by repeated measurements. In addition, in 
benchmark studies which investigated circadian IOP rhythms nocturnal period was 
limited to a dark i.e. sleep period (Appendix 19). Here the authors chose to extend it to 
11 hrs. However, as the participants were allowed to sleep in their habitual hours and 
the average sleep time was only 5.7 hours, for almost half of the nocturnal period the 
measurements were not performed in sleep. Also, the follow up time between the 
baseline measurements and the measurements performed on CPAP varied widely 
between 1 month and 6.7 months. To what extent all these factors may have influenced 
rhythm classification and assessment of the subsequent response to CPAP is unclear. 
It should also be noted that adherence to CPAP was low, averaging only 3.6 hours. Three 
out of 12 patients who returned for repeated measurements were not using CPAP at all 
at home. Yet, it was reported that one night of CPAP use in the sleep laboratory restored 
their IOP rhythm which was either inverted or absent at baseline. This is surprising and 
would rather point to more immediate mechanisms than IOP rhythm restoration. For 
CPAP to alter biological processes, such as blood pressure control, endothelial 
dysfunction, sympathetic activation at least several weeks of regular use with coverage 
of the whole sleep period is required (109,232). 
It has also been argued that CPAP may be raising IOP by restoring slow wave sleep the 
proportion of which is substantially reduced in severe OSA. Slow wave sleep was thought 
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to be associated with highest IOP in a couple of early studies in which subjects 
undergoing polysomnography were awakened for repeated IOP measurements 
(233,234). In the study by Pepin et al., with CPAP treatment the proportion of slow wave 
sleep increased from 6% to 13%. This still gives little opportunity to, by chance, capture 
slow wave sleep during scheduled one hourly measurements so that it would make a 
difference to the mean nocturnal IOP. Nonetheless, in a more recent study where IOP 
was measured continuously with CLS on non-OSA subjects without the need to awaken 
participants, the findings of the previous studies were disputed (235). In contrast, the IOP 
signal values were significantly higher during rapid eye movement (REM) sleep and 
progressively decreased during the non-REM stages reaching the lowest points in slow 
wave sleep. 
From the physiological perspective a fall in IOP in non-REM sleep makes more sense 
as it is well established that sympathetic activation is higher in REM than in slow wave 
sleep (236). Circulating catecholamines could contribute to IOP increase by augmenting 
aqueous humour production through the stimulation of the ocular β-adrenergic receptors. 
It is well documented that interventions which reduce sympathetic stimulation of the 
ciliary epithelium, such as administration of topical or systemic beta-blockers, cause a 
reduction of IOP. OSA enhances sympathetic activity in all sleep stages. CPAP can 
restore autonomic balance at night and this effect carries over to wakefulness so that, 
for instance, blood pressure is reduced both at night and during the day (237–239). Pepin 
et al. proposed that one of the reasons why CPAP normalises nyctohemeral IOP pattern 
could be by the reduction of diurnal sympathetic tone. Whilst this is possible, it is unclear 
why CPAP would then have the opposite effect on nocturnal IOP. If augmented 
sympathetic activity was an important factor in IOP regulation it would be expected that 
patients with OSA would have higher baseline IOP both at night and during the day and 
that it would be reduced during both periods by CPAP therapy.  
All these considerations should be taken into account when trying to understand the 
physiological mechanisms responsible for IOP change. The IOP rhythm restoration 
hypothesis per se offers little insight into these mechanisms. In an attempt to pursue it 
further, an assumption that OSA somehow either phase shifts the circadian clock or 
influences mediators of circadian rhythm which are also relevant to IOP regulation would 
have to be made. By causing sleep fragmentation OSA certainly has the potential to 
dysregulate circadian rhythms of various biological processes. So far, there is no 
convincing evidence that it affects the rhythmicity of the master circadian clock. For 
instance, most studies have not shown an altered melatonin profile in OSA subjects or 
that CPAP therapy changes melatonin secretion (240–242). Similarly, studies which 
looked at the profiles of various hormones including cortisol, which could be potentially 
important to IOP entrainment, did not find consistent evidence that these are altered in 
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OSA (243–245). Nevertheless, circadian dysregulation is still a relatively 
underinvestigated area in the OSA field and much more is to be learnt, particularly when 
it comes to clock gene expression.  
As for the above hypothesis, based on the presented arguments I would conclude that 
whilst certain aspects of it, such as establishing whether circadian regulation of IOP is 
truly altered in OSA, are worth further exploration the current evidence does not support 
the notion that CPAP acts by simply restoring nyctohemeral IOP rhythm.  
 
Kiekens et al. and others favoured the pressure transmission hypothesis according to 
which positive pressure generated by the CPAP machine is passed through the 
intrathoracic space to the ocular venous system impairing aqueous humour outflow and 
thereby increasing IOP. In the current study, there was a positive association between 
CPAP level and the magnitude of IOP increase which gives some support to this 
hypothesis. However, only 19% of the variance in IOP change could be attributed to 
CPAP level indicating that other mechanisms may be more important. Furthermore, while 
the average CPAP level in the current study was 12cmH2O, the participants of the study 
by Kiekens et al. received surprisingly low pressures which averaged at only 6cmH2O, 
yet the nocturnal IOP did increase. Further examination of this hypothesis and the 
association between CPAP level and IOP will be conducted in Chapter 6.  
What may also matter is the control of repeated intermittent upper airway obstructions of 
OSA which may be causing rapid nocturnal IOP fluctuations. Respiratory effort against 
the occluded upper airway during apnoeic events generates large negative intrathoracic 
pressure swings which can reach values lower than -50 cmH2O, compared to levels of 
approximately -10 cmH2O in quite, unobstructed breathing. This in turn can increase 
right-sided venous return by enhancing the pressure gradient from extrathoracic to 
intrathoracic veins which would facilitate aqueous outflow and momentarily lower IOP. In 
a well-designed study Lundmark et al. demonstrated an immediate decline in IOP during 
the Mueller manoeuvre. This manoeuvre simulates the acute haemodynamic effects of 
negative intrathoracic pressure during an obstructive apnoea (246). Healthy volunteers 
were first trained to breath in against an occluded mouthpiece connected to a manometer 
and to reproducibly generate two levels of negative pressure: -20cmH2O and -
40cmH2O. IOP was measured at baseline, 5-15s into the manoeuvre and immediately 
upon recovery using a pneumatic tonograph. There was a significant fall in IOP during 
the manoeuvre. Further, the authors showed a dose-response relation between the 
inspiratory effort and the magnitude of IOP change. Interestingly, oesophageal pressure 
measurements performed during sleep in OSA patients indicate that respiratory effort 
during upper airway occlusion is lower in REM than in non-REM sleep (247). This could 
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be another potential explanation for why IOP may be lower during slow wave sleep than 
in REM sleep.   
The previously mentioned CLS device recently developed for continuous 24-hour 
measurements of IOP is a promising tool and may also give some insight into the pattern 
of IOP changes in OSA. The device consists of a silicone contact lens with embedded 
strain gauges which capture circumferential changes at the corneoscleral junction (248). 
The assumption behind this technology is that variations in IOP lead to changes in ocular 
volume and dimensions which are being detected by the micro-sensor. The device output 
is expressed in mVeq and cannot be easily converted to mmHg. Therefore, it provides 
data only on relative changes in IOP rather than absolute values and its ability to estimate 
IOP in comparison to other methods is yet to be established. Nevertheless, it does show 
some promise in certain situations such as when profiling IOP change at night. 
So far only one small study has been published in people with OSA using the CLS device 
(122). In that study, IOP fluctuations were recorded overnight in 7 patients with moderate 
to severe OSA who were undergoing polysomnography. The focus was to compare CLS 
output during apnoeic events with this during non-obstructed breathing. The sampling 
frequency was every 5 minutes with the measurement time of 30 seconds. For this 
reason, only apnoeas longer than 20 seconds were selected for the analysis. The 
authors found that IOP recorded during apnoeic events was significantly lower than 
during normal breathing. However, it was also noted that the amplitude of IOP signal 
fluctuations related to changes in breathing pattern was 11 times smaller than the 
difference between minimum and maximum values on the overall nocturnal curve which, 
of note, was in keeping with normal nyctohemeral IOP increase. Whether these micro-
fluctuations of CLS signal during apnoeic and non-apnoeic breathing truly represent IOP 
changes in keeping with those demonstrated during Mueller manoeuvre is yet to be 
established. 
The tonometer used in the current study allowed us to measure IOP probably closer to 
transition from sleep to wakefulness than devices used in the two previous studies 
(138,139). Nevertheless, the measurements were still performed in wakefulness and it 
is unclear whether the potential impact of obstructed breathing on IOP could have been 
captured.  
 
Lastly, one further mechanism potentially contributing to IOP increase during CPAP 
therapy is a change in the volume of extracellular body fluid.  Nocturia and nocturnal 
polyuria are common complaints of patients with untreated OSA. They have been 
attributed to raised levels of atrial natriuretic peptide (ANP) generated in response to 
mechanical stretch of the atria during negative intrathoracic pressure swings. The main 
effect of ANP is reduction of extracellular fluid volume by increasing renal sodium 
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excretion and nighttime urine production (249). CPAP lowers plasma levels of ANP and 
by this mechanisms improves nocturia and reduces the volume of urine produced at 
night (250). This in turn leads to plasma volume expansion and lowering of haematocrit 
(251–253). A relative increase in extracellular fluid can contribute to IOP elevation. By 
analogy, the water drinking test which was first developed as a provocation test for 
glaucoma work up but later abandoned as a diagnostic tool due to its poor discriminative 
properties and low reproducibility, is still occasionally used to estimate peak IOP. 
Consumption of a relatively small volume of fluid such as 500ml can significantly increase 
IOP in people with glaucoma (254). Further, ANP itself may be involved in IOP regulation 
(255). ANP is present in aqueous humour and there is some evidence that it increases 
uveoscleral outflow (256,257). Intravenous injection of ANP or increasing the 
endogenous ANP within the physiological range lowers IOP (258). Thus, CPAP therapy 
by normalising augmented ANP secretion could increase IOP.  
 
5.4.3 Clinical significance of CPAP related nocturnal IOP increase 
The recognition that IOP control throughout the 24-hour cycle is important in glaucoma 
management has been a significant paradigm shift in the last decade (259). It comes 
with challenges related to IOP monitoring outside office hours and the selection of 
treatment which would cover the 24-hour period.  
One of the first issues to consider when discussing the potential long-term impact of a 
CPAP related nocturnal IOP increase on glaucoma progression is whether the 
magnitude of the demonstrated IOP change is large enough to be clinically relevant.  
Patients with OSA are advised to use CPAP for the entire sleep period which for most of 
them is between 7 and 8 hours. Thus, people who adhere to this recommendation would, 
on average, spend a third of the 24-hour cycle with IOP 2-3 mmHg higher than it would 
be otherwise. This could potentially make a difference. For example, if we consider a 
patient with NTG whose pre-treatment IOP is 15mmHg. Target IOP is set on an individual 
basis but, in general, a 20% reduction would be considered an acceptable response, that 
is in this case 3 mmHg. CPAP could nullify this reduction making the treatment ineffective 
during the night. Another perspective on this is provided be epidemiological longitudinal 
studies, which show that lowering IOP by 1mmHg decreases the risk of glaucoma 
progression by 10% (260). Therefore, even small IOP changes may be important. In 
addition, as is often the case, average values do not tell the whole story. Complicating 
matters further is the variability of IOP elevation in POAG patients. Whilst in some 
patients IOP only increases minimally with CPAP, in others the increase is several times 
greater reaching values which may pose a more immediate risk to the optic nerve. As 
currently there is no practical way of checking nocturnal IOP during CPAP therapy 
outside the hospital setting, it is important to identify other factors associated with 
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significant IOP changes. This knowledge could help to determine which patients are at 
risk of potential complications from higher nocturnal IOP. The current study identified 
CPAP level as one of the predictors but there are probably others. Elucidating which of 
the potential mechanisms drives IOP elevation could also help in understanding the 
impact of CPAP on glaucomatous neuropathy. 
 
5.4.4 Changes in nocturnal OPP and BP 
Calculated OPP has long been used in glaucoma research as a surrogate marker of 
ocular perfusion. A large number of studies looking at its relevance to glaucoma 
development and progression have been published (261). The results have not been 
consistent probably in part because it is a crude marker of ocular perfusion and it is 
unclear how well it estimates the actual ocular blood flow. In addition, it is difficult to 
separate out the influence of IOP from the impact of blood pressure. Nevertheless, as 
CPAP treatment can potentially impact both components of OPP and in the absence of 
other tools to more precisely measure it at night, OPP was calculated in this study. In 
line with the data reported by Kiekens et al. in the current study OPP was lower on CPAP 
than at baseline in the control group. This represents the combined effects of IOP 
elevation and a non-statistically significant BP reduction. However, in the POAG group 
OPP has not changed as IOP elevation was counterbalanced by an unexpected increase 
in nocturnal BP. 
Almost twice as many patients in the control group as in the POAG group had a diagnosis 
of essential hypertension and therefore CPAP could have had larger impact on BP in 
that group. Still, this would not explain why BP increased during CPAP therapy in POAG 
patients. Whether this is a type I error in a relatively small sample of patients or a true 
phenomenon indicating a differential effect of CPAP on BP in people with and without 
POAG requires further assessment in a larger sample, ideally with continuous beat-to-
beat BP monitoring. The latter is however not inconceivable. Systemic autonomic 
dysfunction and vascular dysregulation have been documented in numerous studies and 
seem to be inherent features of POAG and are probably independent of OSA (262,263). 
Paradoxical autonomic responses to various provocation tests and metabolic stimuli 
have also been found in patients with POAG (264–266). Perhaps some of the seminal 
studies which assessed the impact of CPAP on endothelial dysfunction or sympathetic 
activation should be also carried out in people with POAG. At present, it is simply 
assumed that CPAP has the same beneficial effect on the cardio-vascular system in 
patients with POAG as it does in people without glaucoma but this may not be true.  
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5.4.5 Study limitations  
The main limitation of this study is that participants were awakened for IOP and BP 
measurements. This is a common drawback in studies assessing nocturnal IOP but it 
should not affect pre- and post-CPAP comparisons. There is also some evidence that 
nocturnal hourly awakenings when compared with uninterrupted CLS measurements do 
not alter the mean variables of 24-hour IOP pattern (267). 
Since the two previous studies  showed no significant IOP changes during the day the 
focus of the current study was on assessing nocturnal IOP rather than the 24-hour IOP 
profile. Also, due to logistic difficulties and anticipated lower recruitment rate if 
participants were to be admitted for 24-hours, daytime IOP was self-measured by the 
participants at home. The device used for this (IcareHome) operates on exactly the same 
rebound technology as the one used for the nocturnal measurements (IcarePro) and has 
been previously validated against Goldmann tonometer(268). Nevertheless, as relatively 
large proportion of daytime IOP measurements were missing, the comparison of diurnal 
IOP is considered less robust. 
Whilst the study was adequately powered for comparisons of the multiple repeated 
measurements, as discussed previously, the sample size may have been insufficient to 
detect small but potentially clinically relevant differences between the group in baseline 
characteristics. 
The study assessed only patients with POAG and therefore the results are not 
generalisable to patients with other glaucoma subtypes or people with ocular 
hypertension in whom IOP control is also important. In addition, most of included POAG 
patients had mild visual field impairment which leaves uncertainty of how patients with 
more severe glaucoma would respond to CPAP. Due to small sample size it was not 
possible to examine the impact of different ocular hypotensive medications on CPAP 
related IOP changes. These are potential directions for future research.  
Lastly, since polysomnography was not performed it is not possible to comment on what 
impact CPAP therapy had on sleep structure and sleep stages. Based on the oximetry 
monitoring an adequate control of OSA was achieved in the majority of patients, apart 
from two patients with severe OSA who could not tolerate higher levels of CPAP (in each 
the ODI has reduced by approximately 50% only from the pre-treatment baseline) and 
one other patient in whom CPAP probably induced complex sleep apnoea (the ODI has 
doubled with a characteristic oximetry pattern of central sleep apnoea).  
 
5.5 Conclusions 
This study provides further evidence that CPAP therapy leads to nocturnal IOP elevation. 
For the first time, this has been demonstrated in people with POAG. There was no overall 
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difference in IOP elevation between the groups (people with POAG and people without 
glaucoma) but patients with POAG had more variable responses. The IOP increase was 
not prevented by ocular hypotensive medications, although the impact of different 
therapies could not be established in this study. There are no reports that POAG is more 
common among CPAP users and it may be that these observations are only relevant to 
patients who already have or are at risk of developing optic neuropathy and require 
treatment for OSA. The mechanisms behind the IOP increase are unclear and it is yet to 
be determined whether IOP changes are CPAP specific or perhaps result from abolishing 
intermittent airway obstructions and the physiological consequences of this. The CPAP 
level does seem to be relevant. Ultimately, only longitudinal studies can determine 
whether CPAP treatment affects glaucoma progression. Until such data are available 
CPAP related IOP elevation should not be simply ignored. It will be appropriate, as a 
minimum, for sleep clinicians initiating patients with POAG on CPAP to liaise with our 
ophthalmology colleagues to ensure ongoing surveillance for deterioration in vision.  
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Chapter 6: PAIR I study: Does intraocular pressure change 
in response to CPAP applied in wakefulness?  
 
Null hypothesis:  
A short exposure to CPAP administered within the pressure range used in clinical 
practice does not cause an immediate IOP elevation in awake subjects.  
 
6.1 Introduction  
The study reported in the previous chapter demonstrated that CPAP increases IOP at 
night in both healthy subjects and in people with POAG. However, the mechanisms 
responsible for CPAP related IOP increase are unclear. One of the most commonly cited 
hypotheses is the mechanical pressure transmission from the upper airway through the 
intrathoracic space to the ocular venous system which would impede aqueous humour 
outflow via the episcleral veins (138,269–272). Data from physiological studies lend 
some support to this hypothesis. CPAP has been shown to increase intrathoracic 
pressure and right atrial pressure in a manner proportionate to the pressure level set on 
the machine (273–276). Reduction of venous return as a consequence of hydrostatic 
pressure changes is also believed to be responsible for the well documented IOP 
elevation when lying down. Upon assuming a supine posture both IOP and episcleral 
venous pressure (EVP) increase in parallel within a few minutes (277–279). The 
magnitude of these postural changes varies widely in the range of 1.6 to 8.6mmHg but 
several studies have found that, on average, it is greatest in people with glaucoma (280–
284). Even slight elevation of the head by 20-30 degrees when lying down can alter IOP 
(285). Therefore, if CPAP raised IOP by a similar mechanism resulting in impaired 
drainage from the ocular venous system, one could not only expect prompt IOP changes 
shortly after CPAP application and irrespective of whether subjects are asleep or awake, 
but also that these changes are dose dependent. Following this mechanistic hypothesis, 
it could be further speculated that the magnitude of CPAP induced IOP change may be 
influenced by body weight or extra-thoracic restriction. The rationale for this assumption 
comes from observations that obese subjects develop intrinsic positive end-expiratory 
pressure (PEEPi) and have relatively high gastric and oesophageal pressures, 
particularly when supine (286). Glaucoma severity may also be a relevant factor. For 
instance, some studies found that orthostatic IOP changes correlate positively with the 
severity of visual field impairment in glaucoma (282,287).  
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Knowing the relationship between CPAP and IOP may be important from the clinical 
perspective as it could guide positive pressure titration, and perhaps inform the choice 
of positive pressure modality for people with OSA and concomitant POAG, in whom IOP 
elevation is likely to be particularly undesirable. In Chapter 3 it was demonstrated that 
nocturnal IOP changes after CPAP are more variable in people with glaucoma than in 
controls. In some patients the average increase in the overnight IOP was as high as 8 
mmHg. It would probably be valuable to identify such patients early in their treatment 
pathway. Currently, in most sleep centres CPAP is initiated on an outpatient basis with 
the aid of automatically titrating devices (auto-CPAP). In comparison to an overnight 
manual pressure titration in a sleep laboratory environment, this model of care delivery 
has been shown to be cost-effective and non-inferior in the majority of long-term 
treatment outcomes (288,289). One opportunity to assess individual IOP responses to 
CPAP would be by measuring it during ambulatory CPAP set up visits. Clinicians could 
then decide on the maximum allowed CPAP level for patients with glaucoma or perhaps 
choose to treat those with high positive pressure requirements with a bi-level ventilator 
instead. The latter strategy allows the application of lower expiratory pressure, potentially 
reducing pressure transmission whilst still effectively controlling intermittent upper airway 
collapses (276). However, for this exercise to be valid we need to first understand 
whether a short-term diurnal application of CPAP can induce IOP changes of similar 
magnitude to those observed during nocturnal therapy and whether any potential 
changes are dependent on the CPAP level.  
Therefore, the main aim of this study is to determine whether CPAP applied in 
wakefulness and set within a pressure range most commonly used in clinical practice 
alters IOP in people with and without glaucoma. Another goal is to examine whether any 
potential IOP changes correlate with the CPAP level and whether patients with treated 
and untreated POAG respond to CPAP differently. In addition, potential covariates of the 
hypothesised IOP change in response to CPAP are explored.   
 
6.2 Methods 
6.2.1 Participants and settings  
Three groups of participants were recruited: newly diagnosed treatment naïve POAG 
patients (group I), POAG patients established on treatment (group II), and control 
subjects without glaucoma (group III). Patients in group I were recruited from glaucoma 
clinics following their diagnosis of POAG and before they started IOP-lowering treatment. 
According to the study protocol the treatment could have not been delayed by 
participation in the study for more than 4 weeks and if more urgent therapy was indicated 
based on clinical discretion, the potential participants were not approached. Participants 
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to group II and III were recruited among patients who had previously taken part in the 
POSAG study. 
All participants were over 40 years old and had not used CPAP before. They all had a 
prior comprehensive ocular examination which consisted of the following tests: 
automated visual fields (HFA, SITA-Fast, Carl Zeiss Meditec, Jena, Germany), slit-lamp 
biomicroscopy and gonioscopy (Haag-Streit International, Koeniz, Switzerland), 
Goldmann applanation tonometry (Haag-Streit International, Koeniz, Switzerland), 
central corneal thickness measurement (Pachmate 2, DGH Technology Inc., Exton, 
USA), fundus photography and SD-OCT (Heidelberg Engineering Inc. MA, USA). As part 
of the POSAG study patients in groups II and III were previously investigated with an 
rPG sleep study. OSA status was unknown for participants in group I.  
The exclusion criteria were as follows: 
 previous surgical treatment for glaucoma 
 current or recent (within 4 weeks) CPAP or non-invasive ventilation use 
 history of face mask intolerance 
 contraindications to rebound tonometry (including: corneal scarring, 
microphtalmos, buphthalmos, nystagmus, keratoconus, abnormal central corneal 
thickness, corneal ectasia, active corneal infection) 
 concomitant eye diseases known to affect IOP (including: wet ARMD, CRVO, 
BRVO, uveitis and diabetic retinopathy) 
 significant lung diseases (including: previous pneumothorax, previous or current 
respiratory failure of any aetiology, chronic obstructive pulmonary disease, 
bullous lung disease, difficult to control asthma, acute chest infection) 
 significant cardiac diseases (including: heart failure, unstable arrhythmias, 
pulmonary hypertension).  
The study was conducted in a tertiary sleep centre at the Royal Papworth Hospital in 
collaboration with the Eye Clinic at Hinchingbrooke Hospital, North West Anglia 
Foundation Trust, UK. Ethical approval was given by the East of England – Cambridge 
South Research Ethics Committee (REC number 16/EE/0073) and the Anglia Ruskin 
University Research Ethics Panel (ref. 16/17 011) (Appendix 20). The tenets of the 
Declaration of Helsinki were followed. Written informed consent was obtained from all 
participants.  
 
6.2.2 Study procedures 
Following a written informed consent all subjects underwent upright spirometry and 
baseline anthropomorphic measurements. IOP was first measured in a sitting position 
and again 30 min later in a supine position. Whilst IOP increases within a few minutes, 
the 30 min time interval was chosen for consistency with the majority of previous studies 
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examining orthostatic IOP fluctuations, and to allow sufficient time for IOP to stabilise 
before application of CPAP (279). A NIPPY 3+ ventilator (Breas Medical) was used to 
deliver CPAP. This ventilator alarms instantly in case of significant air leaks which allows 
the operator to immediately adjust the mask. In addition, prior to each set of repeated 
measurements the circuit pressure was monitored using a manometer with a pressure 
transducer in line between the mask and the tubing. 
All participants were fitted with a full face mask. CPAP was set at four pressure levels: 
6, 10, 13 and 16cmH2O which were administered in a random order to eliminate CPAP 
exposure time as a confounder (Table 6-1). CPAP level sequences were computer 
generated in R (version 3.4.1) and randomly allocated to consecutive participants. They 
were provided to the investigator in sealed envelopes after consenting. Each CPAP level 
was applied for 30 min. IOP was checked repeatedly in both eyes using a rebound 
tonometer (IcarePro) which allows the user to obtain accurate measurements in both 
sitting and supine positions without interrupting CPAP administration. The person 
obtaining IOP measurements was blinded to the CPAP level. BP and SpO2 were 
checked repeatedly at each CPAP level and prior to IOP measurements. Participants 
remained lying down in a supine position for a total of 2.5 hours. The head end of the 
bed was raised up to 20° and one thin pillow was allowed for comfort (Appendix 21). 
Once all measurements were completed, participants were provided with an eye 
lubricant to use at home in case of symptoms of dry eyes.  
 
Table 6-1. Illustration of repeated measurements sequence with an example of 
randomly allocated CPAP level order.   
Time/CPAP/Position SpO2 BP IOP right and left eye 
0 min/no CPAP/upright ✓ ✓ ✓ 
30 min/no CPAP/supine  ✓ ✓ ✓ 
60 min/16 cmH2O/supine ✓ ✓ ✓ 
90 min/10 cmH2O/supine ✓ ✓ ✓ 
120 min/13 cmH2O/supine ✓ ✓ ✓ 
150 min/6 cmH2O/supine  ✓ ✓ ✓ 
Abbreviations: CPAP=continuous positive airway pressure, SpO2=oxygen saturation, 
BP=blood pressure, IOP=intraocular pressure.  
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6.2.3 Study outcomes 
Primary: 
Change in IOP after application of CPAP (difference between baseline supine IOP and 
IOP on CPAP).  
Secondary:  
i. Differences in IOP change (ΔIOP; IOPCPAP -IOPbaseline) between the groups. 
ii. Minimum CPAP level which leads to IOP increase in each group. 
iii. Correlation of IOP change (ΔIOP) in response to CPAP with: CPAP level, OSA 
severity (AHI), BMI, %predicted FVC. 
iv. BP and SpO2 changes in response to CPAP across the groups.  
 
6.2.4 Statistical considerations  
 
6.2.4.1 Sample size  
This was an exploratory study and there were no reliable published data to enable an 
accurate sample size calculation for repeated comparisons. Nevertheless, IOP variability 
among patients with and without POAG was known from the POSAG study and certain 
assumptions could be made in addition, to guide the minimum required sample size. The 
mean±sd postural IOP increase in 398 POSAG patients was 1.5±2.0mmHg (F=190.5, 
p=0.000) with a calculated partial effect size of 0.32 (partial η2). To compute the required 
sample size for repeated measures model with 5 repetitions per subject, it was assumed 
that the same proportion of within group variance in IOP could be explained by the effect 
of CPAP as it was by the posture change in POSAG. Another assumption was that a 
correlation among repeated IOP measurements is 0.5. Based on this, and provided there 
were no missing data, only 6 patients per group would be required to detect IOP 
difference on any CPAP level with 95% power and 5% significance. However, to account 
for incomplete measurements from subjects who could not tolerate higher CPAP levels 
and also to allow subsequent subgroup analyses, including multivariate analyses in case 
several variables were found to predict IOP response to CPAP, the study aimed to recruit 
up to 30 participants per group. An interim analysis was planned after recruiting at least 
50% of all subjects which would allow early termination of recruitment if there was no 
indication that significant differences in IOP could be detected within the originally 
planned maximum sample size. The sample size was calculated in G*Power, version 
3.0.10 (Appendix 22).  
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6.2.4.2 Statistical analysis  
Continuous data are presented as mean (SD) or median (IQR) depending on the 
distribution. Categorical data are reported as percentages. Comparisons of baseline 
characteristics between the groups were performed using one-way ANOVA with post 
hoc Bonferroni tests if significant differences were detected. Assumptions of normality 
and equality of variance were assessed using the Shapiro-Wilk and Levene’s 
homogeneity of variance tests, respectively. If either of these assumptions was violated, 
or in case of categorical data, the Kruskal-Wallis H test was used.  
A mixed-model ANOVA with CPAP level (supine off CPAP, 6, 10,13 and 16cmH2O) and 
eye (right and left) as within-subjects factors was built to assess IOP responses to CPAP. 
For between group comparisons of CPAP related IOP change, ΔIOP, defined as: 
IOPCPAP-IOPsupine, was calculated for each CPAP level and plotted as a within-subject 
factor. This allowed for anticipated baseline differences in IOP to be accounted for 
between the groups. Post hoc pairwise comparisons with Bonferroni correction were 
performed for any variables with a significant within-subject effect and interactions. 
Sphericity was evaluated and in cases where sphericity was violated, the sphericity-
corrected P value is reported. Pearson test was used to examine correlations between 
ΔIOP and potential linear co-variates. The level of significance for each comparison was 
set at p < 0.05. All analyses were conducted using SPSS software version 22.0 (IBM 
SPSS, IL, USA).  
 
6.3 Results 
 
6.3.1 Included participants 
Following an interim analysis, the Trial Steering Committee took a decision to terminate 
the study prematurely. This was dictated by meeting the pre-defined termination criteria 
for the primary outcome. At that point a total of 46 participants (51% of the original sample 
size) had been enrolled. This included: 8 untreated POAG patients, 21 treated POAG 
patients and 17 controls. Tables 6-2 and 6-3 describe baseline characteristics of included 
participants.  
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Table 6-2. Baseline characteristics of participants who took part in PAIR I study (one-
way ANOVA or Kruskal-Wallis H test). 
 Untreated POAG 
N=8 
Treated POAG 
N=21 
Controls  
N=17 
P value  
Age (yr), sd 62±11.6 71±4 70.3±3.5 0.16 
Sex (% Male) 75 67 47 0.32 
BMI (kg/m2),sd 25.5 ±.4.4 27.1±3.3 27.3±4 0.71 
Neck (cm),sd 38.3±2.6 39.7±4.2 38.9±4.2 0.4 
FEV1 predicted (%), sd 103±20 102±15 100±0.14 0.87 
FVC predicted (%), sd 105±13 102±14.3 102±12.4 0.65 
FEV1/FVC 0.78±0.1 0.78±0.1 0.77±0.1 0.95 
Antihypertensive  
Medications (%) 
37.5 33.3 52.9 0.46 
Abbreviations: BMI=body mass index, FEV1=forced expiratory volume in one second, 
FVC=forced vital capacity, POAG=primary open-angle glaucoma.  
 
Table 6-3. Ocular characteristics of participants with POAG who took part in PAIR I study. 
 Right Eye  Left Eye  
Untreated POAG   
        MD (dB), IQR -1.6±3.1 -1.9±3.8 
        VFI, (%), IQR 97.5±5  94±8  
        Highest ever recorded IOP, (mmHg), sd 21.8±4.2 22.8±4.1 
        CCT, sd 543±21.9 541±20.6 
Treated POAG   
        MD (dB), IQR -2.1±3.4 -5±8.4 
        VFI, (%), IQR 96.5±6 88.5±26 
        Highest ever recorded IOP, (mmHg), sd 21.1±3 21.2±3.5 
        CCT, sd 541.4±24 541±18.5 
     Topical treatment (%):    
                Prostaglandin analogue 71.4 76.2 
                Beta blocker 38.1 42.9 
                Carbonic anhydrase inhibitor 28.6 38.1 
                Alpha agonist  9.5 9.5 
                Cholinergic agonist  4.8 4.8 
Abbreviations: MD=mean deviation, VFI=visual field index, CCT=central corneal 
thickness, IOP=intraocular pressure, POAG=primary open-angle glaucoma. 
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6.3.2 Postural IOP changes  
Baseline IOP measured in an upright position was significantly higher in the untreated 
POAG group than in the two other groups (Table 6-4). There was no difference in IOP 
between the treated POAG group and the control group which is in keeping with 
adequately controlled IOP in the former. Upon assuming a supine position IOP increased 
by a mean of 1.8±2 mmHg across the 3 groups (F=27.3, p=0.000). The magnitude of 
positional IOP change was not significantly different between the groups (F=1.23, 
p=0.32, Table 6-5).  
 
Table 6-4. Baseline upright IOP across the groups (one way ANOVA).  
 Untreated 
POAG-I 
Treated POAG-II Controls-III P value  
Right Eye, mmHg, sd 19.2±3 15.2±2.8 15.8±2.7 0.005* 
Left Eye, mmHg, sd 19.1±3.4 15.4±3 15.8±2.8 0.017† 
Abbreviations: IOP=intraocular pressure, POAG=primary open-angle glaucoma.  
*I vs II p=0.004; I vs III p=0.023; II vs III p=1  
† I vs II p=0.016; I vs III p=0.049; II vs III p=1 
 
 
Table 6-5. Postural IOP change across the groups (mixed model ANOVA).  
 Untreated 
POAG-I 
Treated 
POAG-II 
Controls-III P value  
 IOPupright-IOPsupine, mmHg, sd -1.4±2 -2.3±1.8 -1.3±2.2 0.32 
Abbreviations: IOP=intraocular pressure, POAG=primary open-angle glaucoma. 
 
6.3.3 Primary Outcome: IOP changes in response to CPAP  
Following application of CPAP, there was no significant change in IOP across all CPAP 
levels and in relation to the supine measurements off CPAP (n=44; IOPsupine: 
17.9±3.2mmHg, IOP6cmH2O: 18.1±2.8mmHg, IOP10cmH2O: 17.7±2.8mmHg, IOP13cmH2O: 
18.3±3.3mmHg, IOP16cmH2O: 18.1±2.9mmHg,  F=1.2, p=0.35), see Figure 8. The three 
groups did not differ in their responses to CPAP (ΔIOPCPAP-Supine; group I: -
0.69±1.4mmHg, group II: 1.2±1.4mmHg, group III: 0.44±1.4mmHg, F=1.6, p=0.21) 
(Figure 6-1). 
In order to check whether the duration of CPAP exposure was important, an additional 
analysis was conducted. In this analysis, time rather than CPAP level was used as within-
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subject factor. The results indicated that IOP remained fairly constant during the two 
hours of CPAP application (n=44, IOPsupine: 17.9±3.3mmHg, IOP30min: 18±3.1mmHg, 
IOP60min: 17.9±2.8mmHg, IOP90min: 18.1±2.9mmHg, IOP120min: 18.2±3.3mmHg, F=0.48, 
p=0.75). The actual frequencies of each CPAP level at each time point were not 
statistically different from the expected frequencies confirming that randomisation of 
CPAP level sequence was successful (Table 6-6).  
The circuit pressure measurements taken on expiration at the CPAP mask just prior to 
IOP measurements indicated good control of air leaks (Table 6-7 and Figure 6-2).  
 
Figure 6-1. IOP response to posture change and CPAP in PAIR I study (repeated 
measures ANOVA).  
 
Abbreviations: IOP=intraocular pressure, POAG=primary open-angle glaucoma, NS=not 
statistically significant, SEM=standard error of mean.  
 
 
Table 6-6. CPAP sequence randomisation-distribution of frequencies (%) of each CPAP 
level in time order. 
CPAP level  Time 1 (30 min) Time 2 (60 min)  Time 3 (90 min)  Time 4 (120 min)  
6 cmH2O 15.2 28.3 28.3 28.3 
10 cmH2O 28.3 30.4 15.2 26.1 
13 cmH2O 34.8 10.9 30.4 23.9 
16 cmH2O 21.7 30.4 26.1 21.7 
p value* 0.27 0.18 0.47 0.93 
Abbreviations: CPAP=continuous positive airway pressure.  
*Chi-square test  
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Table 6-7. Circuit pressure measured at the mask on each CPAP level. 
CPAP level set (cmH2O) 6 10 13 16 
Actual circuit pressure, (cmH2O), IQR 6±0.1 10±0.1 13±0.2 15.9±0.4 
Abbreviations: CPAP=continuous positive airway pressure.  
 
 
Figure 6-2. Histograms showing distribution of positive pressured measured in the circuit 
for each CPAP level.  
 
 
 
Abbreviations: CPAP=continuous positive airway pressure. 
 
 
 
 
 
 
118 
 
6.3.4 Subgroup analyses  
To examine whether IOP behaves differently in response to CPAP in people with OSA, 
excessive weight, and more severe glaucoma the following subgroup analyses were 
conducted.  
 
OSA vs no OSA  
OSA status was known for the treated POAG group and the control group. In these two 
groups, 23 out of 38 participants were diagnosed with OSA (mild: n=15; moderate: n=7; 
severe: n=1). IOP change after exposure to CPAP was not significantly different between 
people with and without OSA (ΔIOP; OSA group: 0.53±1.3mmHg, no OSA group: -
0.13±1.3mmHg, F=2.3, p=0.14).  
 
BMI 
Participants were categorised according to their BMI into 3 groups: 1. 
BMI<25kg/m2(n=12), 2. BMI ≥25 to <30 kg/m2 (n=22) and 3. BMI≥30kg/m2 (n=10). There 
was no between group difference in IOP change after exposure to CPAP (ΔIOP; group 
1: -0.25±1.4mmHg, group 2: 0.24±1.4mmHg, group 3: 0.25±1.4mmHg, F=0.54, p=0.59).  
 
Glaucoma Severity  
The severity of glaucoma was determined based on visual field defect in the worse 
affected eye. First, each patient with POAG was categorised into one of seven stages of 
glaucoma severity according to the classification by Brusini (enhanced Glaucoma 
Severity Staging system-eGSS) which was described in Chapter 3 (164). Then, a 
consolidated glaucoma staging system proposed by Ng et al. was used (290). According 
to the latter classification there are 4 stages of glaucoma: CS1-Normal (eGCS-stage 0 
and Border), CS2-Mild (eGCS-stage 1), CS3-Moderate (eGCS-stage 2 and 3), CS4-
Severe/End-Stage defect (eGCS-stage 4 and 5). We identified 11 participants in CS1 
(median MD: -1.8±1dB), 11 in CS2 (median MD: -5.7±2.7dB) and 6 in CS3 (median MD: 
-11.8±5.7dB). There were no patients with severe/end-stage defect.  
When the three stages of glaucoma severity were compared, there was no significant 
between group difference in IOP change in response to CPAP (ΔIOP; CS1: 
0.9±1.5mmHg, CS2:0.36±1.5mmHg, CS3: -1.2±1.4mmHg, F=2.3, p=0.12). 
 
Further, there were no correlations between IOP change on the highest level of CPAP 
(ΔIOP; IOP16cmH2O-IOPsupine) and: AHI (n=37, Right eye: r=0.03,p=0.84; Left eye: r=-0.09, 
p=0.59), BMI (n=45, Right eye: r=0.19,p=0.2; Left eye: r=-0.013, p=0.93), predicted FVC 
(n=45, Right eye: r=-0.09,p=0.55; Left eye: r=-0.11, p=0.47) and MD (n=29, Right eye: 
r=-0.09,p=0.65; Left eye: r=0.26, p=0.17).  
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6.3.5 Changes in vital signs  
Both SBP and DBP decreased significantly after participants rested in a supine position 
for 30 minutes: 133.2 vs 127mmHg (p=0.00, paired t-test), 77.4 vs 74.2mmHg (p=0.011, 
paired sample t-test), respectively. SpO2 remained unchanged (96.1±1.8% vs 96±1.9%, 
p=0.67).  
Application of CPAP led to an increase in SBP and DBP which was significant for nearly 
all CPAP levels (Table 6-8). No differences in the magnitude of SBP and DBP change 
were detected between the groups (ΔSBPCPAP-Supine; group I: 4.9±11.3mmHg, group II: 
5.1±11.5mmHg, group III: 6.1±11.2 mmHg, F=0.05, p=0.96, ΔDBPCPAP-Supine; group I: 
5.5±5.4mmHg, group II: 6.9±5.5 mmHg, group III: 5.1±5.4 mmHg, F=0.56, p=0.58). 
CPAP increased SpO2 in a dose dependent manner across the groups (Figure 6-3).  
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Table 6-8. Vital signs according to CPAP level (repeated measures ANOVA).  
 Off CPAPSupine CPAP6cmH20 CPAP10cmH20 CPAP13cmH20 CPAP16cmH20 p value  
SBP, mmHg, sd 127.3±15.4 132.7±14.1 132.8±14.1 134.6±13.4 132.8±14.8 0.010* 
DBP, mmHg, sd  74.5±8.7 80.2±8.3 78.1±7.9 81.4±8 82.5±6.8 0.000† 
SpO2, %, sd 96±1.9 97.0±1.8 97.4±1.6 97.6±1.2 97.7±1.4 0.000& 
 
Abbreviations: CPAP=continuous positive airway pressure, SBP=systolic blood pressure, DBP=diastolic blood pressure, SpO2=oxygen 
saturation.  
For all comparisons: n=45. 
* Off CPAPSupine vs CPAP6cmH20, p=0.049; Off CPAPSupine vs CPAP10cmH20, p=0.017; Off CPAPSupine vs CPAP13cmH20, p=0.003; Off CPAPSupine 
vs CPAP16cmH20, p=0.098 
† Off CPAPSupine vs CPAP6cmH20, p=0.000; Off CPAPSupine vs CPAP10cmH20, p=0.011; Off CPAPSupine vs CPAP13cmH20, p=0.000; Off CPAPSupine 
vs CPAP16cmH20, p=0.000; CPAP10cmH2O vs CPAP13cmH20, p=0.024; CPAP10cmH2O vs CPAP16cmH20, p=0.003. 
& Off CPAPSupine vs CPAP6cmH20, p=0.001; Off CPAPSupine vs CPAP10cmH20, p=0.000; Off CPAPSupine vs CPAP13cmH20, p=0.000; Off CPAPSupine 
vs CPAP16cmH20, p=0.000; CPAP6cmH2O vs CPAP16cmH20, p=0.025.
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Figure 6-3. Changes in oxygen saturation in relation to CPAP level. 
 
 
Abbreviations: SpO2= oxygen saturation, CPAP=continuous positive airway pressure, 
SE=standard error.  
 
6.3.6 Missing data 
One control patient could not tolerate the highest level of CPAP and, as such, IOP 
measurements could not be performed on this CPAP level. In addition, despite several 
attempts we could not perform reproducible IOP measurements in one eye for one 
untreated POAG patient on a CPAP level of 10cmH2O. Therefore, there were 3 missing 
IOP variables out of 460 used in the analysis of the primary outcome. As the ANOVA 
test does not tolerate any missing data those two patients were excluded by default from 
the repeated measures model. However, in a subsequent sensitivity analysis the missing 
variables were substituted with IOP readings obtained on a prior CPAP level for each 
patient. This allowed inclusion of both subjects into the analysis with no important 
changes to any of the reported models. For instance, for the primary outcome model 
mean IOP values and the p value remained practically unaltered (n=46; IOPsupine: 
17.9±3.2mmHg, IOP6cmH2O: 18.0±2.8mmHg, IOP10cmH2O: 17.7±2.8mmHg, IOP13cmH2O: 
18.32±3.3mmHg, IOP16cmH2O: 18.1±2.9mmHg,  F=1.2, p=0.32).  
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6.4 Discussion 
6.4.1 Summary of the main findings  
This study challenges the concept of mechanical positive airway pressure transmission 
as a predominant mechanism behind IOP elevation during CPAP therapy. IOP is a 
dynamic parameter and can change in a matter of seconds to minutes. If IOP increase 
was caused by impaired drainage from the ocular venous system, one would expect 
prompt IOP changes after CPAP application, similar to those occurring during changes 
in posture. In line with well-established evidence, in this study IOP also increased 
significantly across all three groups upon assuming a supine position. However, there 
were no further IOP changes after CPAP administration for up to 2 hours. This is despite 
application of positive pressure of up to 16cmH2O which is considered to be moderate 
to high in clinical practice of OSA treatment. 
It could be argued that only certain patients are at risk of IOP increase from exposure to 
CPAP and that the effect size could have been diluted by analysing data in the whole 
cohort of participants. To investigate this, the three groups of participants were compared 
and additional subgroup analyses were performed which indicated that glaucoma status, 
topical medications used to lower IOP, BMI, OSA status and glaucoma severity were not 
important factors in IOP response to CPAP. 
 
6.4.2 Physiological interpretation of the main results  
Posture induced EVP changes are believed to be directly responsible for IOP elevation 
in the supine position. It is unknown whether CPAP raises EVP but it is likely that, even 
if it does, any potential changes would be of a lesser magnitude than those observed 
during orthostatic fluctuations. In the supine position venous pressure in the ocular 
vessels is close to central venous pressure measured at the right atrium which, in 
euvolaemic subjects, nearly doubles upon lying down (291,292). Elevation of CVP is the 
driving force for EVP increase although the corresponding changes in EVP seem 
smaller, ranging between 0.8 to 3.6 mmHg, and this is likely related to a tonic neural 
control present in the episcleral circulation (277,278,293,294). CPAP also increases right 
atrial pressure but to a lesser degree. Studies which examined the haemodynamic 
consequences of PAP indicate gradual pressure loss on this upstream pathway from the 
upper airway to the right atrium. For instance, Becker et al. who applied three levels of 
CPAP: 5,10 and 15cmH2O, showed a linear increase in end-expiratory oesophageal 
pressure with an approximate transmission ratio of 2:1 (276). Van den Berg et al. 
demonstrated during gradual titration of PEEP from 0 to 20cmH2O that, on average, only 
32±20% of the increase in airway pressure was translated into the increase in right atrial 
pressure (273). Thus, in healthy subjects the impact of CPAP on haemodynamic 
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parameters relevant to IOP regulation seems smaller than the impact of gravity observed 
during the postural changes. 
Another possible route of CPAP transmission discussed in the literature is via the 
intracranial space. Raised intrathoracic or intraabdominal pressure can be transmitted 
into cerebro-spinal fluid (CSF) system through the dural venous sinuses, epidural venous 
plexus and probably to some degree directly via the intervertebral foramina (295,296). 
Increased CSF pressure could then raise IOP via the lamina cribrosa. It has been well 
established that the Valsalva manoeuvre elevates CSF pressure (297). However, the 
corresponding IOP changes are several times smaller. For example, in a study by Zhang 
et al. CSF pressure increased by 10.5 mmHg but IOP only by 1.9mmHg during the 
Valsalva manoeuvre (298). Whether CPAP is capable of altering CSF pressure is still 
unclear. Studies using the same level of PAP but in different groups of patients yielded 
contradictory results (299–301). Nevertheless, the amplitude of any potential CPAP 
related changes would likely be much smaller than during forced expiratory manoeuvres 
and thus have minimal impact on IOP. Furthermore, if any IOP changes occurred via this 
hypothetical transmission route they would have been detected in the time frame of the 
current experiment.  
 
In summary, whilst there is little doubt that very high intrathoracic pressure, such as that 
generated during the Valsalva manoeuvre, will inevitably increase IOP irrespective of the 
pressure transmission route, the CPAP levels used to treat OSA do not seem high 
enough to directly raise IOP in a short space of time and in absence of other factors 
related to sleep (302,303).  
 
6.4.3 Comparison with previous studies  
To my knowledge only one previous study sought to examine a direct impact of CPAP 
on IOP in awake subjects (272). In that study 18 patients with glaucoma and 22 subjects 
without glaucoma were exposed to 12cmH2O of CPAP administered via a nasal mask 
for 15 min. IOP was measured with a Goldmann tonometer in an upright position 
immediately after removing the mask. The authors reported that IOP increased by an 
average of 2 mmHg only in patients with glaucoma. On this basis, they advocated caution 
when using CPAP in patients with confirmed or suspected glaucoma. The contradictory 
results of the current study in the glaucoma groups, may be explained by more robust 
design which allowed several biases to be eliminated and methodological limitations of 
the previous study. Firstly, in the current experiment patients used CPAP for a longer 
period and were lying down during the measurements which is the usual position 
assumed by CPAP users. As the gradient for venous return from the upper body 
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decreases in the supine position the additional impact of raised intrathoracic pressure 
from CPAP on venous return and already relatively high IOP may be different. Secondly, 
applying CPAP via a full face rather than a nasal mask meant that air leaks were 
minimised. The absence of a significant loss of positive pressure was confirmed by 
measuring it directly in the circuit. The measurements were performed during continues 
application of CPAP rather than directly after removing the mask. Thirdly, as opposed to 
using Goldmann tonometry which, as already discussed, is a largely operator dependent 
technique, in the present study IOP was measured with IcarePro reducing the risk of 
operator dependent bias. Furthermore, the ophthalmologist taking the measurements 
was blinded to the CPAP level applied. Fourthly, the study not only examined a wider 
group of patients, including those with untreated POAG who would be potentially more 
susceptible to any factors altering aqueous outflow, but also used several levels of 
CPAP, with the highest two being greater than the single CPAP level selected in the 
previous experiment. Whilst the sample size of the current study was only slightly larger, 
performing repeated measurements for each patient meant that the study power is likely 
to be substantially higher giving more confidence in the obtained results.  
 
6.4.4 Changes in vital signs  
As could be expected, CPAP increased oxygen saturation. This is likely a direct result of 
increased functional residual capacity and alveolar recruitment well described after 
CPAP application (304). 
Persistent elevation of blood pressure was not anticipated but is in keeping with findings 
of another recent study in which the authors examined the acute impact of CPAP titration 
on a beat-to-beat blood pressure in awake subjects (305). They found significant 
increases in SBP and DBP which were correlated with incremental CPAP levels. In the 
present study the effect of CPAP on blood pressure was not dose dependent but this 
may be due to only intermittent blood pressure monitoring as opposed to continuous 
beat-to-beat recording which better reflects any haemodynamic changes. It should also 
be noted that, in the current study, each CPAP level was applied for 30 min rather than 
only for 3 min as in the previous study. Thus participants had more time to acclimatise 
to changing CPAP levels. Still, one possible explanation for the blood pressure increase 
is anxiety and stress associated with using CPAP by participants who had no prior 
experience with it. However, as the blood pressure remained elevated for up to 2 hrs and 
participants otherwise appeared relaxed while resting in a recumbent position, it may be 
that other factors, perhaps related to a direct sympathetic activation from raised 
intrathoracic pressure, play a role. Whether psychological stress also increases IOP is a 
matter of debate. There is no clearly established evidence base for this but a few studies 
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indicated a small elevation in IOP associated with mental stress (306–308). The possible 
mechanisms include dilatation of the pupil, tension of intraocular muscles and activation 
of glucocorticoid and catecholaminergic pathways. Nevertheless, if the blood pressure 
changes observed in our study were indeed caused by a stress reaction, it was not 
severe enough to influence IOP.  
 
6.4.5 Limitations  
The participants in this study remained awake throughout the experiment. This is 
considered as a limitation in examining factors which may be important in sleep. These 
factors were discussed in Chapter 3. 
Oesophageal, right atrial and episcleral pressures were not measured. Therefore, it is 
unclear to what extend CPAP altered intrathoracic and venous pressure at each step of 
this hypothesised upstream pathway. Whilst such measurements could further our 
understanding of this problem, it is technically challenging to perform all of them 
simultaneously and they involve invasive techniques with a significant risk of adverse 
events in an experiment with human subjects. Incorporating these measurements a priori 
without first establishing whether IOP actually increases after application of CPAP, would 
be ethically questionable and counterintuitive. The observation that SpO2 levels were 
higher during CPAP application would indicate that both airway and intrathoracic 
pressure have increased. The study did not examine a full range of CPAP level used in 
OSA treatment. Therefore, it is still possible that CPAP set above 16cmH20 raises IOP. 
The average CPAP level used for chronic treatment of OSA varies slightly depending on 
the titration process and the mode of CPAP used but it is in the range of 10-12cmH2O 
(309). The maximum recommended pressure level is 20cmH2O but CPAP above 
15cmH2O is rarely required and can be poorly tolerated. The American Academy of 
Sleep Medicine guidelines recommend consideration of switching CPAP to a bi-level 
ventilation if pressure above 15cmH2O is reached (310). The additional concern about 
using a higher CPAP level in this study was that CPAP naïve patients might struggle to 
cope with such high pressure and it would have been more difficult to control air leaks. 
Thus the choice of the CPAP level range was pragmatic but is also believed to be 
representative.  
It cannot be excluded that longer application of CPAP even in awake subjects alters IOP. 
A longer duration study could be considered but it would be more challenging to carry it 
out due to the commitment required from participants to remain in a supine position 
without interrupting CPAP application. Also, one would have to account for individual 
circadian IOP variations if the experiment went on for substantially longer.  
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6.5 Conclusions  
In conclusion, this study demonstrates that application of CPAP for up to 2 hours in 
awake subjects does not cause significant changes in IOP. Therefore, measuring IOP 
during a brief CPAP exposure in office hours is not going to be a useful test to predict 
individual IOP responses to nocturnal CPAP therapy.  
The situation is different at night when OSA subjects intermittently and repeatedly 
obstruct their upper airway when asleep. The physiological changes from re-establishing 
upper airway patency may be more important to the IOP alteration. CPAP transmission 
may still play a role in combination with other factors but is less likely to be a sole 
mechanism of IOP elevation at night. Indeed, a combination of: mechanical pressure 
transmission, elimination of intrathoracic pressure swings, changes in extracellular fluid 
level and possibly other factors, could be what leads to IOP increase. Future studies 
which set to investigate the potential mechanisms of CPAP related IOP elevation should 
take into account that sleep is essential to observe the relationship between CPAP and 
IOP.  
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Chapter 7: Does a short course of CPAP therapy in people 
with OSA cause changes in ocular microvasculature? A pilot 
study.  
 
Null hypothesis:  
A short course of CPAP in people with OSA does not alter the optic disc and peripapillary 
blood vessel density measured by OCT angiography in people with OSA with and without 
glaucoma.  
 
7.1 Introduction  
Ocular blood flow has long been implicated in the pathogenesis of glaucomatous 
neuropathy. According to the ‘vascular’ theory impaired ocular blood flow, particularly at 
night, leads to relative ischaemia which damages the optic nerve (29). Various tools have 
been used to assess vascular dysregulation in glaucoma; from simple formulae based 
on brachial artery pressure and IOP which can merely estimate ocular perfusion pressure 
to sophisticated and complex techniques such as laser Doppler flowmetry and laser 
speckle flowgraphy which require substantial expertise in acquisition of the 
measurements and thus face the problem of reproducibility and generalisability to clinical 
practice (311). The additional limitation of these technologies is the lack of direct 
visualisation of ocular microvasculature and inability to separate different vascular beds 
supplying the optic nerve and the retina. OCT angiography which was described in 
Chapter 2 overcomes several of these limitations. It enables a direct and non-invasive 
examination of the ocular microvasculature, including reproducible and accurate 
quantification of vessel density in the optic disc and peripapillary area (311). In addition, 
automated image reprocessing with software now commercially available on some OCT-
A devices allows for exclusion of larger retinal vessels and a focused assessment of 
capillaries in three dimensional vascular beds. Vessel density is defined as a percentage 
of the selected image area occupied by ‘flowing’ vessels. A lower vessel density indicates 
loss or constriction of blood vessels but the exact physiological nature of these changes 
cannot be elucidated from the image.  
Multiple studies published in the last few years have demonstrated attenuation of the 
network of capillaries directly feeding the optic nerve in glaucomatous eyes (312). 
Moreover, vessel density and indices of blood flow in the optic disc and peripapillary area 
correlate strongly with functional (VF) and structural (RNFL) defects (154,311,313,314). 
It is suspected that these vascular changes may by early signs of glaucoma, although 
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the crucial question of whether they are the cause or the consequences of neural 
damage remains unanswered.  
Blood flow to the retina and the optic nerve can be potentially influenced by OSA and its 
treatment. On one hand, there is a risk that CPAP could reduce ocular perfusion by 
elevating IOP. On the other hand CPAP may hypothetically improve the optic nerve 
function by ameliorating the negative cardiovascular consequences of OSA. Of particular 
interest is endothelial dysfunction which is thought to be an early determinant of future 
vascular damage. CPAP therapy leads to clinically relevant improvement of endothelial 
function assessed by flow-mediated vascular dilatation (109). Also, some studies found 
that CPAP lowers serum levels of endothelin-1, a potent vasoconstrictor, although these 
data are not unanimous (315). Impaired blood flow in the cerebral circulation, which in 
many aspects is similar to the ocular circulation, has been demonstrated in people with 
OSA and there is some evidence that CPAP improves cerebral blood flow and reverses 
attenuated cerebrovascular responses to hypoxia (316–318). 
The development of OCT angiography gives a unique opportunity to study networks of 
capillaries in OSA. So far this has been done in two recent studies (187,188). Yu et al. 
assessed retinal microvasculature in 69 Asian patients with untreated OSA and found 
that vessel densities in the peripapillary and parafoveal areas decreased with increasing 
severity of OSA. The peripapillary retinal vessel density was negatively correlated with 
AHI and SpO2, after adjusting for several potential co-variates, including age, BMI and 
OPP.  These findings were however not confirmed in the study by Moyal et al. who, using 
the same OCT-A device, examined 53 slightly older Caucasian patients with mild, 
moderate and severe OSA and 28 control subjects at low risk of OSA.  They found no 
significant differences in the optic disc, peripapillary and macular vessels densities 
across the groups.  
There are no studies which examined the potential changes in OCT-A derived 
microvascular parameters after CPAP therapy. Hypothetically, by improving endothelial 
function and reducing endothelin-1 level and sympathetic activity CPAP would lead to 
relative dilatation of the retinal microvessels which could be detected as increased vessel 
density on OCT-A images.   
The PAIR 2 study described in Chapter 4 was dedicated to assessment of nocturnal IOP 
changes but it also created an opportunity to examine OSA patients with POAG and 
healthy eyes before and directly after CPAP therapy with a newly acquired OCT-A 
device. This Chapter will examine the potential alterations in the microvasculature of the 
optic disc and peripapillary area after 4-6 weeks of CPAP therapy.  
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7.2 Methods  
7.2.1 Study population and procedures  
Participants of the PAIR 2 study were examined with an OCT-A device (AngioVueHD, 
Optovue Inc., Fremont, CA; Version: 2017.1.0.151) described in Chapter 2. The device 
was transported from Hinchingbrooke Hospital for each study visit to facilitate on site 
examination. Also, it was anticipated that acquisition of the images shortly after the 
participants woke up in the morning at Visit 1 (before CPAP) and Visit 2 ( after CPAP) 
would increase the chance of detecting changes to the ocular microvasculature 
potentially induced by CPAP at night.  
All vascular parameters were automatically calculated by the Avanti SDOCT software 
(version: 2017.1.0.151). Whole image ONH vessels density measurements were taken 
from en face images acquired using the instrument defined 4.5 mm x 4.5 mm field of 
view centred on the optic disc. The cross-sectional boundaries of the examined tissue 
slab were defined by the internal limiting membrane and the RNFL. Circumpapillary 
vessel density measurements were calculated from a software defined 750 µm wide 
elliptical annulus extending outward from the optic disc boundary. The optic disc vessel 
density was measured based on the area inside the optic nerve head boundary. For the 
purpose of the analysis the following angiographic parameters were extracted:  
- whole image optic nerve head vessel density (wiVD) 
- circumpapillary vessel density (cpVD) 
- optic disc vessel density (odVD)  
For each of these parameters the vessel density was calculated for all vessels and, after 
exclusion of large vessels, separately for capillaries (see Appendix 3 for example of the 
software output).  
Up to three repeated images were obtained from un-dilated eyes and the best quality 
image was then selected for each eye. The image quality index was automatically 
generated by the software which is programmed to rate each image on the scale from 1 
(worst quality) to 10 (best quality). The following parameters are taken into account: 
signal strength, image clarity, residual motion artefacts, segmentation and disc centring.  
As advised by the manufacturer, image qualities of 5 and 6 are considered borderline 
and may potentially affect the calculation of vessel density (see Appendix 23 for 
examples of a range of different quality images). For this reason only participants with 
image quality of 7 and above in both eyes were included in the analysis.  
The OCT-A examination was part of the PAIR 2 study protocol approved by the East of 
England – Cambridge South Research Ethics Committee (REC number 16/EE/0074, 
Appendix 12).  
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7.2.2 Statistical analysis  
Comparisons of clinical characteristics between the groups, with the exception of 
ophthalmic variables, was performed using independent-samples T-test or, if the data 
were not normally or approximately normally distributed, and in case of categorical 
variables, using the Mann-Whitney U test. For ophthalmic data analysis both eyes were 
included. Baseline ophthalmic characteristics were compared using mixed model 
ANOVA with right and left eye as a within-subject factors and the study groups (POAG 
vs Control) as between-subject factors. To examine differences in pre- and post-CPAP 
OCT-A derived variables a repeat measures ANOVA was build.  
Continuous data are presented as mean (SD) or median (IQR) depending on the 
distribution. Categorical data are reported as percentages. Normality was checked using 
Shapiro-Wilk test and by assessment of skewness and its standard error.  
The level of significance for each comparison was set at p < 0.05. All analyses were 
conducted using SPSS software version 22.0 (IBM SPSS, IL, USA). 
 
 
7.3 Results  
Of the 26 patients who took part in the PAIR 2 study, 13 participants including: 7 patients 
with POAG (14 eyes) and 6 control subjects (12 eyes) were included in the analysis. The 
OCT-A scans could not be obtained during one study visit due to technical problems with 
the device. This resulted in a loss of angiographic data on 2 patients. The remaining 11 
cases were excluded based on a suboptimal OCT-A image quality in at least one eye 
pre- or post-CPAP therapy. Demographic and clinical characteristics of participants are 
summarised in Table 7-1. 
All OCT-A indices in eyes of POAG patients were significantly lower than in control 
subjects. The differences remained strongly significant after adjusting for age (Table 7-
1).  
However, in neither group were there any significant changes in the optic disc, 
peripapillary area and the whole image vessel densities after CPAP therapy (Table 7-2).  
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Table 7-1. Baseline characteristics of participants included in the study (T-test or Mann-
Whitney U test or mixed model ANOVA). 
 POAG 
N=7 (14 eyes) 
Controls 
N=6 (12 eyes)  
P value  
Age (yr), sd 67±5.6 59±10.3 0.082 
Sex (% Male) 43 67 0.41 
BMI (kg/m2), sd 33.9±5.4 35±5.8 0.74 
AHI (per h), sd 30.6±13.1 36.7±19.6 0.52 
SBPupright (mmHg), sd 149±11.5 138±26 0.33 
DBPupright(mmHg), sd 85±14.5 84±8.3 0.86 
Hypertension,% 43 50 0.81 
    
CPAP level (cmH2O), sd 10.1±2.2 11.5±2 0.24 
CPAP usage (h/nt), sd 5.3±1.7 4.8±1.9 0.62 
Residual ODI (per h), IQR 6.8±2.2 2.8±9.4 0.2 
ΔOPP(Visit2-Visit1), mmHg, sd  1.4±3.6 -7.1±6.2 0.011 
    
VA (LogMAR), sd 0.041±0.12 0.017±0.12 0.72 
MD (dB), sd -2.5±1.3 -1.1±1.3 0.1 
cRNFL (μm), sd 86.7±7.6 111.4±7.6 0.000 
    
OCT-A Vessel Density 
 
   
   wiVDA (%), sd 49.7±2.7 55.5±2.7 0.003
∞ 
   wiVDC (%), sd 43.2±2.7 49.0±2.7 0.003
® 
   idVDA (%), sd 56.1±2.9 62.1±2.9 0.003* 
   idVDC (%), sd 48.8±3.2 54±3.2 0.015
# 
   cpVDA (%), sd 51.5±2.6 57.7±2.7 0.002
& 
   cpVDC (%), sd 44.9±3.2 51.6±3.2 0.003
† 
    Abbreviations: BMI=body mass index, SBP=systolic blood pressure, DBP=diastolic 
blood pressure, AHI=apnoea-hypopnoea index, CPAP=continuous positive airway 
pressure, Residual ODI=oxygen desaturation index measures on CPAP at Visit 2, 
VA=visual acuity, MD=mean deviation, cRNFL=global circumpapillary retinal nerve fibre 
layer thickness, ΔOPP=change in calculated nocturnal ocular perfusion pressure 
between visit 2 and visit 1, OCT-A=ocular coherence tomography angiography, 
VDA=vessel density for all vessels, VDC=vessel density for capillaries, wi=whole image 
area, id=inside the optic disc, cp=circumpapillary.  
After adjusting for age the following p values were obtained respectively: ∞0.008,  ®0.006 
*0.012, #0.031, &0.004, †0.005.
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Table 7-2. Comparison of the optic nerve vessel density (OCT-A indices) before and 
after CPAP therapy (repeated measures ANOVA). 
 Before CPAP  After CPAP  P value  
POAG group, N=7 (14 eyes)    
   wiVDA (%), sd 49.7±2.9 49.4±2 0.7 
   wiVDC (%), sd 43.2±3.1 43.1±2.6 0.89 
   idVDA (%), sd 56.1±3.4 55.6±5.3 0.77 
   idVDC (%), sd 48.8±4.1 48.6±5.6 0.89 
   cVDA (%), sd 51.5±3.1 51.5±3 0.97 
        Superior hemifield, sd 52.2±3.2 52.1±3.2 0.93 
        Inferior hemifield, sd 50.6±3.4 50.8±3 0.82 
   cVDC (%), sd 44.9±3.9 45.1±4.23 0.73 
        Superior hemifield, sd 45.3±4.2 45±.4.8 0.88 
        Inferior hemifield, sd 44.3±4 44.6±4 0.67 
Control group, N=6 (12 eyes)     
   wiVDA (%), sd 55.5±2.4 55.8±2.8 0.6 
   wiVDC (%), sd 49±2.1 49.3±2.42 0.56 
  idVDA (%), sd 62.1±1.8 61.9±3.9 0.86 
  idVDC (%), sd 54±1.57 54.1±3.7 0.97 
   cVDA (%), sd 57.7±2.1 58.1±2.3 0.61 
        Superior hemifield, sd 58.9±2.3 59.4±2.7 0.56 
        Inferior hemifield, sd 56.4±2.4 56.6±2.9 0.69 
   cVDC (%), sd 51.6±1.9 51.9±2.16 0.59 
        Superior hemifield, sd 52.7±2.1 53±2.8 0.65 
        Inferior hemifield, sd  50.3±2.4 50.7±2.7 0.57 
Abbreviations: BMI=body mass index, CPAP=continuous positive airway pressure, OCT-
A=ocular coherence tomography angiography, VDA=vessel density for all vessels, 
VDC=vessel density for capillaries, wi=whole image area, id=inside the optic disc, 
cp=circumpapillary. 
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7.4 Discussion  
The development of OCT-A opens new opportunities not only to examine the role of 
retinal microvasculature in glaucoma and other ocular conditions but may also provide 
new insights into the systemic cardiovascular impact of diseases such as OSA or 
essential hypertension. However, this is a new technology and much is still to be learnt 
about its advantages, limitations and, importantly, the underlying physiological 
mechanisms which drive the alterations in OCT-A defined vessel density and blood flow. 
It is yet to be established whether these vascular measurements have sufficient dynamic 
range to allow detection of clinically significant changes in response to an intervention. 
Undoubtedly, more studies comparing ocular microvasculature in people with and 
without OSA well matched for variables which have been shown or may be potentially 
associated with the angiographic parameters, are clearly needed. 
This study confirms that in POAG patients, even in those with mild visual field 
impairment, there is a significant drop out of retinal capillaries when compared with the 
control group. However, no changes in the angiographic parameters were observed after 
CPAP therapy in either group. Despite between-group differences in CPAP related 
change in calculated OPP the microvascular indices remained unaltered in both groups. 
These results provide some reassurance that nocturnal IOP elevation caused by CPAP 
is not high enough to compromise retinal microvasculature, at least when it is measured 
shortly after the sleep period. However, it is also possible that OCT-A may not be 
sensitive enough to detect the impact of smaller IOP changes which may compromise 
ocular perfusion in addition to causing mechanical stress to the optic nerve. Indeed, a 
relationship between IOP and angioflow indices measured by OCT-A was demonstrated 
in a recent proof-of-concept study but a reduction of IOP by at least 50% from baseline 
values of IOP≥35 mmHg in patients with newly diagnosed HTG and ocular hypertension 
was needed to observe potentially clinically meaningful increase of peripapillary capillary 
perfusion in the RNFL (319). Similarly, another study also reported reduction of the area 
of vascular drop out in the peripapillary microvasculature associated with reduction of 
IOP from 26 to 13mmHg three months after trabeculectomy (320).  
The current study raises doubts on whether CPAP therapy could improve blood supply 
to the optic nerve in the age range when glaucoma is typically diagnosed. Age has been 
identified as a factor in OCT-A measured retinal vessel density; older patients have lower 
macular and peripapillary vessels densities  than younger counterparts (321). Age, as 
well as cardiovascular co-morbidities, may also be factors in reversibility of the potential 
OSA related changes in the ocular microvasculature. The association between OSA and 
hypertension, cardiovascular diseases and mortality is much stronger in younger people 
(322,323). Thus, it could be hypothesised that with increasing age the likelihood of 
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reversing cardiovascular changes with CPAP decreases even if they are contributed by 
OSA. Interestingly, in a recent study in paediatric patients an improvement in some 
microvascular retinal indices measured with OCT-A was reported one month after 
adenoidectomy, although that study had some important weaknesses, including the lack 
of objective confirmation of OSA with a sleep test in operated children (324).  
There are two main limitations of the current opportunistic study. Firstly, the sample size 
was small and may have been insufficient to demonstrate significant differences in the 
paired OCT-A measurements. As complete angiographic data suitable for analysis (two 
eyes, two repeated measurements) were available only for 50% of all subjects I cannot 
exclude selection bias. The main reason for exclusion was suboptimal image quality. In 
total, 96 scans were obtained on 24 subjects. Of these, 29.8% images were low quality. 
This is in keeping with the proportion of poor quality scans excluded in other studies 
(321). One specific challenge for obtaining high quality OCT-A images in the current 
study was corneal dryness from repeated IOP measurements at night which affected 
some patients and which was not always immediately helped by application of lubricants. 
Also, as most of our participants wished to drive back home straight after completing all 
study assessments, we could not use mydriatic eye drops. It is therefore possible that if 
the scans were taken in different circumstances the proportion of rejected images would 
have been lower.  
Secondly, the CPAP treatment period was relatively short which would allow detection 
of only early vascular changes. Whilst some studies found significant improvement in 
endothelial function after only 4 weeks of CPAP therapy a longer period of treatment may 
be required for the microvascular changes to be demonstrated with OCT-A (325). In 
addition, it is not yet established whether patients with OSA have reduced retinal vessel 
density. Since, unlike for structural RNFL measurements, there are no reference values 
available yet, I could not determine if the baseline OCT-A indices in the control group 
were lower than what would be expected for a population based sample of the 
corresponding age.  
Because of these limitations firm conclusions cannot be drawn from this pilot study. 
However, these data could be helpful in designing future studies which should consider 
allowing longer period of CPAP therapy and potentially recruiting younger patients with 
OSA and without established cardiovascular risk factors. It would be also interesting to 
examine how OCT-A indices relate to the established markers of endothelial dysfunction 
such as flow-mediated vasodilatation.  
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7.5 Conclusions 
In this pilot study there were no significant changes in the indices of the optic nerve 
microvasculature assessed with OCT-A after 4-6 weeks of CPAP therapy in people with 
and without glaucoma. Longer duration and larger studies are needed to determine 
whether a long-term use of CPAP affects the vascular parameters potentially relevant to 
the progression of the optic neuropathy.  
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Chapter 8: Conclusions  
OSA has been proposed to be linked with POAG for over two decades but it is still 
unclear how relevant it is to the development and progression of glaucomatous 
neuropathy. Given the irreversible nature of vision loss in glaucoma and limited treatment 
options, particularly for those patients who have progressive disease despite adequate 
IOP lowering, it is important that the relevance of this common sleep disorder is 
established.  
Despite the routine practice of treating patients with OSA and concomitant glaucoma 
with CPAP there is a lack of evidence on what effect, if any, CPAP has on their IOP. 
These gaps in our knowledge prevents clinicians from giving appropriate advice to 
patients with glaucoma commencing CPAP therapy about the possible side-effects and 
potential ways of mitigating them. 
The studies described in this thesis clarify some of these pertinent issues and provide 
better quality evidence in several areas but also raise more questions which could set 
directions for future research. 
Below, I summarise the main findings of the five thesis chapters which reported the 
results of original studies and the conclusions drawn from them. I then summarise the 
novel contributions of the thesis and describe further questions arising from this 
research.  
 
8.1 Summary  
The study described in Chapter 3 investigated the prevalence of OSA among unselected 
POAG patients recruited from glaucoma clinics in a secondary care hospital in the United 
Kingdom. The prevalence of OSA was found to be comparable to that reported in the 
general population of middle to elderly age people and no different to statistically 
matched control subjects. Importantly, the burden of OSA including its traditional severity 
markers and the associated sleepiness did not differ between POAG patients and 
controls. Thus, it was concluded that if routine OSA screening was implemented in 
glaucoma clinics it would likely yield a similar proportion of patients who would then be 
considered for OSA treatment as screening conducted in the general population of a 
similar age range. Moreover, it was demonstrated that the STOP-BANG questionnaire 
which had been proposed for OSA screening in glaucoma patients, has no useful 
discriminative value and should not be used in this disease-specific cohort of patients. 
Although it has been suspected that OSA may be more relevant in NTG than in HTG, 
both subgroups  of POAG had the same prevalence and severity of OSA. I have found 
no correlation between OSA severity and markers of functional and structural 
glaucomatous damage in the cross-sectional analysis.  
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The study reported in Chapter 4 retrospectively assessed rates of structural POAG 
progression in people with and without OSA. The key finding was that patients with 
untreated OSA had significantly faster rates of RNFL loss independently of other 
examined systemic and ocular factors previously associated with glaucoma progression. 
It was argued that the observed differences in RNFL thinning may be clinically relevant 
although this would require confirmation in future prospective studies with concomitant 
monitoring for structural and functional progression of glaucomatous damage.  
The study in Chapter 5 sought to determine whether CPAP therapy increases IOP at 
night in people with and without glaucoma. This was examined by repeated IOP 
measurements performed during two separate visits before and during CPAP 
application. The findings of two previous studies which demonstrated a significant CPAP-
induced IOP elevation at night in people without glaucoma were confirmed. Importantly, 
for the first time, the same effect of CPAP has been demonstrated in people with POAG 
in whom IOP elevation was not prevented by ocular hypotensive therapy. A moderate 
correlation between CPAP level and the magnitude of IOP increase observed in this 
study indicates that it would be reasonable to avoid high CPAP level for patients with 
glaucoma although IOP increase is unlikely to be explained by the level of CPAP alone.  
The experiment described in Chapter 6 was designed to examine the hypothesis of 
pressure transmission as the predominant mechanisms of IOP elevation during the 
CPAP exposure. It was assumed that if this hypothesis was correct a correlation between 
IOP and incremental levels of CPAP would be detected during a daytime CPAP 
application. However, no significant change in IOP was observed in awake subjects with 
or without glaucoma, including untreated glaucoma, despite CPAP application for up to 
2 hours and in the pressure range most commonly used in clinical practice. It was 
concluded that whilst positive pressure transmission may still occur at night other 
mechanisms could play a part in CPAP related IOP increases and that sleep is essential 
to observe the relationship between CPAP and IOP.  
Chapter 7 described a pilot study which explored whether a short course of CPAP to 
treat OSA in people with and without glaucoma induces changes in the optic nerve 
microvasculature examined with a novel angiographic imaging technique (OCT-A). The 
study found that the vascular parameters potentially relevant to the progression of the 
optic neuropathy remained unaltered after 4-6 weeks of CPAP therapy.  
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8.2 Thesis contributions 
 
This thesis has contributed to the field in multiple ways:  
- The thesis has produced the largest to date prospective study with detailed ocular 
and sleep apnoea assessment which examined the prevalence of OSA among 
glaucoma patients in a ‘real-world’ clinic scenario and had a concurrent control 
group. Through this, the thesis has provided estimates of OSA frequency and 
severity among unselected POAG patients and contributed to the debate on the 
role of systematic screening for OSA in glaucoma clinics.  
- The thesis has established that the STOP-BANG questionnaire is not a useful 
screening tool in POAG patients.  
- The thesis has found that the burden of OSA is not different in patients with NTG 
and HTG and that there is likely no need to separate out these two subgroups of 
POAG when examining the effects of OSA in future studies.  
- The thesis has established that there is no cross-sectional association between 
OSA severity and the severity of POAG measured by functional and structural 
indices.  
- The thesis has found that among POAG patients the rate of RNFL loss is 
significantly faster in people diagnosed with OSA than in those without OSA and 
that OSA may be an independent risk factor for structural progression of POAG.  
- The thesis has confirmed that CPAP raises IOP at night in people with healthy 
eyes and provided new evidence that this treatment also causes statistically and 
potentially clinically significant elevation of nocturnal IOP in people with treated 
POAG and that IOP elevation is partly dependent on the CPAP level.  
- The thesis has refuted the previous suggestion that the application of CPAP 
causes an immediate IOP increase in awake subjects which weakens the 
previously proposed hypothesis of mechanical pressure transmission as the 
predominant mechanism of CPAP related IOP elevation.  
- The thesis has assessed ocular microvasculature using OCT-A in OSA patients 
with and without POAG and in a pilot study found no indication that CPAP alters 
these microvascular parameters in the short-term.  
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8.3 Final conclusions and future directions 
The relationship between OSA and POAG is complex and multilevel. Future, well-
designed studies are needed to unravel various aspects of it and provide good quality 
evidence to guide clinical practice.  
This thesis has not directly examined whether OSA is an important risk factor for the 
development of POAG but the observation that people with POAG are not more likely to 
be diagnosed with OSA and that the severity of it is not associated with POAG severity 
would argue that OSA is not potent enough to alone cause glaucomatous damage. It 
may however be an important progression risk factor in people who have already 
developed POAG as a result of unfavourable balance between IOP and the optic nerve 
head pressure sensitivity or other risk factors. This is one of the most important directions 
for future research. Prospective longitudinal studies with concomitant monitoring for 
structural and functional progression whilst accounting for other risk factors and perhaps 
with repeated assessment for OSA severity, could provide essential data and are the 
natural way forward before interventional studies are considered. This thesis provides 
data to help with design of such studies, not only in terms of the sample size calculation 
but also in terms of ethical considerations. It was demonstrated that the majority of POAG 
patients diagnosed with OSA do not have relevant symptoms which would require 
treatment with CPAP based on the current practice, and thus a longer monitoring period 
without an intervention which could potentially affect glaucoma progression outcomes, 
would be ethically justifiable.  
Equally important is to establish whether CPAP is a safe treatment modality for patients 
with POAG. The demographics of POAG and OSA overlap in that sense that POAG is 
typically diagnosed after the age of 50 years and OSA prevalence peaks at the age of 
around 65 years. As both conditions are common, despite the lack of cross-sectional 
association between them we are likely to encounter POAG patients who require CPAP 
therapy for coexisting OSA. The IOP raising effect of CPAP is likely to go unnoticed as 
it does not carry over to wakefulness and IOP is typically only monitored during the 
daytime office hours in glaucoma clinics. Given this, and the slowly progressive nature 
of glaucomatous neuropathy nocturnal IOP may remain elevated for a long before CPAP 
is considered as a potential contributor, if indeed the treating clinicians ever developed 
this hypothesis. This thesis demonstrated that CPAP raises nocturnal IOP and this is 
something that both sleep specialist and ophthalmologists as well as patients should be 
aware of. However, it does not mean that CPAP would necessarily have a negative 
impact on important glaucoma outcomes. In fact, the reverse may be true. Currently, 
there is no sufficient ground to recommend changes in practice. The long-term effect of 
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CPAP on glaucomatous neuropathy can only be established in RCTs with well-matched 
groups and this would be another direction for future research. Further physiological 
studies dedicated to a better understanding of mechanisms behind CPAP induced IOP 
elevation could inform the design of such interventional studies and guide clinicians in 
what steps could be taken to mitigate the possible adverse effects of CPAP therapy.  
Also, on the physiological level there is a need to understand which of the deleterious 
systemic effects of OSA are most relevant to RGCs degeneration. Although CPAP can 
reverse endothelial dysfunction the results of RCTs dedicated to examining the role of 
CPAP in preventing important cardiovascular outcomes have been mostly and 
disappointingly negative. Demonstrating cardiovascular or cerebrovascular benefits of 
CPAP may be even more challenging in the middle to elderly age groups. If, however, 
OSA affects RGCs directly by augmenting oxidative stress or worsening hypoxia in the 
cells particularly sensitive to it, CPAP may stand a better chance of making a positive 
difference. Establishing whether there is a relationship between intermittent hypoxia and 
oxidative stress in the ocular tissues in POAG patients would inform this debate.  
Beyond glaucoma, the OCT measurements provide easily accessible window to the 
central nervous system and the RNFL could be a useful biomarker in OSA research on 
neurodegeneration. According to a recent population based study conducted in the UK 
a thinner RNFL is associated with worse cognitive function also in individuals without a 
neurodegenerative disease and carries a greater likelihood of future cognitive decline 
(326). Thus retinal degeneration has been proposed as a biomarker of preclinical 
dementia (327). RNFL assessment could aid risk stratification and potentially help to 
identify those OSA patients who are at a higher risk of future cognitive dysfunction. It 
could also be an intermediate outcome measure in interventional studies examining the 
role of CPAP in reducing the risk of dementia. Studies dedicated to assessment of 
longitudinal RNFL changes in OSA patients with healthy eyes are yet to be performed.  
 
In summary, this thesis found no epidemiological links between OSA and POAG but has 
provided data in support of the role of OSA in the progression of glaucomatous 
neuropathy in people with already established POAG. In addition, it has been 
demonstrated that CPAP raises IOP also in people with treated POAG. Future studies 
should focus on examining the long-term effects of OSA and CPAP therapy on important 
glaucoma outcomes.  
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Appendix 1. Example of rPG recording with manually scored respiratory events in a 
patient with POAG who was found to have moderate OSA.  
 
The screenshot represents just under 5 minutes of recording with two long obstructive 
apnoeas leading to oxygen desaturation to 84% and 77%, respectively. 
Description of signals: 1. Nasal flow (used for scoring hypopnoeas), 2. Thermistor signal 
(used for scoring apnoeas), 3. Chest respiratory movements, 4. Abdominal respiratory 
movements, 5. Oximetry, 6. Activity signal, 7. Body position signal.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
168 
 
 
Appendix 2. Example of HFA output in a patient with glaucomatous visual field defect.  
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Appendix 3.  Example of OCT-A images acquired on a POAG patient with mild visual 
field defect.  
 
A. “Angio disc” images demonstrating automated optic disc boundary 
determination based on scanning laser ophthalmoscopy (SLO) and radial peripapillary 
capillaries (RCP) layer determination on cross sectional images.  
 
 
 
B. En face OCT-A images of three layers of the disk and peripapillary area 
(the vitreous level, the radial peripapillary capillaries layers-RCP, and the superficial 
choroid) with software output for vessels densities in the RCP layer. 
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Appendix 4. IcarePro (top pictures)  and IcareHome (bottom pictures) tonometers.  
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Appendix 5. Ethical approvals for the POSAG study (Chapters 3 and 4) 
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Appendix 6. Sample size calculation for the POSAG study and a plot demonstrating the 
required sample size as a function of OSA prevalence in the POAG group (G*Power 
output) 
 
- Saturday , November 21, 2015 -- 18:54:51 
z tests - Proportions: Difference between two independent proportions 
Analysis: A priori: Compute required sample size  
Input: Tail(s) = Two 
 Proportion p2 = 0.56 
 Proportion p1 = 0.43 
 α err prob = 0.05 
 Power (1-β err prob) = 0.8 
 Allocation ratio N2/N1 = 1 
Output: Critical z = 1.959964 
 Sample size group 1 = 232 
 Sample size group 2 = 232 
 Total sample size = 464 
 Actual power = 0.801686 
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Appendix 7. Baseline demographic characteristics of invited POAG patients.  
 
 
 
Appendix 8. Predictors of OSA (AHI≥5) in the entire POSAG study cohort based on 
univariate logistic regression analyses.  
Predictor  Nagelkerke R2 OR 95% CI P value  
Age  0.055 1.05 1.023-1.071 0.000 
Male sex 0.021 1.67 1.1-2.5 0.013 
BMI 0.12 1.16 1.1-1.23 0.000 
Neck size 0.09 1.16 1.09-1.2 0.000 
Diabetes 0.018 2.25 1.1-4.6 0.028 
Definition of abbreviations: OSA=obstructive sleep apnoea, AHI-apnoea-hypopnoea 
index, BMI=body mass index. 
 
 
 
 POAG patients who 
took part in the study 
(n=251) 
POAG patients who declined 
participation in the study 
(n=307) 
P value 
Age, yr, (sd) 70.8 (10)  77.4 (8.9) 0.000 
 
Male sex, % 
 
56.5 
 
46.9 
 
0.025 
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Appendix 9. Comparison of POAG patients with more severe visual field defect (eGSS 
stages 2-5) with the control group in relation to OSA.  
 POAG patients 
(n=177) 
Controls  
(n=160) 
P value 
 
 
OSA, n (%) 
Moderate to severe OSA, n (%) 
AHI, per h, (IQR) 
ODI, per h, (IQR) 
T90, %, (IQR) 
MeanSpO2, %, (IQR) 
MinSpO2, %, (IQR) 
ESS score, (IQR) 
101 (57.1) 
38 (21.5) 
5.9 (11) 
3.8 (7.1) 
14 (78) 
93.1 (1.9) 
86 (6) 
6 (6) 
87 (54.4) 
26 (16.3) 
5.7 (9.7) 
3.3 (7.1) 
15 (76) 
93 (2.0) 
86 (6.0) 
5 (6.0) 
0.66 
0.27 
0.48 
0.63 
0.77 
0.84 
0.92 
0.92 
      
Definition of abbreviations: POAG=primary open-angle glaucoma, eGSS=enhanced 
Glaucoma Staging System, OSA=obstructive sleep apnoea, AHI=apnoea-hypopnoea 
index, ODI=oxygen desaturation index, T90=time spent with oxygen saturation less than 
90%, MeanSpO2=mean oxygen saturation, MinSpO2=minimum oxygen saturation, 
ESS=Epworth Sleepiness Scale.  
 
Appendix 10. HTG vs NTG-Baseline Characteristics of Participants. 
 HTG subgroup 
(n=139) 
NTG subgroup 
(n=77) 
P value 
 
Baseline characteristic of participants in relation to OSA 
 
Male sex, n (%) 
Age, yr, (sd) 
White European, n (%) 
BMI, kg/m2, (sd) 
 
89 (64) 
69.8 (9.3) 
137 (98.6) 
27.9 (4.3) 
 
34 (44.2) 
71 (9.4) 
72 (93.5) 
26.6 (4.3) 
 
0.006 
0.375 
0.14 
0.041 
 
Diabetes type 2, n (%) 
Hypertension, n (%) 
IHD, n (%) 
CVA, n (%) 
Atrial Fibrillation, n (%) 
 
15 (10.8) 
64 (46) 
14 (10.1) 
8 (5.8) 
7 (5) 
 
10 (13) 
36 (46.8) 
10 (13) 
3 (3.9) 
5 (6.5) 
 
0.66 
1.00 
0.51 
0.75 
0.76 
 
AHI, per h, (IQR) 
ODI, per h, (IQR) 
T90, %, (IQR) 
MeanSpO2, %, (IQR) 
MinSpO2, %, (IQR) 
 
ESS score, (IQR) 
 
 
6.1 (11.4) 
4.1 (7.3) 
15.5 (76) 
93 (1.7) 
86 (6) 
 
5.5 (5.3) 
 
 
5.5 (8.9) 
3.7 (6.3) 
14 (82) 
93 (2.4) 
85 (6.5) 
 
6 (6.0) 
 
 
0.76 
0.79 
0.89 
0.74 
0.37 
 
0.9 
 
Baseline characteristic of participants in relation to ocular parameters&  
 
MD, dB, (IQR) 
 
-4.0 (6.6) 
 
-2.7 (6.6) 
 
0.30 
VFI, %, (IQR) 92 (17) 93 (19) 0.78 
cRNFL (μm), sd 66.5 (16) 72.8 (14.8)  0.001 
CDR, IQR 0.8 (0.3) 0.8 (0.3) 0.71 
180 
 
      
 & Based on data from both eyes 
Definition of abbreviations: HTG=high tension glaucoma, NTG=normal tension 
glaucoma, BMI=body mass index, IHD=ischaemic heart disease, CVA=cerebrovascular 
accident, AHI=apnoea-hypopnoea index, ODI=oxygen desaturation index, T90=time 
spent with oxygen saturation less than 90%, MeanSpO2=mean oxygen saturation, 
MinSpO2=minimum oxygen saturation, ESS=Epworth Sleepiness Scale, MD=mean 
deviation, VFI=visual field index, cRNFL=circumpapillary retinal nerve fibre layer 
thickness, CDR= cup to disc ratio (determined by the optometrist during a slit lamp 
examination). 
 
Appendix 11. Missing data and exclusions for the analysis of associations between AHI 
and ocular parameters in the POSAG study cohort.  
Reason for exclusion  POAG group  
N=235 
Control group  
N=160 
Treated OSA, n (%) 
 
2 (0.85) 0 (0) 
Ocular comorbidities, n (%) 
 
17 (7) 7 (4.4) 
Inadequate quality OCT images, n (%) 
(relevant to all RNFL regression models) 
  
14 (6) 7 (4.4) 
Missing at least one covariate, n (%) 
(relevant to fully adjusted RNFL regression 
models)  
13 (5.5) 15 (9.4) 
Definition of abbreviations: AHI=apnoea hypopnea index, POAG=primary open-angle 
glaucoma, OCT=ocular coherence tomography, OSA=obstructive sleep apnoea, 
RNFL= Retinal Nerve Fibre Layer. 
 
 
Appendix 12. Criterion values and coordinates of ROC curve for the STOP-BANG 
questionnaire in matched POAG patients ( for AHI≥5, POSAG study).  
Crite
rion 
Sensitivity 95% CI Specificity 95% CI +PV 95% CI -PV 95% CI 
>0 100 96-100 1 0.03 - 7 54 53 - 55 100   
>1 95 89 - 99 14 7 - 24 56 54- 59 71 45- 88 
>2 77 66- 85 42 31 - 54 61 55 - 66 61 49 - 71 
>3 58 47 - 69 66 54- 77 67 58 - 74 58 50 - 65 
>4 27 18 - 37 84 73 - 91 66 51 - 78 50 46- 54 
>5 13 7 - 22 95 87 - 99 73 48 - 89 48 46 - 51 
>6 3 1 - 10 99 93 - 100 75 24- 97 47 46- 48 
>7 1 0.03 -6 100 95 - 100 100   47 46 - 47 
>8 0 0- 4 100 95- 100     46 46 - 46 
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Appendix 13. Summary of the linear mixed effects models examining the association 
between OSA status and the rate of global RNFL thinning [RNFLlast-RNFLbaseline, 
μm/year ], (n=167 eyes). 
Model Estimate Standard 
Error 
95% CI t 
value 
P 
value  
 
Unadjusted: 
     
OSA  
(reference to no OSA) 
-0.44 0.21 -0.86 to -0.03 -2.1 0.038 
AHI -0.41 0.25 -0.91 to 0.09 -1.6 0.11 
Adjusted      
OSA  
(reference to no OSA) 
-0.51 0.20 -0.91to -0.11 -2.5 0.014 
CVS co-morbidities 
(reference to no CVS  
co-morbidities) 
-0.43 0.21 -0.8.5 to -0.002 -2.0 0.049 
Baseline RNFL thickness  -0.014 0.006 -0.03 to -0.002 -2.2 0.028 
IOPcurrent -0.064 0.028 -0.12 to -0.009 -2.3 0.024 
Previous filtration surgery 
(reference to no surgery)  
-0.30 0.25 -0.79 to 0.19 -1.2 0.23 
Corneal Hysteresis 0.028 0.048 -0.067 to 0.12  0.58 0.56 
Age 0.007 0.012 -0.017 to 0.03  0.57 0.57 
      
       Abbreviations: OSA= obstructive sleep apnoea, Baseline RNFL thickness measured on 
the first scan included in the analysis, AHI=apnoea-hypopnoea index, 
IOPcurrent=intraocular pressure recorded at the study visit, CVS=cardiovascular co-
morbidities (at least one of the following: diabetes, hypertension, ischemic heart disease, 
atrial fibrillation, cerebro-vascular accident, heart failure, over 20 pack year smoking 
history).  
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Appendix 14. Ethical approval for the PAIR 2 study (Chapters 5 and 7) 
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Appendix 15. Sample size calculation for PAIR 2 study (G*Power output).  
Saturday, December 12, 2015 -- 13:45:39 
t tests - Means: Difference between two dependent means (matched pairs) 
Analysis: A priori: Compute required sample size 
Input: Tail(s) = Two 
Effect size dz = 0.9541603 
α err prob = 0.05 
Power (1-β err prob) = 0.8 
Output: Noncentrality parameter δ = 3.164592 
Critical t = 2.228139 
Df = 10 
Total sample size = 11 
Actual power = 0.813361 
 
 
 
Appendix 16. Repeated IOP measurements from the sleep period at Visit 1 and Visit 2 
obtained on a POAG patient (subject 27) who could not tolerate CPAP but attended for 
both visits and had IOP measured off CPAP on both occasions.  
 
14
15
16
17
18
19
20
21
22
Repeated IOP measurements- Subject 27
Visit 1 Visit 2
IO
P
 (
m
m
H
g
)
00 am 2 am 4 am 6 am 8 am
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Appendix 17. Average 24-hour IOP in OSA patients at baseline and during CPAP 
therapy in the study by Kiekens et al.  
Adopted from: Kiekens S, Veva De Groot  null, Coeckelbergh T, Tassignon M-J, van de 
Heyning P, Wilfried De Backer  null, et al. Continuous positive airway pressure therapy 
is associated with an increase in intraocular pressure in obstructive sleep apnea. Invest 
Ophthalmol Vis Sci. 2008 Mar;49(3):934–40. 
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Appendix 18. Three groups of OSA patients with normal, absent and inversed IOP 
rhythm at baseline and during CPAP therapy according to Pépin et al.  
Adopted from: Pépin J-L, Chiquet C, Tamisier R, Lévy P, Almanjoumi A, Romanet J-P. 
Frequent loss of nyctohemeral rhythm of intraocular pressure restored by nCPAP 
treatment in patients with severe apnea. Arch Ophthalmol Chic Ill 1960. 2010 
Oct;128(10):1257–63. 
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Appendix 19. 24-hour IOP rhythm in young healthy subjects and in older people 
according to a study by Liu et al. Measurements were taken in supine and habitual 
positions  
Adopted from: Liu JH, Kripke DF, Twa MD, et al. Twenty-four-hour pattern of 
intraocular pressure in the aging population. Invest Ophthalmol Vis Sci. 1999 
Nov;40(12):2912-7. 
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Appendix 20. Ethical approvals for the PAIR 1 study (Chapter 6). 
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Appendix 21. Illustration of IOP measurement with IcarePro tonometer on two patients 
who took part in the PAIR I study (with written consent to share the images).  
 
 
 
Appendix 22. Sample size calculation for PAIR 1 study (G*Power output).  
Saturday, December 12, 2015 -- 20:30:40 
F tests - ANOVA: Repeated measures, within factors 
Analysis: A priori: Compute required sample size 
Input: Effect size f = 0.6859943 
α err prob = 0.05 
Power (1-β err prob) = 0.95 
Number of groups = 1 
Repetitions = 5 
Corr among rep measures = 0.5 
Nonsphericity correction ε = 1 
Output: Noncentrality parameter λ = 28.235291 
Critical F = 2.866081 
Numerator df = 4.000000 
Denominator df = 20.000000 
Total sample size = 6 
Actual power = 0.978563 
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Appendix 23. Examples of different quality ONH and macular OCT-A images provided 
by the manufacturer.  
 
 
 
 
 
 
 
 
